annual report corporate website brochure meet global challenge product commitment innovation health access medicine responsibility therapy area community mission research development well future investor like know medium centre career gsk wwwgskcom corporate annual responsibility review report human access medicine interview research innovation chairman ceo ethical conduct focus patient annual employee year vaccine human right growing brand report environment power performance community investment performance highlight business operating review summary remuneration report interview corporate governance chairman ceo summary financial statement financial summary shareholder information description business chairman ceo corporate governance closing letter remuneration report operate financial review prospect financial statement note financial statement investor information feel well live long head office register office glaxosmithkline plc great west road design cgi london brentford middlesex print midas press paper united kingdom production document pulp harvest tel sustainable forest sawmill residue wwwgskcom forest thinning elemental chlorinefree feel well live long glaxosmithkline annual report discover important medicine eradicate disease improve quality people live make medicine available great number people matter people garnier leave sir christopher gent rightthank effort employee world successful year gsk good year financial standpoint substantial progress pipeline innovative medicine vaccine garni chief executive officer interview sir christopher gent chairman garni chief executive officer year success progress gsk deliver excellent financial performance year vaccine turnover billion grow constant exchange landmark year gsk vaccine business sale rate cer earning share ep growth increase company number cer put gsk tier global significant strategic acquisition acquisition biomedical pharmaceutical company term performance important gsk say strengthen position global flu vaccine marketand increase figure confirm excellent growth key product ability prepare respond potential flu pandemic efficiency global operation say pharmaceutical industry make gsk performance drive sale key pharmaceutical product sale seretideadvair avandia coreg lamictal positive improvement people live valtrex continue impressive growth say noble purpose develop medicine see good performance number new vaccine save life product include avodart enlarging prostate boniva people feel well bonviva osteoporosis requip restless leg syndrome great promise future sir christopher gent chairman patient gsk acquire plant marietta pennsylvania look strong growth see key product access tissue culture technology vaccine vaccine business expect continue manufacture acquisition corixa give valuable anticipate ep growth cer adjuvant technology enable boost human immune response vaccine pipeline progress gsk continue meet challenge increase research gsk good progress pipeline new vaccine development productivity discover new medicine expect major vaccine launch year fast economically company pipeline say exciting cervarix cervical cancer large promising industry project expect file approval europe march clinical development end february usa end year include new chemical entity nce product line improve access medicine extension ple vaccine gsk continue seek new way improve access anticipate good news gsk latestage medicine people need able pipeline develop fast pace major new obtain challenge particularly acute develop asset schedule enter phase iii double world gsk offer medicine latestage pipeline say vaccines notforprofit price year gsk annual report address challenge gsk tragedy year bring home extent work gsk organisation bill pharmaceutical industry make positive melinda gates foundation highlight benefit public improvement people live say sir christopher private partnership provide way company noble purpose develop medicine vaccine save asgsk private sector work typically gsk life people feel well provide technology manufacturing distribution human expertise partner government help fund continue meet challenge improve productivity development delivery cost ensure patient access medicine gsk enter groundbreaking publicprivate poor part world thisreporthighlight partnership develop vaccine big cause work implement strategy meet death develop world today aid malaria challenge human story tuberculosis thank employee effort commitment passion individually publicprivate partnership use teamwork help gsk success today respective strength partner appreciate great support employee receive bring good family work gsk importantly model work grateful significant contribution tachi yamada chairman executive director retire june reach patient welcome moncef slaoui succeed tachi gsk introduce strengthen number effect stjune like thank jack initiative aim improve patient understand gsk ziegler president gsk consumer healthcare retire medicine programme help gain access company january welcome successor john initiative include gskspioneere clinical trial registerwhich clarke wealso thank lucy shapiro retire non expand contain summary clinical trial executive director company annual general meeting end welcome tom swaan join board january new nonexecutive director usa gsk place emphasis education patient directtoconsumer advertising provide people advice gsk programme industry partnership prescription assistance help people gain access medicine need initiative seek differentiate gsk company find solution healthcare challenge society face believe way achieving say sir christopher abroader contribution sir christopher gent garni gsk global community investment activity chairman chief executive officer value million equivalent group profit tax year see number natural disaster include asian tsunami guatemalan hurricane new orleans flood earthquake strike part india pakistan gsk quick respond help victim tragedy thank employee response crisis make proud lead organisation commit compassionate people respond effectively help people real need say disaster gsk contribute morethan million cash donate medicine vaccine value million relief effort gsk annual report content report director financial summary description business corporate governance remuneration report operate financial review prospect financial statement director statement responsibility independent auditor report consolidated income statement consolidate balance sheet consolidate cash flow statement consolidate statement recognise income expense note financial statement financial statement glaxosmithkline plc investor information financial record shareholder information taxation information shareholder glossary term index annual report approve board director onst march publish onrdmarch website glaxosmithkline website wwwgskcom give additional information group information available website constitute annual report gsk annual report financial summary growth cer turnover operatingprofit profit taxation profit taxation year profit attributable minority interest profit attributable shareholder earning share dilute earning share dividend share net cashinflow operating activity net asset history development company glaxosmithkline plc public limited company incorporate december english law share areliste london stock exchange new york stock exchange december company acquire glaxo wellcome plc smithkline beecham plc english public limited company way scheme arrangement merger company glaxo wellcome smithkline beecham major global healthcare business gskplcand subsidiary associated undertakingsconstitute major global healthcare group engage creation discovery development manufacture marketing pharmaceutical consumer healthrelate product gskha corporate head office london operational headquarters philadelphia research triangle park usa operation somecountrie product sell overcountrie principal research development facility usa japan italy spain belgium product currently manufacture country major market group products usa france japan italy germany spain business segment gskoperate principally industry segment pharmaceutical prescription pharmaceutical vaccine consumer healthcare overthecounter medicine oral care nutritional healthcare group multinational business operate country earn revenue incur cost currency result group report sterling affect movement exchange rate sterle overseas currency average exchange rate prevail period translate result cash flow overseas subsidiary associate undertaking joint venture sterling period end rate translate net asset undertaking currency influence translation dollar euro japanese yen order illustrate underlying performance group practice discuss result term constant exchange rate cer growth represent growth calculate exchange rate determine result overseas company sterling remain unchanged previous year cer represent growth constant exchange rate represent growth actual exchange rate cautionary statement forwardlooke statement group report file furnish securities exchange commission sec include document write information release oral statement public future behalf group contain forwardlooke statement forwardlooke statement group current expectation forecast future event investor identify statement fact relate strictly historical current fact use word anticipate estimate expect intend project plan believe word term similar meaning connection discussion future operate financial performance particular include statement relate future action prospective product product approval future performance result current anticipate product sale effort expense outcome contingency legal proceeding financial result group undertake obligation update forwardlooke statement result new information future event forwardlooke statement involve inherent risk uncertainty group caution investor number important factorsinclude document cause actual result differ materially contain forwardlooke statement factor include limit discuss risk factor pagestoof annual report gsk annual report srotcerid eht troperdescription business description business discuss strategy activity resource andoperate environment business identifie development achievement follow heading strategy strategyand business driver business driver build good product pipeline industry achieve commercial operational excellence improve access medicine good place good people well work global manufacturing supply corporate responsibility community investment annual report review product competition report annual report glaxosmithkline plc year pharmaceutical end december prepare accordance united consumer healthcare kingdom requirement regulatory environment summary report year annual review intend regulation investor need detail annual report intellectual property produce separate document responsibility environment health safety annual review include joint statement chairman discussion group management structure corporate chief executive officer summary review operation summary governance procedure set corporate governance page financial statement summary remuneration report annual review issue shareholder annual report remuneration report give detail group policy issue shareholder elect receive document director remuneration amount earn director available glaxosmithkline corporate website wwwgskcom senior management pagesto discussion group operate financial performance financial resource give operate financial review prospect pagesto gsk annual report srotcerid eht troper mission global quest improve quality human life enable people feel well live long spirit undertake quest enthusiasm entrepreneur excite constant search innovation value performance achieve integrity attain success world class global leader people contribute passion unmatched sense urgency report glaxosmithklinethe groupor gskmeans glaxosmithkline plc subsidiary undertaking company mean glaxosmithkline plc glaxosmithkline share mean ordinary share glaxosmithkline plc american depositary share ad represent glaxosmithkline share report figure quote market size market share market growth rate relate month end september later available gsksestimate base recent datum independent external source value sterle relevant exchange rate figure quote product market share reflect sale gskand licensee brand name appear italic report trademark own andor license glaxosmithkline associate company exception baycoland levitra trademarks bayer bonivabonviva trademark roche entereg trademark adolor corporation usa hepsera trademark gilead sciencesin country include usa integrilin trademark ofmillennium pharmaceutical micropump trademark flamel technologies natrecor trademark scios janssen navelbine atrademark pierre fabre mdicament nicoderm atrademarkof sanofiaventis elan novartis glaxosmithkline certain countriespritor trademark boehringer ingelheim andvesicare trademark yamanouchi pharmaceuticals japan south korea trademark astellas pharmaceuticalsall certain country license groupstrategy business driver glaxosmithklineis address key challenge face corporate responsibility pharmaceutical industry society working tomeet challengesand implement thesebusiness driversgsk recognise responsibility support improve productivity research development delivery well healthcare education underserve ensure patient access new medicine community connect business decision ethical social environmental concern gsk commitment theseisoutlinedon strategy meet challenge focus business pagestowith information available corporate driver responsibility report available website build good product pipeline industry wwwgskcom group aim create good product pipeline industry benefit patient consumer society include develop focus portfolio strategy support pipeline manage life cycle compound launch prescription medicine overthecounter product appropriate strategy include selective licensing efficient execution development commercialisation supply chain process gsk organisation measure productivity number innovation product create commercial value theseproduct ability address unmet need consumer include patient healthcare professional budget holder regulator perspective constitute valuable new product detail give page achieve commercial operational excellence gsk link research commercial operation closely order maximise value portfolio compound develop test marketing campaign sale effort plan appropriate market group aim build strong relationship patient consumer ultimate user medicine common approach management process business function internationally diverse talented management team order create sustain competitive advantage market detail give page improve access medicine gsk create extensive programme design improve healthcare people limited access medicine develop develop worldthese set improve access medicine section report page good place good people well work single great source competitive advantage organisation people group ambition tobethe place great people apply energy passion difference world skill intellect key component successful implementation group strategy work environment support inform empower resilient workforce group value draw diverse knowledge perspective experience style global community detail give page gsk annual report srotcerid eht troper description businessbuild good product pipeline industry research development pharmaceutical cedd responsible assess safety development characteristic lead compound preclinical screen gsk strategic intent indisputable leader involve animal allow selection industry success depend bedrock group good candidate new medicine achieve business vibrant productive research development cedd responsible demonstrating compound function develop new way help patient satisfied proof therapeutic concept midstage clinical trial support exist product decision information available justifie focus thepatient compound progression latestage drug development rdsfocuson patientinvolvesseekingthe views patient largescale clinical trial conduct register commercialise family understand important aspect product disease impact live information conjunction discussion key opinion leader compound enter clinical trial time shape drug development programme new medicine agsk research facility focus new therapy treatment likely benefit patient neurodegenerative illnessessuch alzheimer diseasewas open find candidate compound singaporein component need early stage find new application experimental medicine major opportunity medicine target show affect mechanism industryan important tool field clinical image important pathological process human disease compound enable visualisation change body response able modulate behaviour specific target administration new medicine worldclass image disease arise complex interaction gene expert wererecruite usaand gsk prepare variant environmental factor gsk genetic research open clinical imaging centre hammersmith hospital aim advantage identifyinggene influence london addition establish global common disease large unmet medical need major patient collaboration academic imaging centre aleader burden insightshelp search fortarget know application imaging drug discovery development relevance disease great chance deliver convert candidate medicine benefit patient preclinical development pcd include wide range activity discovery research produce lead compound entire drug development process involve influence target whichform basis drug discovery effort enhancement exist product devise convenient gsk centre excellence drug discovery cedd formulation early development process metabolism perform million assay provide cedd safety compound evaluate laboratory animal highquality new lead compound investment testing human test require animal highly regulate focused increase quality quantity lead animal research page compound available pcd researcher investigate appropriate dosage form example select good candidate molecule tablet inhaler develop formulation enhance drug fundamental step turn lead compound drug effectiveness ease use patient process candidate optimise potency efficacyandsafety support analytical method drug synthesis product demonstrate validity therapeutic hypothesis early formulation delivery scale meet increase supply clinical trial result candidate requirement lead technical transfer process method manufacture new product supply process step help rapid informed decision make creative partnership global manufacturing supply solution issue inevitably arise phase development ensure robust product develop largescale commercial gsk hasdesignedthe ceddswhich focus specific disease manufacturing launch areasto nimble entrepreneurial seven cedd base europe usa provide focus development process major functional component clinical medical biomedical datum regulatory biopharmaceutical stevenage safety integrate single management organisation cardiovascular urogenital disease upper merion usa worldwide development wwd metabolic viral disease research triangle park usa microbial musculoskeletal proliferative disease include cancer gsk medicine development centre mdc provide focus upper providence usa latestage development responsible creating value neurology gastrointestinal disease harlow delivery product development plan manage dayto psychiatry verona italy day operational activity latestage development portfolio respiratory inflammation stevenage ensure strong partnership cedds global commercial strategy gcs gsk annual report srotcerid eht troper description businessbuild good product pipeline industry continue mdc base major usaand site align extend use exist product follow therapeutic area product launch important establish additional way patient help cardiovascularmetabolic investigate illness treat infectious disease include disease develop world product development additional convenient dosage ddw form development reflect feedback patient musculoskeletalinflammationgastrointestinalurology medical profession result continue research neuroscience psychiatryneurology disease cause oncology respiratory example importance lifecycle management gsk include new indication restless leg syndrome requipand monthly team responsible maximise worldwide dose boniva simplify administration prevention development opportunity product remit osteoporosis line extensionsaddsignificantvalue totheproduct information need support registration safety portfolio recent examplessuch augmentin esxr seroxatpaxil programme price formulary negotiation available crand wellbutrin achieve sale millionin need commercial input global commercial strategy ensure regional marketing need integrate development productivity plan early stage challenge increase productivity continue programme identify association disease gene addition investigate new way operate enableit help point area researchmorelikely produce new way respond variety external pressure industrysuch help patient increase automation screen provide increase regulatory stringencyso thatit ispositione ensure high quality lead compound quickly thateffective new medicine reach patient soon possible progress portfolio communicate investor medium gsk believe pharmacogenetic research correlate regular interval year amajor presentation genetic datum response medicine help reduce pipeline vaccine portfolio hold june oncology supportive attrition improve productivity collect dna sample care portfolio november details gsk product clinical study identify pharmacogenetic information help development pipeline give pagesto predict patient response information intend define patient group likely gain benefit treatment suffer manage portfolio effecta compound progress development improve productivity compound progress clinic ultimately pharmacogenetic promise provide later phase development progress put demand physician information help select medicine resource important look objectively dose likely benefit patient portfoliokey project reach significant milestone review month product management board pmb take approach improve responsible determine asset meet criterion pass productivity clinical trialsinclude increase use country phase development outside western europe usaand introduction direct electronic datum capture new clinical trial gsk continue identify compound company improvement productivity continue go forward enhance portfolio create innovative collaboration ensure group regard partner choice large clinical trial sponsor gsk irrespective small company place conduct accord international standard good clinical practice applicable law regulation protocol specific centre excellence external drug discovery review external regulatory agency relevant create small internal management team responsible country require protocol consider ethic deliver compound clinical proof concept establish review committeewhose remit cover site study manage longterm strategic collaboration biotechnology place safety datum routinely collect development company small midsized pharmaceutical company programme report national regional regulatory academic institutionsthe group commit fund agency line applicable regulation year collaboration option renew additional year gsk global safety board responsible internally approve pivotal study investigate issue relate patient safety inlicense arise development programmeduring gsk take inlicense comarketingcopromotion agreement conclude step make information clinical trial widely easily available extend clinical trial register public website development commercialisation vertexpharmaceutical clinical trial datum publish regulatory authority inc nav nachannel blocker plus backup molecule continue inform datum generate pain preclinical reassuredofthe safety efficacy gsk productsthe clinical trial development promotion allergan inc botox japan register enhance ability clinician informed clinical china judgements benefit patient development commercialisation renin inhibitor program preclinical vitae pharmaceuticals inc gsk annual report srotcerid eht troper description businessbuild good product pipeline industry continue exercise optionfor theravance inc inhale muscarinic gskmade number ofinvestment thatstrengthen antagonist beta agonist programme preclinical vaccinecapabilitie exercise option human genome science inc significant increase flu vaccine manufacturing development lymphostat complete phase iia rheumatoid arthritis capacity systematic lupus erythematosus mapatumumab trail acquire idbiomedical north american developer vaccine monoclonal antibody cancer indication phase infectious disease producer influenza vaccine discontinuation site canada usa million carry risk failure lead compound show positive investing million extend german vaccine facility activity validate target proveinsufficiently safe purchase vaccine manufacturing site usa introduce human orimpossible manufacture commercial acquiringus base corixa corporation developer innovative scale compound expect benefit vaccine adjuvant approximately million patient large scale clinical testing discontinuation occur enter groundbreake publicprivate partnership despite extensive predictive testing develop vaccine big killer develop worldaid malaria tuberculosis latestage project terminate phase iii include aplaviroc hiv avandiafor psoriasis gsk expect launch major new vaccine year lamictal xrfor schizophrenia ahumanpapillomavirusvaccinepreventingcervical cancer usa launch vaccine rotavirus induce research development vaccine gastroenteritisand strengthen presence international majority gsk vaccine activity conduct market biological headquarters rixensart belgium theseincludeclinical vaccine pneumococcal disease development regulatory strategy commercial strategy scale improve vaccine influenza vaccine production packaging support function vaccine combination meningitis scientist devote develop new vaccine costeffective convenient combination vaccine prevent strength gsk vaccine pipeline expect provide infection cause medical problem worldwidegsk opportunity gsk todeliver new vaccine year come target therapeutic vaccine prevent relapse disease develop world cancer patient continue investment research disease disproportionately vaccine discovery involve collaborationswith academia affect develop world essential longterm thebiotech industry worldwide allow identification new improvement health people live region vaccine antigen express yeast bacteria gsk response challenge operate drug discovery unit mammalian cell purify high level dedicated find new medicine disease base tre canto spain work undertake tre canto focus malaria follow formulation clinical lot vaccine tuberculosis work group involvemixe antigen select novel proprietary adjuvant hivaid vaccine mean gsk addressing prevention design stimulate goodimmune response treatment world health organization step evaluate safety efficacy candidate vaccine priority disease preclinical setting usually involve animal model candidate vaccine test clinical trial healthy individual evaluate gsk currently clinical programme relevance develop safety andeffectivenessin induce immune response protect world aim produce vaccine medicine body frominfectionencountere later natural settingphase disease disproportionately affect develop country iii largescale field trial healthy individual follow establish publicprivate partnership ppp remain essential fund research safety efficacy cross section populationphase iii commercially viable market potential product result obtain clinical trial datum gsk leader working ppp continue collaborate closely development quality largescale production process government academic centre united nations agency facility combine regulatory file submit global funding body area maximise expertise authority country vaccine knowledge dual benefit encourage research available development accelerate access medicine develop world example gsk announce partnership launch post marketing study considerable size set global alliance drug development aeras global assess vaccination programmesimpact monitor vaccine tbvaccine foundation international aids vaccine initiative safety phase gsk malaria falcipain inhibitor project choose medicine vaccine manufacture particularly complex requires use malaria venture project year award living microorganism sophisticatedqualityassurance andquality control procedure place ensure quality safety vaccinesand commonly include animal usedue biological nature health authority maysubject vaccine second controlto guarantee high quality standard gsk annual report srotcerid eht troper description businessbuild good product pipeline industry continue animal research gsk submission regulatory authority usa ethical regulatory scientific reason research animal time approval remain small vital research development new usa europe medicine vaccine gsk use animal submission alternative number require test group approval strive exceed regulatory standard care use animal use undergoe internal external review assure standard latestage pipeline expect expand vast majority experimental method use animal major asset anticipate enter phase iii development gsk actively engage research develop validate test gsk anticipate seven product approvedandor avoid use animal research reduce number launch seven product filing plan detail need animal research unnecessary pain development expect gsk outlook suffer scrupulously avoid page gsk understand use animal research purpose gsk policy obtain patent protection significant product command high level public interest glaxosmithkline public discover develop activity patent protection policy position care ethical use animal research new active ingredient available significant market information report available website protection obtain new pharmaceutical formulation wwwgskcomor secretariat manufacturing process new medical use special device administer product research development consumer healthcare key align closely new consumer healthcare vaccine operating model structure global brand mirror pharmaccine commercial structure team pair commercial compound shionogiglaxosmithkline pharmaceutical llc joint team locate principal centre consumer healthcare venture weybridge parsippany usa inlicense alliance relationship party colocation site term innovation centre focus date submission identification rapid development novel date regulatory approval maa approval letter product bring benefit consumer overthecounter approvable letterindicate ultimately approval give otc oral care nutritional healthcare market subject resolution ofdeficiencie maa marketing authorisation application europe gsk pipeline nda new drug application usa phase evaluation clinical pharmacology usually conduct volunteer charton rightshow new chemical entity nceandproduct phase determination dose initial evaluation efficacy conduct line extension ple project clinic small number patient end february gsk hadnearly pharmaceutical vaccine phase iii large comparative study compound versus placebo andor establish project development clinic comprise treatment patient establish clinical benefit safety nce ple vaccine compare number project late stage developmentha increase maturity late stage pipeline expect lead increase registration come year content drug development portfolio change time new compound progress discovery development development market owe nature drug development process compound especially early stage investigation terminate progress development phase nce multiple indication count nce later phase count indication competitive reason new project preclinical development disclose project type identify gsk annual report srotcerid eht troper description business pip eline stage pipeline growth nce phase iii nce phase registration ple nce phase vaccinesbuild good product pipeline industry continue estimate filingdate compoundproduct type indication phase maa nda cardiovascular metabolic high affinity nicotinic acid receptor dyslipidaemia hma agonist kinase inhibitor atherosclerosis rheumatoid arthritis chronic obstructive pulmonary disease copd factor inhibitor prevention stroke atrial fibrillation kinase inhibitor atherosclerosis rheumatoid arthritis copd rilapladib lipoproteinassociate phospholipase atherosclerosis lppla inhibitor peroxisome proliferatoractivator receptor dyslipidaemia ppar delta agonist ppar alpha agonist dyslipidaemia odiparcil indirect thrombin inhibitor prevention thrombotic complication cardiovascular disease darapladib lppla inhibitor atherosclerosis lliii arixtra synthetic factor inhibitor treatment acute coronary syndrome iii coreg beta blocker hypertension congestive heart failure oncedaily submit sdec metabolicprojects ppar pan agonist type diabete glucagonlike peptide agonist type diabetes melanin concentrate hormone antagonist obesity radafaxine noradrenalinedopamine reuptake inhibitor obesity fibromyalgia neuropathic pain depression sodium dependent glucose transport sglt type diabete inhibitor ppar pan agonist type diabete sglt inhibitor obesity denagliptin dipeptidyl peptidase dpp inhibitor type diabete solabegron beta adrenergic agonist type diabete overactive bladder avandamet ppar gamma agonist metformin type diabete extend release iii avandia simvastatin ppar gamma agonist statin type diabete iii avandaryl ppar gamma agonist sulphonylurea type diabetes fix dose combination approve smay adec infectious disease oral pleuromutilin treatment ofbacterial infection oral pleuromutilin treatment bacterial infection phospholipid antiendotoxin emulsion sepsis farglitazar ppar gamma agonist hepatic fibrosis sitamaquine aminoquinoline treatment visceral leishmaniasis chlorproguanil dapsone antifolate artemisinin treatment uncomplicated malaria iil artesunate cda etaquine aminoquinoline malaria iii altabaxretapamulin topical pleuromutilin bacterial skin infection submit snov antiviral dna antiviral vaccine hiv infection brecanavir aspartyl protease inhibitor hiv infection relenza neuraminidase inhibitor influenza prophylaxis submit snov snov musculoskeletal inflammation gastrointestinal urology oxytocin antagonist threaten preterm labour gselective oestrogen receptor modulator treatment menopausal symptom vitronectin integrin antagonist agerelate macular degeneration potassium channel opener overactive bladder relacatib cathepsin inhibitor osteoporosis osteoarthritis bone metastasis calcium antagonist osteoporosis parathyroid hormone agonist osteoporosis tyrosine kinase inhibitor psoriasis pde inhibitor topical atopic dermatitis corticotrophin release factor crf antagonistirritable bowel syndrome depression anxiety dutasteride testosterone alpha reductase inhibitor testosterone hypogonadism fix dose combination solabegron beta adrenergic agonist overactive bladder type diabete endothelial cell adhesion molecule inhibitor inflammatory bowel disease selective inos inhibitor rheumatoid arthritis migraine kinase inhibitor rheumatoid arthritis atherosclerosis copd dual alpha integrin antagonist vla inflammatory bowel disease multiple sclerosis kinase inhibitor oral rheumatoid arthritis atherosclerosis copd casopitant antagonist overactive bladder depression anxiety chemotherapy induce postoperative nausea vomit mepolizumab antiil monoclonal antibody eosinophilic esophagitis asthma nasal polyposis rosiglitazone ppar gamma agonist rheumatoid arthritis alzheimer disease avodart alpha blocker alpha reductase inhibitor alpha blocker benign prostatic hyperplasia fix dose combination iii avodart alpha reductase inhibitor reduction risk prostate cancer iii enteregentrareg peripheral muopioid antagonist opioid induce symptom iii mepolizumab antiil monoclonal antibody hypereosinophilic syndromealso asthma nasal polyposisiii enteregentrareg peripheral muopioid antagonist post operative ileus approvable aljul bonivabonviva bisphosphonate treatment postmenopausal osteoporosis approve sapr ajan ivinjection gsk annual report srotcerid eht troper description businessbuild good product pipeline industry continue gsk annual report srotcerid eht troper description business estimate filing date compoundproduct type indication phase maa nda neuroscience presynaptic mix antagonist depression anxiety histamine antagonist dementia endothelin antagonist stroke gap junction blocker migraine epilepsy neuropathic pain dualacte cox inhibitor acute chronic pain condition include neuropathic pain schizophrenia endothelin antagonist stroke antagonist depression anxiety noncannabinoid agonist inflammatory pain crf antagonist depression anxiety irritable bowel syndrome radafaxine noradrenalinedopamine reuptake inhibitor fibromyalgia neuropathic pain obesity selective ino inhibitor migraine rheumatoid arthritis triple htnoradrenalinedopamine reuptake depression attention deficit hyperactivity disorder inhibitor glycine antagonist smoking cessation dual alpha integrin antagonist vla multiple sclerosis inflammatory bowel disease transient receptor potential vanilloid acute migraine trpv antagonist antagonist dementia mix htdopaminergic antagonist schizophrenia casopitant antagonist depression anxiety overactive bladder chemotherapy induce postoperative nausea vomit radafaxine noradrenalinedopamine reuptake inhibitor depression obesity rosiglitazone ppar gamma agonist alzheimer disease rheumatoid arthritis talnetant antagonist schizophrenia vestipitant paroxetine antagonist selective serotonin reuptake depression anxiety inhibitor dualacte cox inhibitor acute chronic pain iii lamictal sodium channel inhibitor bipolar disorder acute treatment iii lamictal sodium channel inhibitor epilepsy oncedaily iii requipextende release nonergot dopamine agonist restless leg syndrome iii requipmodutabxl nonergot dopamine agonist parkinson disease oncedaily control release submit sdec hour formulation trexima agonist naproxen migraine fix dose combination submit saug wellbutrin noradrenalinedopamine reuptake inhibitor seasonal affective disorder submit sdec wellbutrin noradrenalinedopamine reuptake inhibitor depression approve aaug oncology thrombopoietin agonist thrombocytopaenia kinesin spindle protein ksp inhibitor cancer elacridar oral bioenhancer cancer relacatib cathepsin inhibitor bone metastasis osteoporosis osteoarthritis casopitant antagonist postoperative nausea vomiting overactive bladder depression anxiety casopitant antagonist chemotherapy induce nausea vomiting overactive bladder depression anxiety ethynylcytidine selective rna polymerase inhibitor solid tumours iboctadekin recombinant human immunomodulator immunologicallysensitive cancer melanoma renal cell ispinesib ksp inhibitor nonsmall cell lung cancer tumour pazopanib vascular endothelial growth factor vegf solid tumours tyrosine kinase inhibitor vestipitant antagonist postoperative nausea vomit eltrombopag thrombopoietin agonist thrombocytopaenia iii hycamtin topoisomerase inhibitor ovarian cancer firstline therapy iii hycamtin topoisomerase inhibitor small cell lung cancer secondline therapy oral formulationiii tykerbtycerb erbb epidermal growth factor receptor breast cancer renalhead neck cancer iii egfr dual kinase inhibitor hycamtin topoisomerase inhibitor cervical cancer secondline therapy submit sdec arranon guanine arabinoside prodrug acute lymphoblastic leukaemia lymphomas approve aoct hycamtin topoisomerase inhibitor small cell lung cancer secondline therapy approve ajan anovbuild good product pipeline industry continue gsk annual report srotcerid eht troper description business estimate filing date compoundproduct type indication phase maa nda respiratory pde inhibitor inhale asthma copd allergic rhinitis muscarinic acetylcholine antagonist copd kinase inhibitor oral copd atherosclerosis rheumatoid arthritis novel glucocorticoid agonist asthma muscarinic antagonist beta agonist copd longacte beta agonist copd copd asthma combination glucocorticoid agonist longacting beta agonist copd copd asthma combination glucocorticoid agonist muscarinic acetylcholine antagonist copd longacting beta agonist copd copd asthma combination glucocorticoid agonist longacting beta agonist copd copd asthma combination glucocorticoid agonist longacting beta agonist copd copd asthma combination glucocorticoid agonist kinase inhibitor oral copd rheumatoid arthritis atherosclerosis glucocorticoid agonist asthma copd combination longacting beta agonist allergic rhinitis glucocorticoid agonist asthma copd combination longacting beta agonist mepolizumab antiil monoclonal antibody asthma nasal polyposis hypereosinophilic syndrome eosinophilic esophagitis avamysallermist glucocorticoid agonist allergic rhinitis iii seretideadvair beta agonistinhale corticosteroid copd mortality claim iii seretide beta agonistinhale corticosteroid asthma initial maintenance therapy submit saug ariflo pde inhibitor oral copd approvable aloct seretideadvair beta agonistinhale corticosteroid asthma noncfc inhaler approve ajun aloct oct paediatric vaccine hibmencytt conjugate neisseria meningitis group disease haemophilus influenzae type disease prophylaxis menacwytt conjugate neisseria meningitis group disease prophylaxis globorix conjugate diptheria tetanus pertussis hepatitis haemophilus lll influenzae type disease neisseria meningitis group disease prophylaxis streptorix conjugate spneumoniae disease prophylaxis child lll priorixtetra live attenuate measle mump rubella varicella prophylaxis submit sapr rotarix live attenuate oral rotavirus induce gastroenteritis prophylaxis submit sdec menitorix conjugate neisseria meningitis group diseasehaemophilus approve adec influenzae type disease prophylaxis vaccine hiv recombinant hiv infection prophylaxis pneumoniae elderly recombinant pneumoniae disease prophylaxis pneumoniae paediatric recombinant pneumoniae disease prophylaxis pgcvax varicella zostervirus recombinant varicella zoster prevention tuberculosis recombinant tuberculosis prophylaxis iii dengue fever attenuate tetravalent vaccine dengue fever prophylaxis epsteinbarr virus recombinant ebv infection prophylaxis flu improve inactivated splitadjuvanted influenza prophylaxis flu intranasal fluinsure inactivate splitadjuvanted influenza prophylaxis hepatitis virus recombinant hepatitis prophylaxis mosquirix recombinant malaria prophylaxis cervarix recombinant human papilloma virus infection prophylaxis lll fluviral inactivate split influenza prophylaxis lll simplirix recombinant genital herpe prophylaxis lll flu pandemic inactivate wholealuminium salt adjuvant influenza prophylaxis submit sdec pharmaccine recombinant treatment prostate cancer recombinant treatment breast cancer lii mage recombinant treatment nonsmall cell lung cancer melanoma llachieve commercial operational excellence gskundertake range activity maximise commercial consumerhealthcare marketing excellence potential intellectual property introduce innovative product structure ofthisbusiness redesign order focus market possible accelerate processof bring brand growth opportunity brand new product market increase brand recognition ensure sale multiple marketsa new team call future group patient access new medicine pharmaceutical create develop global approach support global consumer healthcare business focus way improve brand brand large market exist performance commercial operational excellence territory generally lead marketone anchor market initiativessome team lead development lead market brand remain valuable localbrand managedthrougha new modelwhich worldwide pharmaceutical sale force excellence retain local responsibility brand communication gskssale force rank high survey healthcare innovation local enterprise brand support globally professional worldwide sale force excellence wsfe aims regionally ensure application good practice cross improve customer satisfaction pollination innovation time available physician learn new medicine maintain high standard clinical study precious wsfe initiative sale gsk expect employee meet high ethical standard aspect representative strengthen product knowledge learn deliver business conduct activity honesty integrity patientspecific treatment option efficiently adhere corporate responsibility principle comply effectively research show sale visit highly effective applicable law regulation gsk audits operation ensure representative engage physician dialogue patient type relevant standard expect marketing practice support message visual aid illustrate clinical result reach exceed group introduce single global sale model focus commitment gsk code conduct reinforce year treat patient dialogue gsk senior management certification programme medicine appropriate effective administer manager certify complied performance safelyall field people group key market train integrity principle new approach entire sale organisation isnow involvedin wsfe bring cultural change patient advocacy raise ethical standard helps build longterm trusting patient advocacy initiative demonstrate significant progress relationship healthcare community inception rationale strategy centre enhance access group medicine connect pharmaceutical marketing excellence patient group ensure informed disease treatment large number patient suffer effect disease improvinggsksreputation patientcentric group continue unable benefit innovative medicine treatment gsk goal provide accurate balanced initially launch usprogramme itisnowa critical initiative information group product allow people strategic plan world patientadvocacy team possible benefit gsk medical advance example usa europe share good practice establish process europe patient suffer chronic obstructive optimise interaction patient group patientadvocacy pulmonary diseasecopdare diagnose leader summit hold usa europe canada receive regular maintenance drug therapy gsk marketing initiative patient advocate attend gsk sponsor meeting implement programme overcome barrier proper diagnosis world diabetes summit hold minority treatment programme begin effect legislative group usa hope develop base societal cost disease decrease extent gsk product future legislation awareness activity choose patient treatment group benefit vision factory marketing code gsk introduce vision factory initiative global manufacturing gsk commit ethical responsible patientcentred supply identify improvement productivity cost marketing group pharmaceutical marketing promotional reduction increase operational excellence activity policy govern marketing activity apply manufacturing operation ensure product quality patient safety employee supplier contractor agent policy require paramount marketing promotional activity base valid procurement scientific evidence comply applicable law regulation gsknonproduction operation support number policy support regional marketing practice code party purchase worldwide cover area include medium europe gsk international region japan usa codes travel itand marketing purchase manage apply ethical standard reflect difference market procurement behalf internal customer cover structure national healthcare system regulation assurance supply service quality cost innovation widely incorporate principle industry code practice recognise industry analyst global good practice leader european federation pharmaceutical industry association procurement work collaboratively business develop international federation pharmaceutical manufacturer association implement source strategy ensure gsk receive good value japan pharmaceutical manufacturers association pharmaceutical buying good service research manufacturers america marketing code gsk annual report srotcerid eht troper description businessimprove access medicine access healthcare develop world achieve sustainable progress occur significant barrier stand way well access access healthcare develop country remain major healthcare tackle share responsibility sector global challenge global community problem root society government international agency charitie academic poverty lack political continue demand significant institution pharmaceutical industry mobilisation resource true spirit partnership gsk continue play vital role commitment access medicine thedevelope world disease particularly prevalent develop world programme preferential pricing antiretroviral arvs anti programmes usa malarial vaccine community investment gski work provide meaningful access medicine people programme willingness seek innovative solution limit financial resource prescription drug voluntary licencing arrangement insurance gsk uspatient assistance program provide million worth medicinesvalued wholesale acquisition cost preferential pricing programme toqualifye low income resident gsk offer vaccine key organisation vaccination programme develop country preferential price uninsure americans qualify medicare year group set single notforprofit price medicaid gsk pharmaceutical company create arvs antimalarial wide range customer access programme qualified individual offer develop country definition subsaharan africa reduction usual pharmacy cost onmore medicine country coordinating mechanismproject fullyfunde launch rxaccess global fund fight aid malaria cardholders whosave millionin president emergency plan aid relief pepfar gsk participate partnership prescription assistance ppa gsk commit contribute health improvement large nationalprogrammededicated help people need sustainable manner price arvs antimalarial access prescription medicinesppa match million set level profit direct cost patient need program provide significant help gsk cover allow supply sustain long require pharmaceutical company launch program gsk ship develop country overmillion partnership healthcare physician patient advocacy tablet preferentiallyprice combivirand million tablet organisation preferentiallyprice epivir programme country offer notforprofit price require sustainable framework group introduce orange card provide discount combine gsk commitment preferential pricing certain gsk prescription medicine eligible patient bulgaria commitment government develop world avoid lithuaniaand ukraine nature discount vary price referencing preferentially price medicine help country depend need patient way prevent product diversion gsk take step minimise healthcare system operate threat diversion retrovir syrup epivirsolutioncombivir epivir prepare flu pandemic tablet trizivirare available special access pack group commit support country differentiate red oppose traditional government health authority world plan white combivir epivir tablet register response possible global influenza pandemic gsk number international market gsk company company submit mockup dossier emea apply register arvs european union antidiversion pandemic influenza vaccine marketing authorisation regulation continue encourage allow accelerate final registration pandemic country necessary step ensure introduction declare gskis develop prototype pandemic strict enforcement appropriate antidiversion measure vaccine clinical trial testing vaccine flu innovative solution strain take place increase performance gsk show industry leadership grant voluntary licence prototype pandemic vaccine gsk develop innovative seven generic company manufacture supply arvs adjuvant allow loweramount antigento public private sector subsaharan africa essential formanufacture large number dosesin event pandemic look ahead gskwill continue build product pricing partnership commitment help improve healthcare develop world significant increase fund global community need important maintain incentive protection intellectual property gsk annual report srotcerid eht troper description businessbe good place good people well work glaxosmithkline people group commit employment policy free discrimination potential exist staff ground glaxosmithkline commit create good place good age race ethnic national origin gender sexual orientation faith people good work deliver group business strategy disability gsk commit offer people disability group employ people country access range recruitment career opportunitiesevery recruitment talent management leadership effort retain support employee disabled development working group attract good people industry critical enhance communication employee involvement sustain gsk performance group recruiter usaand good internal communication important achieving gsk business arefocussedon proactive identification talente external objective create open inclusive work environment candidate key job act internal headhunting function range communication channel employee annual performance development planning pdp process uptodate gsk news enable feedback ensure employee set objective align corporate include strategy set behavioural goalsand create development plan pdps mygsk global intranet site provide news update review year culminate end year section employee question directly chief review factor compensation decision executive officer senior executive question annual talent management cycle identify highest performing answer month news section gsk people business function individual give feedback intranet give group position important issue link development need key talent develop press story gsk exceptional management leadership programme detail spirit gsk internal magazine reach employee group corporate responsibility report exposure world time year management programme chief executive forum confidential feedback mechanism enable employee raise stretch assignment pool successor identify concern include gsk integrity helpline vicepresident position critical role organisation group conduct global leadership survey gls year performance reward gls conduct reward system design support culture high manager gauge opinion critical issue culture performance attract retain good people performance confidence group future result show significant base pay share award share option align employee interest improvement item compare result accomplishment business target compare global benchmark manager rate highly foster alignment personal goal glaxosmithkline mission business ethic reputation foster environment ethic integrity survey performance integrity central operating gsk manager proud glaxosmithkline recent global leadership survey show believe gladly refer friend family member work gsk people department commitment performance integrity enhance manager leader skill programme leadership survey business areasconduct survey ethical decisionmake run attend bypeople employee gauge level engagement satisfaction training area plan motivation business function develop action plan address area improvement base result gls pdp process include assessment employee survey implement gsk spirit principle define group culture significant impact bonus payment group consult employee change affect potentially reduce zero employee find discuss development business european follow spirit affect future career development employee forum similar committee incountrieswhere way group hold employee accountable deliver nationalpractice performance high standard integrity protect enhance health wellbeing gsk reputation healthy employee healthy way work contribute togsk diversity sustain performance global policy employee health gsk diversity initiative focus improve performance support mandatory standard integrate employee health respond diverse need employee customersand external safety environmental requirement standard stakeholder annual multicultural marketing diversity apply group facility operation worldwide awards entrants usa continental europe commitment flexible working flexitime tele highlight innovative activity demonstrate business impact conference remote working flexible work schedule recognise global management population wasmaleand employee work good environment help integrate female detail diversity measure work personal livesdure group employee employment practice section corporate responsibility report health management function personnel todaysmanage health work awardin recognition impact promote healthy workplace gsk annual report srotcerid eht troper description businessglobal manufacturing supply gsk large portfolio product range tablet new product global supply toothpaste inhaler complex capsule different new product global supply focus ensure pack size presentation appropriate technical competency exist support rapid successful new product introduction work closely rd manufacture medicine begin development development team ensure secure supply key therapeutic active ingredient bulk active select formulation brand sell market global distribution global manufacturing supply gms develop manufacturing division focal point develop introduce new process scale volume production active compound secondary manufacturing technology gmsit coordinate primary manufacturing site convert active compound primary supply operation ensure alignment finished dosage formulation responsibility secondary division value stream approach introduce new manufacturing site product site country new product gms operate single global network site country global supply year gms produce tonne bulk active operational excellence billion pack package deliver sale gmsha develop set measure uniform way working country world support drive business improvement activity mainly focus new product line extension launch year increase quality product supply customer extensive adopt lead edge practice develop people gms leadership education carry reinforce culture expect derive benefit continuous improvement staff involve solve problem rigorous control structured way provide secure source supply high quality product capability improve significantly performance accelerate compliance regulatory requirement customer expectation delivery benefit manufacture network good class cost formation gsk merger rationalisation operational organisation excellence initiative reduce number manufacture site supply division foursupply division site group base external supplier common business driver area expertise commercial manufacturing spend billion external supplier activity support division describe year include purchase active ingredient chemical intermediatesandpartfinished finished product gms take primary supply andantibiotic appropriate step protect supply chain disruption primary supply antibiotic focus ensure supply high result interrupt external supply appropriate stock quality competitively price bulk active drive level contract alternative register supplier improvement primary technology process support delivery maximum value antibiotic franchise vaccine supply chain combine primary secondary approach cost competitive europe vaccine manufacturing locate primarily rixensart supply response market opportunity customer need wavre belgium site france germany site country primary supply andantibiotic hungary gsk strengthen global production network north america major acquisition base corixa consumer healthcare supply corporation produce important component consumer healthcare supply focus deliver high quality gsk vaccine development vaccine production site competitivelyproduce product offer capability rapid marietta pennsylvania biomedical flu vaccine new product introduction highly innovative competitive manufacturing facility canada asia new vaccine production business far short time frame pharmaceutical facility build india singapore gsk vaccine division new technology fundamental platform lower hastwo joint venture china russiamanage vaccine cost provide flexibility operation site supply chain involve anticipate market need flexible country consumer healthcare supply approach able meet fluctuation demand base regional pharma supply forecast different market firm order health regional pharma supply focus key activity supply authority mass vaccination campaign product key region supply product bulk filling packaging carefully balanced stocking important particular market tailor vaccine help manage shortterm increase demand packaging meet specific local requirement key focus increasesresult fromdisease outbreak increase demand regional pharma supply team reduce cost gsk public owing disease awareness campaign compete effectively market site country regional pharma supply gsk annual report srotcerid eht troper description businesscorporate responsibility community investment commit corporate responsibility gsk contribute million continue corporate programme charitable activity support gsk commit connect business decision ethical social organisation health medical research science education art environmental concern corporate responsibility environment addition group company integral embed way gsk business provide million charitablepurpose gsk publish set corporate responsibilityprinciple corporate programme north america focus improve provide guidance standard group commit public education access well healthcare child set approach area standard ethical conduct senior fund ofalmost millionin additionthe group research innovation product customer access usbased business donatedmillionto regional community medicine employment practice human right community activity investment care environment leadership advocacy engagement stakeholder groupreport annually gsk operate single charitable foundation community progress uphold principle corporate responsibility investment programme number country base report available website wwwgskcom foundation grant foundation include investment total partnership success gsk work partner underserved communities global health programme develop develop world support programme eliminate lymphatic filariasis innovative sustainable bring real benefit group effort help rid world disable disease community group engage numerous external lymphatic filariasis continue close partnership stakeholder fund communityle initiative world government ofcountrieswhere disease endemic donate medicine support humanitarian effort community partner organisation gsk commit donate base healthcare antiparasitic drug albendazole require treat billion people risk country community investment million albendazole treatment worth million wholesale gsk global community investment activity value acquisition cost donate country global million equivalent group profit tax elimination programme start cumulative total comprise product donation million cash give million albendazole treatment donate million inkind donation million cost programme reach million people million manage deliver community programme gsk open new million manufacturing facility cape town country south africa produce albendazole product donation cash giving follow positive action hivaid positive action gsk pioneer global programme work productdonation community affect aid start support communitybased organisation deliver effective hiv aids education prevention healthcare service positive action work partner support programme country programme support participation community involvement regional international aids conference glaxosmithkline african malaria partnership partnership support behavioural gsk cash giving target primarily health education development programme work african country initiative programme target nearly million people focus particularly young child pregnant woman encourage breakdown cash give effective prevention measure prompt treatment antenatal malaria management extend programme group announce threeyear grant malaria consortium new initiative mobilise malaria increase sustained advocacy activity europe african country programme aim increase awareness malaria mobilise resource gsk annual report srotcerid eht troper description business patient assistance program million albendazole million humanitarian product donation million health education art culture environment corporate responsibility community investment continue phase education initiative phase initiative personal hygiene sanitation education gsk effort improve public science education include initiate gsk provide education thousand threeyear grant national board professional school child kenya ugandazambia nicaragua peru teaching standard increase number science teacher improve health hygiene fight infectious disease pursue certification north carolina philadelphia area group commit year funding gsk lead group company come extend programme bangladesh partnership save create business education network ben ben new children usa business coalition staff center corporate citizenship humanitarian product donation chamber commerce dedicated harnessing gsk donate essential productssuch antibiotic power business community address issue face nonprofit partner include americare map international education system project hope support humanitarian relief effort gsk continue support innovative scheme postdoc community healthcare december medicine donate research education inspire develop partnership groupwere ship support south asia imperial college london specialist schools academie tsunamirelief effort gsk continue donate life trust million donation year inspire place save medicine tsunamiaffecte country affect postdoctoral researcher specialist science school assist disaster include hurricane usa science teach total value group international humanitarian science summer free librarybase science education product donation wasmillion exclude albendazole donate programme philadelphia area teach basic scientific concept group commitment lymphatic filariasis continue receive support grant science elimination programme product donation value wholesale worldisan awardwinninginternational education programme acquisition cost wholesale list price include use webbase resource promote discussion science issue discount standard industry method teacher child school community initiative country grant gsk dedicate strengthen fabric community bringinggsk total contribution programmeto live work provide health education initiative year support local civic cultural institution improve employee involvement quality life gsk employee encourage contribute local gsk contribution improve healthcare include new grant community employee volunteer scheme support million year children health fund expand varie world include employee time cash referral management initiative rmi site philadelphia donation charity employee volunteer matching include delaware valley community health center rmi gift programme ensure continuity specialistmedical care highrisk children usa group match thanemployee homeless retiree gift value ofovermillion group match annual impact award recognise excellence work non million employee donation gsk annual profit community health organisation united way campaign gsk program provide grant great philadelphia area usa charity receive organisation employee unrestricted award work deal diverse issue volunteer domestic community violence sexual health service young gsk make difference programme provide grant peopleand bereavement counselling service nonprofit organisationsandregistere medical research provide charity base employee involvement medical charity alzheimer research trust british liver trust meningitis samantha dickson research trust childhood brain tumour gsk support art group sponsor popular garden glass chihuly kew innovative exhibition work dale chihuly contemporary glass artist royal botanic gardens kewnearlondon gsk annual report srotcerid eht troper description businessproduct competition pharmaceutical product antiviral combivir combination retrovirand epivir consolidated glaxosmithkline principal pharmaceutical product currently position reverse transcriptase inhibitor direct therapeutic area analysis sale cornerstone multiple antihiv product regimen physician therapeutic area description principal product acceptance clearly demonstrate value place minimise setout pill burden face patient ziagenis reverse transcriptase inhibitor product potency ease turnover therapeutic area use resistance profile allow play significant role respiratory variety highly active tolerate andsimplified hiv treatment central nervous system regimen antiviral antibacterialsantimalarial triziviris combination combivirand ziagen combine anti metabolic hiv therapie tablet twice daily administration vaccine epzicomkivexa approve use usa europe oncology emesis combination epivirand ziagenthat take tablet cardiovascular urogenital oncedaily dose hivaid combination antihiv drug lexivatelziris protease inhibitor treatment hivthat tolerate convenient agenerase sale werehigher cer termsand sterling term supersede lexiva take twice daily daily boost ritonavir product formulation approve zeffixhas approve marketing usa europe china indications market available market treatment chronic hepatitis respiratory valtrexis treatment episodic genital herpe long seretideadvair combination sereventand flixotide offer term suppression reduction transmission genital herpe act bronchodilator antiinflammatory single inhaler zoster shingle cold sore chicken pox valtrex supersede approve treatment asthma copd zovirax treat herpe infection flixotidefloventand becotidebecloventare inhale steroid antibacterial antimalarial treatment inflammation associated asthma copd augmentinis broadspectrum antibiotic suitable treatment sereventis longacte bronchodilator treat asthma wide range common bacterial infection particularly copd ventolinis selective shortacting bronchodilator effective respiratory tract infection augmentin esis treat bronchospasm extra strength suspension specifically design treat child recurrent persistent middle ear infections augmentin xris extra flixonaseflonaseand beconaseare steriod intranasal preparation strength tablet form adult combat difficult treat infection treatment perennial seasonal rhinitis zinnatis oral antibiotic primarily communityacquire central nervous system cns infection lower respiratory tract seroxatpaxilis selective serotonin reuptake inhibitor ssri treatment depression panic obsessive compulsive disorder post malarone oral antimalarial treatment traumatic stress disorder social anxiety disorder premenstrual prophylaxis malaria cause plasmodium falciparum dysphoric disorderand generalise anxiety disorder lapdapi effective tolerate therapy treatment wellbutrin antidepressant available usa malaria develop publicprivate international market normal sustainedrelease daily collaboration formulation imigranimitrexis receptor agonist treatment ofsevere frequent migraine cluster headacheand reference product sector naramigamergeis new migraine product lamictal establish treatment epilepsy indicate bipolar disorder requipi specific dopamine receptor agonist indicate treatment ofparkinson disease approve product restless leg syndrome rls gsk annual report srotcerid eht troper description businessproduct competition continue metabolic oncology emesis avandia potent insulin sensitise agent act zofran prevent nausea vomiting associate underlie pathophysiology type diabete chemotherapy radiotherapy cancer available bothoral injectable form approve use avandametis combination avandiaand metformin hci prevention treatment postoperative nausea vomit medicine target insulin resistance decrease glucose production convenient pill hycamtini second line treatment ovarian cancer forsmall cell lung cancer avandarylis fixeddose combination avandiaand amaryl sanofiaventis product bexxar treatment patient follicular non hodgkin lymphoma transformation bonvivaboniva oncemonthly oral bisphosphonate disease refractory rituximab relapse follow treatment osteoporosis launch usa chemotherapy market cardiovascular urogenital vaccine coregis alphabeta blocker prove effective gsk market vaccine worldwide gsk hepatitis vaccine intreate patient mild moderate severe heart failure heart range havrix protect hepatitis engerixb attack hypertension gsk sole marketing right usa hepatitis canada generic version product available canada twinrixis available combine hepatitis vaccine levitrais pde inhibitor indicate male erectile dysfunction protecting disease vaccine available gsk copromotion right usa adult paediatric strength gsk receive european market approval fendrix vaccine prevent hepatitis patient renal insufficiency include highrisk group pre avodartis ari inhibitor currently indicate benign prostatic haemodialysis haemodialysis patient year age hyperplasia large clinical outcome study underway examining onwards efficacy prevention prostate cancer fluarixis indicate prevention certain type influenza arixtra fraxiparine acquire distribute country approve usa divestitures require merger sanofiand aventis fluarixi vaccine receive fda approval agencys arixtra selective factor inhibitor indicate prophylaxis accelerate approval regulation deep vein thrombosis lead pulmonary embolism infanrixis gsk range paediatric vaccine combination infanrix hip fracture surgery knee replacement hip replacement surgeryand provide protection diphtheria tetanus pertussis abdominal surgery indicate treatment deep vein whooping cough infanrix pentapediarix provide additional thrombosis pulmonary embolism protection hepatitis polio infanrix hexafurther fraxiparine lowmolecular weight heparin indicate add protection haemophilus influenzae type prophylaxis thromboembolic disorder particularly deep vein cause meningitis gsk launch boostrixin usa thrombosis pulmonary embolism general surgery vaccine add protection pertussis whooping cough orthopedic surgery treatment deep vein thrombosis routine tetanusdiptheria booster administer teenager prevention clotting hemodialysis gsk market priorix measle mumps rubella vaccine integrilin iibiiia inhibitor approve typherix vaccine protection typhoid fever varilrix prevention early myocardial infarction patient unstable vaccine varicella chicken pox addition group angina nonqwave market range vaccine prevent meningitis umbrella mencevax gsk recently receive approval new hibmenc vaccine menitorix gsk meningitis category include betnovate thehigher potency dermovateand vaccine portfolio wil compliment new meningitis conjugate new cutivate antiinflammatory steroid product vaccine near future treat skin disease sucha eczema psoriasis relafen nonsteroidal antiinflammatory drug treatment arthritis paediatric franchise gsk develop vaccine zantac treatment peptic ulcer disease range rotavirus induce gastroenteritis launch mexico ofgastric acid relate disorder rotarix license additional country worldwide number latin american country include brazil thephilippines singapore asian country gsk annual report srotcerid eht troper description businessproduct competition continue pharmaceutical competition antiviral gsk pioneer hiv market launch azt retrovir pharmaceutical industry highly competitive gsk principal epivirin today available combivirin single competitorsrange small tolarge international pharmaceutical tablet cornerstone hiv combination therapy launch company substantial resource company ziagen agenerase trizivir lexiva epzicom broaden major product mention thegroup portfolio hiv product major competitor hiv pharmaceutical subject competition product market include gilead bristol myers squibb abbott merck pfizer period patent protection patent valtrexha strengthen group position antiherpe area generic version manufacturer generic product typically gsk valtrex zovirax compete novartis famvir donot bear significant research development education valtrexis market leaderwhilst zoviraxface competition marketing development cost consequently areable offer generic acyclovir hepatitis market gsk zeffixwa product considerably low price thebrande competitor antiviral market gilead hepsera second group research development base pharmaceutical company secure marketing right hepserain key market normally seek achieve sufficiently high profit margin sale volume period patent protection repay original antibacterial antimalarial investment generally substantial fund research forthe generic version augmentinand ceftinzinnatare available future competition generic product generally occur patent usa augmentinalso face generic competition major market expire increasingly patent challenge prior european country augmentin augmentin compete patent expiry claim innovator patent valid andor broad range brand generic antibiotic infringe generic product follow loss patent malarone safety profile convenient dose regimen protection generic product rapidly capture large share helped product strong position versus mefloquine market particularly usa malaria prophylaxis gsk believe remain competitive dependent metabolic discovery development new product effective major competitor avandiais takeda chemical actos market exist product pharmaceutical industry copromote eli lilly usa introduction new product process competitor monthly bonivabonvivacompete merck weekly fosamax affect pricing level result change pattern product use proctor gamblesanofiaventiss weekly actonel generic fosamax assurance productswillnot outmoded alendronate available market canada notwithstanding patent trademark protection addition increase government pressure physician vaccine patient use generic pharmaceutical brandname vaccine market dominate key player gsk major medicine increase competition product long competitor include sanofipasteur merck wyeth protect patent hepatitis market engerixb havrix compete vaccine produce merck respectively comvax recombivax respiratory hepatitis vaqta avaxim hepatitis gsk respiratory franchise drive growth seretideadvair paediatric vaccine field infanrixsmain competitor sps range gain patient competitor product cannibalisation dtpabase combination vaccine infanrix hexa sereventand flixotideflovent major respiratory competitor combination available hexavalent paediatric combination singulair merck especially usa europe symbicort europe astrazeneca spiriva pfizer boehringer ingelheim oncology emesis cns disorder zofranpresently provide gsk leadership position anti major competitor usa paxilare generic form emetic market competitor company include roche sanofi generic fluoxetine generic form eli lillys prozac zoloft aventis recently mgi merck major competitor pfizer forest laboratory celexa lexapro effexor diverse cytotoxic market include bristol myers squibb sanofiaventis wyeth principal competitor usa wellbutrin pfizer novartis gsk cytotoxic portfolio lead hycamtin generic form bupropion generic form ssris effexor currently hold relatively small market position wyeth product paxil oncedaily wellbutrin xlhelp retain strong presence antidepressant market give cardiovascular urogenital availability generic paroxetine bupropion usa gsk markets coregin usa major competitor toprol generic competition seroxatpaxilha commence generic betablocker avodartcompete directly merck number market proscar bph market group copromotion rights usa levitra face competition pfizer viagra lillyicos cialis gsk annual report srotcerid eht troper description businessproduct competition continue consumer healthcare product oral care lead oral care product toothpaste mouthwashe glaxosmithkline principal consumer healthcare product aquafresh sensodyne macleansand odolbrand name major area analysis sale area isset range toothbrush sell aquafreshand good name addition denture care product available principally polident poligripand coregabrand name nutritional healthcare otc medicine oral care lead product category lucozadeglucose energy nutritional healthcare sport drink ribena blackcurrant juicebase drink rich vitamin horlick range milkbase malt food chocolate drink sale werehigher cer term high sterling consumer healthcare competition term gskhold lead global position key consumer product major productswhich necessarily sell marketsare area worldwide large oral care otc category product medicine nutritional healthcare hold lead position india ireland overthecounter medicine analgesic panadol environment consumer healthcare business dermatological zovirax operate challenging abreva consumer demand well quality well value improve gastrointestinal tum performance citrucel respiratory tract contac retailer consolidatedandglobalisedwhich hasstrengthened beecham negotiation power smoking control commit competitor find condition equally challenge nicorette compete aggressively element marketing nicoderm mix niquitin nicabate cycle times innovation reduce natural wellness support abtei main competitor include major international company oral care aquafresh colgatepalmolive johnson johnson pfizer procter gamble good unilever wyeth addition company maclean compete withgskin certain market odol odol med major competitor product otc medicine polident usa metamucil laxative pepcid indigestion private poligrip label smoking control product sensodyne lemsip cold remedy nurofen anadin analgesic nutritional healthcare lucozade nicorette nicotinell smoking control treatment ribena horlick oral care major competitor colgatepalmolive colgate procter gamble crest overthecounter medicine nutritional healthcare major competitor horlicksare ovaltine lead product panadol widely available paracetamol milo malt food chocolate drink competitor acetominophen analgesicnicorettegum usathe nicoderm ribena primarily local fruit juice product lucozade niquitin nicabaterange smoking control productstum compete energy drink calciumbase antacidcitrucellaxativecontacfor treatment coldsabtei natural medicine vitamin rangeand zovirax abrevafor treatment cold sore gsk annual report srotcerid eht troper description businessregulatory environment regulation pharmaceutical recent government healthcare reform country france spain germany restrict pricing reimbursement gsk operate highly regulate environment regional countryspecific law regulation define datum require usa recent legislation healthcare reform crossborder safety efficacy pharmaceutical product govern trade acceleration generic market increase patient testing approval manufacturing labelling marketing drug contribution increase focus pricing currently regulatory requirement major factor determine government price control private sector marketable product successfully develop purchase federal law require pharmaceutical manufacturer time expense associate development pay prescribe rebate certain drug order eligible reimbursement medicaid federal healthcare europe pharmaceutical firm regulator manage programme transition follow implementation new medicine legislation end significant change implement medicare number areasinclude approval procedure post market medicare program federally fund healthcare requirement manufacture control active ingredient insurance program benefit senior citizen certain disabled excipient label requirement pharmacovigilance processesand americans include coverage prescription medicine increase emphasis involvement availability information new benefit medicare program dramatic patient change program inception coverage voluntary include brandname generic drugsand open climate change continue expectation new million americans medicare coverage paediatric regulation finalise stimulate industry research paediatric indication intellectual property incentive number compete private organisation provide new benefit premium subsidise government benefit satisfy european medicine agency emea publish final minimum standard outline federal law law provide version road map strategic plan incentive manufacturer negotiate price withprivate plan additional driver change cover area new technology provide government price control government innovative development approach enhance provision provide additional help million peopleonmedicare agency advice development process limited income resource qualify beneficiaries usa safety issue prescription drug primary focus pay reduce premium deductible low copayment fda congressional oversight committee recent prescription withdrawal product market safety reason value money gsk work closely fda assess impact isincreasingly necessary demonstrate value money current development programme asin new product particularthe impact drug budget expenditure europe evaluation benefit risk continue important burden disease treatedmust apparent consideration approval new drug fda markets requirement satisfy healthcare purchaser fdahas introduce new focus call critical path initiative value money additional hurdle product intend tofacilitateinnovation drug development hopefully acceptance regulatory test ofsafety efficacy allow rapid development approval need quality delay bring effective improve medicine medicine initiative investigate use pharmacogenomic market reduce effective patent protection time surrogate marker efficacy thing manufacture innovation tool rapidly develop market especially usa europe produce safe effective drug unmet medical need difficult significantly improve therapy obtain pharmaceutical industry include gsk collaborate premium price exist medication valuebase pricing fda national institutes health number area difficult apply circumstance usa include use biomarker possible price product reflect value possible predict extent groupsbusiness new health information source launch affect future legislative regulatory development relate government include electronic labelling approve specific pharmaceutical product price prescription drug post day fda approval action immediate accessbyphysician patient gskis provide regulation consumer healthcare labellingto thefdafor product new electronic format new regulation fda implement mid consumer healthcare industry subject national regulation completely change format prescribing information usa testing approval manufacturing labelling marketing product country high standard technical appraisal gsk place manage effectively change external involve lengthy approval process new product launch regulatory environment national regulatory authorisation require approve switch price control product prescription otc requirement include long manycountrie price pharmaceutical product control term experience quality safety efficacy product law government influence price control wide patient population datum confirm relevant national healthcare organisation bear large condition selflimite easily diagnose consumer cost supply product consumer gsk annual report srotcerid eht troper description businessregulatory environment continue intellectual property paxilseroxat patent commercial form paroxetine expire cusa europe litigation relate intellectual property key business asset gsk effective legal validity infringement patent protect product protection intellectual property critical ensure reasonable ongoing usae generic competition commence return investment intellectual property protect usa europe certain market paxil cris protect patent trademark register design copyright domain formulation patent expire generic registration patent trademark right regard manufacturer apply fda approval generic form paxil particularly valuable assert noninfringement patente case generic manufacturer launch attempt launch requip patent ropinirole expire ausa generic version patent drug prior normal patent expiry beurope patent relate use ropinirole argue relevant patent invalid andor parkinson disease expire usa infringe product significant litigation concern europe litigation challenge validity patent ongoing challenge summarise noteto theffinancial statement usae legal proceeding retrovir patent zidovudine patent cover patent pharmaceutical formulation contain zidovudine medical gsk policy obtain patent protection significant product use expire usa expire europe discover develop activity patent protection new active ingredient available significant market seretideadvairthe patent specific combination salmeterol protection obtain new pharmaceutical formulation xinafoate fluticasone propionate expire manufacturing process new medical use special usa beurope application reissue patent device administer product file gskewith patent trademark office uspto january uspto issue final office action patent position respect active ingredient significant reject application gsk seek reconsideration product follow rejectione patent revoke ukcourt patent avandiaand avandamet patent rosiglitazone individual ingredient expire usa expire usa europe patents patent salmeterol xinafoate expire commercial form active ingredient rosiglitazone maleate sereventthe patent salmeterol xinafoate expire expire usa europe litigation usa europe patent expire france challenge validity patent protect product italy ongoing usae trizivir patent method treatment combination avodart patent dutasteride expire lamivudine zidovudine abacavir expire usa beurope usaand europe combivir patent specific combination lamivudine valtrex patent valaciclovir expire zidovudine expire usa beurope usa beurope litigation challenge validity coreg gsk exclusive licensee patent carvedilol patent protect product ongoing usae expire wellbutrin wellbutrin andzybanthe patent active epivir patent lamivudine expire ingredient expire generic competition usa beurope sustain release srand instant release form usa flixotidefloventand flixonaseflonase patent fluticasone europe regulatory datum exclusively provide protection propionate expire usa generic competition markets usa wellbutrin xlis protect formulation flixonaseexist euand fda recently approve generic patent expire litigation relate validity version flonasein usae infringement ofthese patent ongoing usae imigranimitrex patent sumatriptan expire ziagen patent abacavir expire acusa usa generally europe italy beurope litigation challenge validity patent protect product zofran patent ondansetron expire usa ongoing usae europe france italy patent use lamictal patent lamotrigine expire treat emesis expire litigation challenge validity usa litigation challenge validity patent usa emesis use patent ongoing usae settlede europe correspond patent expire generic competition exist include patent term restoration hatchwaxman act include extension term national european supplementary protection levitrad gsk copromotion right uspatent certificate include grant pende extension term paediatric exclusivity vardenafil expire usa register trademark bayer notetofinancial statement legal proceeding lexivatelzir gsk exclusive licensee patent fosamprenavir expire usa europe gsk annual report srotcerid eht troper description businessregulatory environment continue trademark eh management gsk pharmaceutical product protect registered gsk take systematic approach manage ehs risk impact trademark major market local variation framework information programme base global examplein usa trademark paxilis instead seroxat ehsstandard guide management key aspect impact advairis instead seretide risk organisation trademark protection generally extend long ehs audits trademark renew necessary gsk trademark governance responsibility gsk conduct ehs audits pharmaceutical product important maintain brand site assess performance ehsstandard identity product expiration patent assign quantitative performance score site audit achieve audit score well consumer healthcare trademark particularly important continuous improvement process progress business brand orientate product monitor action arise issue raise audits patent protection commitment corporate responsibility pro responsibility environment health safety active management gsk manufacture supply base supplier assess represent priority environment health safety ehsis key element corporate supplier process evaluate management key ehs risk responsibility group high priority responsibility impact human right issue base group eh high level corporate group reporting requirement priority supplier recommendation general counsel overall responsibility provide improvement need governance leadership ehs issue head group make regular report corporate executive team cet ehstarget audit corporate responsibility committee board ehs plan target set year director business operation manager end fiveyear target period target set responsible ehs support sitebase ehs environmental measure measure occupational health occupational health staff safety ehs strategy plan progress meet target track year gsk strategic planning process ehs look forward final datum show level achievement target year review year plan align gsk publish website wwwgskcom significant progress business driver include management performance achievingeightof ehs target measure target progress area plan progress outsourcing process contract particular success incorporate ehs selection manufacturer hazardous waste dispose proportion management contract manufacturer key supplier waste recycle target achievedthe target develop maintain open effective dialogue achieve product transfer facility external stakeholder provide ehsdata decision make appropriate recycling system place recycle system new product process ensure safety health maintenance new product come concern properly address gsk facility minimise risk manufacturing avoid disruption product supply areasforadditional gsk select measure performance improvement base focusare driver safety occupational chemical exposure machine potential adverse impact people environment business guard pharmaceutical environment patient excretion continuity business reputation measure select energy conservation use hazardous chemical similar report company recommend manufacture global reporting initiative longterm multistakeholder strategic focus international undertaking develop disseminate globally plan provide area special focus year applicable sustainability report guideline focus complete core programme programme sustainability essential prevent injury illness harm environment work eventual sustainability gsk address ensure continuity gsk business economic environmental social issue research manufacture common operating location operation different risk sale distribution medicine sustainability start different core need different core healthcare solution find continue sustainable programme programme complete solution manufacture sale consider improve management system place acceptable audit score acceptable operational efficiency new product futurethe ehs plan progress ehstarget excellence propose investigate use renewable resource need operate maintain programme monitor overall balance impact society environment performance continually look improvement progress group seek dialogue external stakeholder consider strategic focus area see audit score progress view develop approach sustainable development target information ehs programme performance find website gsk annual report srotcerid eht troper description businessgsk annual report srotcerid eht troper corporate governance section discuss glaxosmithkline management structure governance procedure contain company report disclosure corporate governance require combined code corporate governance financial reporting council combine code include require statement compliance company report compliance uslaw regulation apply board corporate executive team governance policy dialogue shareholder annual general meeting internal control framework committee report combine code law regulation gsk annual report srotcerid eht troper corporate governance continue board ronaldo schmitz aged appoint nonexecutive director schmitz sir christopher gent age nonexecutive director glaxo wellcome plc appoint june chairman sir christopher chief nonexecutive director legal general group plc member executive officer vodafone plc retirement july board directors rohm haas company cabot nonexecutive director lehman brothers holdings inc corporation member financial reporting councila senior adviser bain chairman advisory board reform lucy shapiro age appoint nonexecutive director shapiro jeanpierre garnier aged nonexecutive director smithkline beecham plc appoint chief executive officer garni ludwig professor cancer research department appoint executive director smithkline beecham plc developmental biology director beckman center chief executive officer april non molecular genetic medicine stanford university school executive director united technologies corporation member medicine nonexecutive director anacor pharmaceuticals board trustees eisenhower exchange fellowship inc hold phd molecular biology hold phd pharmacology university louis pasteur france mba stanford university usa tom swaan aged appoint january nonexecutive director swaan lawrence culp aged member manage board abn amro appoint july nonexecutive director culp chief financial officer december retire president chief executive officer danaher corporation prior board abnamroonst nonexecutive join danaher hold position accenture previously director financial service authority member board andersen consulting institute international finance chairman board sir crispin davis aged netherlands opera member board royal appoint july nonexecutive director sir crispin concertgebouw orchestra chief executive reed elsevi plc prior chief sir robert wilson age executive aegis group plc join guinness plc appoint november nonexecutive director sir robert member main board group manage nonexecutive chairman bggroup plc economist group director united distiller spend early career procter previously executive chairman rio tinto gamble tachi yamada aged julian heslop aged appoint january retire june chairman appoint april chief financial officer heslop join research development yamada nonexecutive director glaxo wellcome financial controller april january subsequently executive director smithkline beecham plc follow merger appoint senior vice president prior join smithkline beecham chairman operation controller prior join glaxo wellcome hold senior department internal medicine university michigan medical finance role grand metropolitan plc school physicianinchief university michigan medical sir deryck maughan aged center trustee rockefeller brothers fundand member appoint june nonexecutive director sir deryck advisory board quaker bioventures inc manage director kohlberg kravis roberts moncef slaoui aged chairman ceo citigroup international salomon chairman designate research development slaoui senior vice brothers inc nonexecutive director reuters group plcas president worldwide business development appoint serve board director carnegie hall lincoln board effect succeed center nyumedical center international advisory yamada chairman research developmentonst june board member british american business inc board member slaoui join gsk biological engineer ofthe trilateral commission serve vice chairman new development robust vaccine pipeline phd molecular york stock exchange biology immunology universit libre bruxelles sir ian prosser age appoint senior independent director sir ian director nonexecutive director smithkline beecham plc john coombe chief financial officer retire chairman chief executive bass plc ultimately board march chairman demerge intercontinental hotels group plc detail membership board committee find chairman world travel andtourism council page london stock exchange list advisory council nonexecutive deputy chairman plca nonexecutive director sara lee corporationanda member cbi president committeegsk annual report srotcerid eht troper corporate governance continue corporate executive team cet david pulman president global manufacturingandsupply garni pulman responsible global manufacturing supply chief executive officer organisation global procurement join glaxo chief executive officer garnier responsible responsible north american supply network manufacturing management group oversee operational aspect strategy logistic current appointment group include establish policy objective initiative direct longterm strategy chief executive david stout officer smithkline beecham join group president pharmaceutical operation stout responsible forallpharmaceutical vaccinesoperation rupert bondy worldwide include usa europe international japan senior vice president general counsel globalmanufacturingand supply join smithkline beecham bondy responsible legal matter group president uspharmaceutical current environmental health safety issue insurance security appointment january lawyer private practice join smithkline beecham chris viehbacher president uspharmaceutical ford calhoun viehbacher responsible pharmaceutical join chief information officer wellcome responsible gsk european calhoun responsible information technology global pharmaceutical business current appointmentin function enable key business process part group doctoral postdoctoral training microbiology andrew witty genetics biomathematic computer science join smith president pharmaceuticals europe kline french wittyisresponsible group pharmaceuticals operationsin europe join glaxo andwa senior vice president asia john clarke pacific current appointmentin president consumer healthcare clarkesucceededmrziegler president consumer healthcare tachi yamada january hejoined beecham progress chairman research development role australasia south africa far east japan canada yamada lead group complex business drug discovery ukfrom john president consumer development create new medicine research join healthcare europe appoint president futures group smithkline beecham nonexecutivedirectorand chairman pharmaceuticals marc dunoyer president pharmaceuticals japan jennie young dunoyer appoint president pharmaceutical japan march senior vice president corporate communication join group senior vice president community partnership regional director japan current appointment mrs young responsible group internal external communication image partnership global communities russell greig join glaxo wellcome director investor relation president pharmaceuticals international appoint current position greig lead pharmaceutical operation outside usa japan europe cover country join moncef slaoui group senior vice president worldwide business chairman designate research development development prior current appointment march slaoui succeed yamada chairman research developmentonst june join cet joined group inand currently senior vice president worldwide julian heslop business development chief financial officer heslop chief financial officer april head member finance function heslop responsible activity coombe retire chief financial officer march financial reporting control tax treasury investor relation ziegler retired head theconsumer healthcare business finance system internal audit real estate join glaxo january wellcome financial controller april ingram continue work parttime vice chairman dan phelan pharmaceutical act special advisor group senior vice president human resource attend cet meeting capacity phelan responsible benefit compensation recruitment organisation development leadership development succession plan human resource information system employee health management lawyer private practice join smith kline french corporate governance continue governance policy board appraise approve major financing investment contractual decision excess define threshold additionthe board corporate executive team board evaluate monitor performance group director list board page include board responsible group system corporate engage board meeting ceo executive governance ultimately accountable group activitie director member cet appropriate financial strategy financial performance operating performance gsk external issue material chief executive officer ceo responsible executive group prospect management group assist cet cet meet evaluate progress achievement group financial time year necessary member business objective annual plan responsibility list corporate executive team monitor report receive directly committee significant risk face group board comprise executive nonexecutive director whilst board consider nonexecutive director board overall responsibility succession plan independent character judgement determine ceo executive director board give ceo nonexecutive director shapiro consider broad authority operate business groupand ceo independent combine code shapiro accountable report board business performance consider independent remuneration cet member regular presentation board area receive group member glaxosmithkline responsibilityand board meet cet member scientific advisory board sir christopher gent appoint annual basis discuss collectively group strategy primary board deputy chairman determined board element induction process new nonexecutive director independent take chairmanship board undertake members cet nonexecutive director january accordance combine code encourage separate informal discussion exclude determination half discretion cetmember board independent nonexecutive director shapiro sir christopher gent hold position board committee board metsixtimes member attend independence require combine code follow board consider culp sir crispin davis sir deryck number meeting number hold whilst board member meeting attend maughan sir ian prosser schmitz swaanand sir robert sir christopher gent wilson independent accordance recommendation jpgarnier combined code heslop date publication majority yamada board member exclude chairman independent non culp executive director sir crispin davis sir deryck maughan sir christopher gent succeed sir christopher hogg january sir ian prosser chairman garnier ceo schmitz chairman lead board represent board ceo shapiro cet members necessary board meeting ceo sir robert wilson manage group implement strategy policy jcoombe adopt board chairman chairmen board committee communicate regularly ceo cet addition schedule meeting board meet member division responsibility role quorate basis ontwooccasion chairman ceo set writing agree board appear website business environment development sir ian prosser senior independent director sid ensure board keep uptodate important matter include legal governance regulatory development presentation regular basis external board process internal adviser board authority accountable shareholder ensure company appropriately manage achieve independent advice strategic objective set board discharge responsibility board recognise occasion annual programme meeting include director feel necessary independent legal andor approval overall budgetary planning business strategythe financial advice company expense agree board review companys internal control risk management procedure enable explain corporate policy approve governance structure code ethic governance section company website gsk annual report srotcerid eht tropercorporate governance continue indemnification director nomination committee qualify party indemnity provision define section nomination committee review structure size company act force benefit composition board appointment member director formerdirector hold office board cet make recommendation board appropriate committee monitor plan succession company secretary board senior management committee consist company secretary responsible board available entirely nonexecutive director majority individual director respect board procedure company independent meet year secretary simon bicknell appoint necessary nomination committee report give page barrister join group secretary board committees corporate responsibility committee corporate responsibility committee consist entirely non boardcommittee executive director provide boardlevel forum regular board establish number ofcommittee provide review external issue potential impact sufficient resource enable undertake duty executive group business oversight reputation director member audit remunerationnomination management committee responsible governance corporate responsibility committee invite oversight group worldwide donation community attend meeting director member corporate support committee meet formally time year administration transaction financial result committee necessary membership thesecommittee show table financial result committee corporate audit remuneration nomination responsibility financial result committee review approve behalf sir christopher gent board annual report form annual review culp convene annual general meeting sir crispin davis preliminary quarterly statement trading result director sir deryck maughan member committee quorum meeting sir ian prosser member quorate meeting include schmitz chairman chairman audit committee ceo shapiro chief financial officer cfo committee meet necessary swaan corporate administration transaction committee sir robert wilson corporate administration transaction committee review swaan succeed schmitz chairman audit committee approve matter connection administration group september business certain corporate transaction committee consist keyc chairmanm member directors cet members company secretary follow summary role term reference committee meet necessary committee current term reference eachcommittee evaluation board board committee director obtain company secretary corporate performance evaluation board committee governance section company website director undertake chairman audit committee implement collaboration committee chairmenwith audit committee review financial internal reporting support company secretary board consider review process system internal control management risk conclusionsatit meet december agree number external internal audit process committee propose minor improvement procedure operate methodology shareholder appointment external auditor senior independent nonexecutive director sir ian prosser directly responsible remuneration oversight work undertake performance evaluation chairman committee consist entirely independent nonexecutive discussion director exclude chairman director meet time year december necessary audit committee report page remuneration committee dialogue shareholder remuneration committee determine term service financial result announce quarterly remuneration executive director member cet assistance external independent advisor evaluate company report formally shareholder twice year make recommendation board overall executive halfyear fullyear result announce fullyear result remuneration policythe committee consist entirely independent include company annual report annual review nonexecutive director meet time year issue shareholder company halfyear result necessary information remuneration director give publish national newspaper shortly release ceo remuneration report pagestothe chairman cfo presentation fullyear result institutional investor company ceo responsible evaluating make analyst medium recommendation board remuneration non executive director gsk annual report srotcerid eht tropercorporate governance continue webcast teleconference release second donation political organisation political quarter result institutional investor analyst expenditure medium annual report annual review quarterly result agm shareholder authorise company available company website donation political organisation incur political expenditure provision political party annual general meeting agm take place london election referendum act year formal notification send shareholder month authority renew annually advance meeting business presentation company intend payment shareholder director able attend available formally donation political party normal meaning theagm informally question committee expression definition legislation political chairman ordinarily attend agm respond shareholder organisation wide extend body company question culp unable attend thecompany agm subsidiary wish support include concerned commitment resolution agm policy review law reform representation business decide poll require company article association community special interest group concerned result poll announce london stock exchange environment donation political post company website detail agm organisation group donation noneu set section annual general meetingsee political organisation total ensure nonexecutive director aware understand view major shareholder company donation usa board place process focus sectorspecific issue canada usa large recipient political donationsand general shareholder preference atitsmeete julythe board reflect political system candidate sponsor receive external review ofshareholder opinion solely donation individual ngos company ceo cfo maintain dialogue institutional shareholder party performance plan objective programme line law corporate donation gsk regular meeting federal level candidate political party state group investor relation department office london local level donation accept practice usa philadelphia act focal point contact investor major employer heavily regulate industry important year gsk engage fully political process donation way gsksupport candidate seek chairman meet regularly institutional investor hear environment appropriately reward highrisk highinvestment viewsand discuss issue mutual importance industry believe free market principle intellectual chairman remuneration committee meet major property right shareholder discuss executive remuneration policy non situation similar canadaand donation follow executive director include new appointee available meet guideline rest world donation rare major shareholder request low value company website give access current financial business gsk political action committee pac usa information group give political donation pac employee organisation share buyback programme allow employee contribute fund political donation atotal billion spend company buy employee decide recipient pac donation share cancellation hold treasury share total donate political organisation gsk billion spend programme cover purchase pac company share cancellation hold treasuryshare accordance authority give shareholder annual general meeting company agm agm hold wednesday company authorise purchase maximum queen elizabeth conference centre broad sanctuary ofmillion share million share represent westminster london swp business transact issue share capitalwere purchasedand hold treasury meeting include share noteto thefifnancial statement share capital receive adopt glaxosmithkline annual share premium account report exact time future purchase extent approve remuneration report repurchase share hold treasuryshare remuneration report page set cancel determine company dependent remuneration policy operate glaxosmithkline disclosure market condition factor director remuneration include require company act director remuneration report regulation resolution propose approve remuneration report gsk annual report srotcerid eht tropercorporate governance continue retirement election reelection director internal control framework rely follow drslaoui swaanhave beenappointeddirectorssince oversee report risk compliance issue agm offerthemselve election boardmr risk oversight compliance council rocc culp sir crispin davis schmitzwill retire offer rocc council senior executive authorise board reelection board article company article assist audit committee oversee risk management associationdr shapiro retire conclusion agm internal control activity group membership comprise offer reelection cetmember head department internal reappointment remuneration auditor control risk management audit compliance responsibility resolution propose reappoint pricewaterhousecoopers rocc meet regular basis review assess significant llp auditor authorise audit committee determine risk mitigation plan rocc respond group remuneration policy refer provide business unit special business framework risk management upward report significant company seek authority risk mitigation planning identification manager overall responsibility management give risk requirement donation political organisation incur political expenditure risk management compliance board rmcbs risk management compliance board rmcbs allotordinaryshare company establish major business unit membership director authority disapply preemption right comprise member senior executive team respective allotting newshare connection right issue business unit augment specialist appropriate rmcbs maximum current issue share capital oversee management risk consider important purchase ordinary share maximum respective business unit include risk designate current issue share capital significant glaxosmithkline increase number risk actively manage group internal control framework rmcb regularly report status significant risk board recognise responsibility present balanced rocc understandable assessment group position prospect compliance function structure accountability audit operate gsk follow number risk area specific standard meet exceed board accountability review approve adequacy requirement applicable law establish specialist audit effectiveness internal control operate group include compliance function example corporate environment financial operational compliance control risk management health safety global quality assurance worldwide regulatory board delegate responsibility review audit compliance assist dissemination implementation audit committee receive report individual identify standard committee report page responsibility corporate ethic compliance cec management cet implement board policy risk rocc support corporate ethic compliance control cet responsible identify approve department responsible support development monitoring enforce key policy heart implementation practice facilitate employee compliance group conduct business internal control framework include law group policy central direction resource allocation risk management key activity research development manufacturing marketing thrust group compliance effort diligence sale legal human resource information system financial preventing detect misconduct noncompliance law practice framework comprehensive planning regulation promote ethical behaviour compliance law system annual budget approve board result regulation corporate responsibility levelsand effective operating unit report monthly compare budget compliance system forecast prepare regularly year cec manage corporate compliance officer extensive financial control procedure selfassessment exercise report directly ceo corporate compliance officer chair risk activity review group internal auditor commercial rocc provide summary report roccs activity financial responsibility clearly delegate local group significant risk cet audit committee business unit support regional management structure regular basisthe corporate compliance officersdirect reporting principle design provide environment central leadership line audit committee provide mechanism bypassing couple local operating autonomy framework executive management need arise exercise accountability control group area potentially significant risk group attach importance clear principle procedure detail risk affect group seenoteto thefifnancial design achieve appropriate accountability control group statement legal proceeding risk factor pagesto policy risk management legal compliance mandate business unit establish process manage monitoring risk significant business group gsk annual report srotcerid eht tropercorporate governance continue effectiveness control accordingly boardchosenot nominate committee internal control framework operation member recent relevant financial experience define year review continue operate date combine code audit committee financial expert approval report system internal control design define bysarbanesoxley manage eliminate risk achieve business arrive conclusion board consider follow point objective provide reasonable absolute schmitz chairman committee april assurance material misstatement loss prior appointment nonexecutive director audit committee receive report area significant risk company nonexecutive director glaxo wellcome plc group relate internal control follow consideration serve audit committee schmitz report audit committee report annually board member executive board director deutsche bank effectiveness control control mitigate retired board charge eliminate risk addition area group investment banking schmitz member business necessary risk achieve satisfactory executive board director basf include return shareholder investment acquire cfo hold mba insead sir ian prosser new product business casesit group objective cfo later ceo bass plc member institute apply expertise prudent management charter accountant england wale sir robert wilson elimination risk director review relate company begin professional career economist chairman subsidiary extend material associated group plc hold senior management position rio tinto plc undertaking joint venture investment culminate appointment executive chairman retired board audit committee review assessment risk internal control framework operate sir deryck maughan appoint member committee glaxosmithkline consider effectiveness system january manage director kohlberg kravis internal control operation group year cover roberts kkr chairman kkr asia chairman report date approval board process ceo citigroup international vice chairman citigroup inc follow board review system internal control prior creation citigroup chairman cochief accord guidance internal control issue turnbull executive officer salomon smith barney chairman committee chief executive officer salomon brothers appoint swaanto thecommittee effect committee report january board determine recent audit committee report relevant financial experience accordance combine code come conclusion board pay particular attention audit committee role flow directly board oversight swaans role chief financial officer abn amro function authorise board investigate activity heretiredon december board consider term reference committee write term swaan audit committee financial experta define reference approved board committee sarbanesoxley report regularly board performance activity assign committee main responsibility include committee support company secretary attend review corporate accounting financial reporting process committee meeting available financial resource monitor integrity financial statement evaluate independent professional advice consider necessary system internal control management risk oversee meeting committee attend chairman ceo activity group compliance audit function cfo general counsel head global internal audit gia corporate overseeing compliance law regulation ethical code compliance officer external auditor practice committee oversight role require address regularly committee work structure programme relationship management internal external activity stand item committee require auditor understand monitor reporting relationship consider meet matter focus tier accountability committee receive regular coincide key event annual financial reporting cycle report member cet senior manager cover key compliance activity group include concern external auditor report committee critical manufacturing sale marketing ehs accounting policy practice company alternative accounting treatment discuss committee member bring considerable financial accounting management resultant conclusion external auditor experience committee work member past employ material write communication management ment experience finance accounting role comparable restriction access information experience corporate activity cfo report financial performance company respect board haddetermine combine technical financial accounting matter qualification experience committee member general counsel report material litigation take modus operandi give committee collectively financial expertise necessary discharge company secretary report corporate governance responsibility gsk annual report srotcerid eht tropercorporate governance continue head group compliance audit group thecommittee recommend board appointment report audit scope annual coverage audit resource sir deryck maughan audit committee january results audits conduct year schmitz remuneration committee mayin february corporate compliance officer report activity committee recommend board moncef undertaken rocc slaoui succeed yamada chairman researchdevelopment retirement company june company secretaryas chairman disclosure committee report matter affect quality timely disclosure addition committee recommend board schmitz financial material information board serve term year nonexecutivedirector public market shareholder enable committee remain chairman audit committee review clarity completeness disclosure september committee recommendation publish annual financial statement interim report quarterly board ralph horwitz appoint nonexecutive preliminary result announcement formal director follow announcement horwitzs appointment announcement relate financial performance prior potential conflict interest disclosedand horwitz decide release board appointment nonexecutive director company audit committee management internal auditor board work ensure quality company corporate recruiting nonexecutive director committee consider account financial reporting committee serve particular skill knowledge experience benefit board primary link board external internal auditor significantly appointment broad selection criterion facilitate necessary independence management focus achieve balance representation encourage external internal auditor communicate freely european market individual ceo regularly committee committee meet experience skill develop sector speciality collectively separately external auditor head particular focus place recruit newnonexecutive gia member management present director recent relevant financial expertise join audit committeeprofessional search agency engage specialise committee primary responsibility make recruitment high calibre nonexecutive director dossier recommendation shareholder appointment reappointment potentialnonexecutive appointee provide committee removal external auditor annually assess candidate shortlist interview consider relevant qualification expertise resource independence external qualification auditor effectiveness audit process customise induction process conduct new making assessment committee consider paper nonexecutive director focus particular experience detail relevant regulatory requirement relate external auditor take account different background process include evaluate report external auditor compliance meeting member cet senior executive visit requirement external auditor provide nonaudit particular operational facility group services committee ensure auditor objectivity independence safeguard policy require preapproval committee continue review succession audit committee service expenditure audit non plan senior executive positionsinclude ceo audit service set page chairman researchdevelopment guideline set company policy engage appointingnew executive director committee consider external auditor provide nonaudit service include ascertain skill knowledge experience require particular skill experience external auditor executive position committee consider potential external suitable supplier nonaudit service adequate safeguard internal candidate recommend board approve place objectivity independence audit new appointmentallnew director offer election compromise fee level relative annual audit fee company agm appointment announce publicly limit set committee committee meet session andtwiceon company wellestablishe policy include code quorate basisall member present meeting ethic available website helpline facility remuneration report report investigation unlawful conductno waiver remuneration report find pagesto code committee meet sessionfivetime andfivetime combined code quorate basis session attend member company comply code provision sir robert wilson unable attend meeting combine code follow nomination committee report bin designing scheme performancerelate remuneration nomination committee term reference include responsibility remuneration committee follow provision propose appointment board committee member schedule code item schedule state general committee recommendation board basic salary pensionable company position appointment ofmr swaanas anonexecutivedirector explain remuneration report pagesto gsk annual report srotcerid eht tropercorporate governance continue board satisfy member sarbanesoxley introduce requirement ceo audit committee recent relevant financial experience cfo complete formal certification confirm company position explain pagesee pagefor review annual report form position january base knowledge contain material misstatement chairman arrange chairman omission audit remuneration nomination committee available answer question agm alldirector attend base knowledge financial statement company position explain page financial information fairly present material respect financial condition result operation cash flow law regulation date period present annual report form number provision law regulation apply gsk company share quote new york stock responsible establish maintain disclosure exchange nyse form adss control procedure ensure material information known evaluated effectiveness nyse rule control procedure year end results general nyse rules permit company follow corporate evaluation contain annual report form governance practice instead ofthoseappliedin usa provide disclose annual report form change company explain significant variation explanation internal control financial reporting period cover ison company websitenyse rule come effect annual report form materially affect require company fileannualand interim write affirmation reasonably likely affect materially company internal concern audit committee company statement control financial report significant difference corporate governance disclose base recent evaluation sarbanesoxley act internal control financial report external auditor follow number corporate accounting scandal usa audit committee significant deficiency material congress pass sarbanesoxley actof sarbanesoxley weakness design operation internal control sarbanesoxley establish new standard corporate account financial reporting reasonably likely affect adversely ability company list usa company company ability record process summarise report corporate governance structurewasbelieve robust line financial information fraud regardless materiality good practice certain change necessary ensure involve person significant role company compliance sarbanesoxley internal control financial reporting recommend security exchange commission sec ceo cfo complete certification gsk establish disclosure committee committee report file sec group form ceo cfo audit committee chair company secretary member consist senior manager control procedure finance legal compliance corporate communication group carry evaluation supervision investor relation participation group management include ceo cfo effectiveness design operation external legal counsel external auditor invite attend group disclosure control procedure december meeting periodically responsibility consider inherent limitation effectiveness materiality information timely basis determine system disclosure control procedure include possibility disclosureof information itha responsibility timely file human error circumvention override control report sec formal review annual report procedure form committee meteleventime accordingly effective disclosure control procedure sarbanesoxley require annual report contain statement provide reasonable assurance achieve control objective member company audit committee base group evaluation ceo cfo conclude audit committee financial expert december disclosure control explanation detail basis board judgement procedure effective provide reasonable assurance matter refer page information require disclose report group file submit securities exchange act accounting period end july sarbane amend record process summarise report oxley require company form contain report state requiredand accumulate communicate responsibility management establish maintain management include ceo cfo appropriate allow adequate internal control financial reporting assess timely decision require disclosure effectiveness company internal control financial reporting change group internal control company require report compliance financial reporting materially affected form management undertake process ensure reasonably likely affect materially group internal control position report compliance date financial reporting gsk annual report srotcerid eht tropergsk annual report srotcerid eht troper remuneration report remuneration report set remuneration policy operate gsk respect director corporate executive team cet member disclosure director remuneration include require director remuneration report regulation regulation accordance regulation follow section remuneration report subject audit annual remuneration nonexecutive director remuneration share option incentive plan performance criterion performance share plan share option pensionsfor opinion thereon express remain section subject auditnorare page refer audit section report submit shareholder board approval annual general meeting reference notice annual general meeting remuneration report executive director cetmember refer executive reference glaxosmithkline share adss mean respectively ordinary share glaxosmithkline plc american depository share glaxosmithkline plc ad represent glaxosmithkline share introduction remuneration policy executive director term condition remuneration nonexecutive director term condition fee director senior management remuneration annual remuneration nonexecutive director remuneration director interest share option incentive plan pension director senior management director interest contract gsk annual report srotcerid eht troper remuneration report continue introduction remuneration policy remuneration committee committee responsible principle make recommendation board company core principle underpin remuneration policy remuneration policy term agree policy glaxosmithkline determine total individual remuneration package secure outstanding executive talent executive pay performance performance remuneration policy set thisreport finalise robust transparent governance structure undertake extensive consultation process shareholder commitment leader good remuneration practice institutional body course pharmaceutical industry chairman remuneration committee continue formulate policy committee decide regular dialogue institutional investor gsk remuneration structure support need business remuneration policy competitive market place glaxosmithkline remuneration policy design establish shareholder guideline follow maximum extent framework remuneration consistent company consistent need business company scale scope operationsmeet recruitment need maintain regular dialogue shareholder business closely align shareholder guideline global pharmaceutical company primary pay comparator december company second large group pharmaceutical company world revenue operationson performance condition base measurable delivery continent product sell overcountrie strong financial performance delivery superior return aroundof sale generate usa shareholders compare pharmaceutical company high proportion total remuneration opportunity remuneration committee base performancerelate remuneration deliver sir robert wilson chairman committee medium long term sir crispin davis culp member remuneration determined project value committee schmitz appoint method benchmarking committee board deem member remuneration structure executive director committee independent nonexecutive director cet performance condition apply accordance combine code equally longterm incentive awards committee meet time member exgratia payment attend follow pay structure simple consistent business need number meeting number meeting hold whilst attend committee member committee member overall policy intend provide median total remuneration median performance poor performance result total sir robert wilson remuneration significantly pay comparator group median culp opportunity earn upper quartile total remuneration sir crispin davis exceptional performance ronaldo schmitz strong alignment performance demonstrably threequorate meeting hold approve formal grant interest shareholder provide executive share option performance share award effect unambiguous signal importance deliver success committee decision companys shareholder exception company secretary employee commitment company involve conduct committee meeting committee apply policy consistent transparent garni ceo senior vice president human resource basis significant change measure assess invite attend meeting committee require performance discuss shareholder use deloitte touche llpdeloitte appoint comparator pay benchmarke committee use committee provide independent advice executive discretion ensure remuneration level reasonable remuneration believe change cause concern shareholder position discuss shareholder prior implementation deloitte provide consulting service gsk year provide advice executive remuneration matter committee tower perrin provide market datum datum analysis committeegsk annual report srotcerid eht troper remuneration report continue pay performance comparator follow independent review committee follow table set company pay deliberate conscious decision use project value method performance comparison pay benchmarking purpose enable comparison market cap package different structural characteristic provide company country insight value gear different equity instrument abbott laboratories usa individual element remuneration astrazeneca balance fix base salary variable annual bristolmyer squibb usa bonus longterm incentive element remuneration change eli lilly usa performance chart show anticipate normal glaxosmithkline range mix fix variable pay different level johnson johnson usa performance ceo typical case executive merck usa directors year range higher low novartis switzerland depend performance company individual pfizer usa roche holdings switzerland ceo sanofiaventis france scheringplough usa takeda pharmaceutical company japan wyeth usa base salary annual bonus longterm incentive merger aventis sanofisynthelabo reduce size comparator group companies glaxosmithkline base salary committee subsequently determine number reason base salary set reference median relevant market include focus operation market capitalisation executivesthis pharmaceutical pay comparator group actual suitable company add group salary level review annually vary depend executive experience responsibility market value change benchmarke usually effect april follow market datum reviewbase benchmarking purpose total remuneration incorporate base salary garni yamada increase salary annual bonus longterm incentive set paythe respectivelywith effect committee regard executive pension arrangement april line state policy relation base salary global pharmaceutical industry primary pay position base salary coombe prior retirement comparator executivesas appropriate marketplace march base salary appointmentfor company senior executive talent instance julian heslop succeed coombe pay benchmarke publicly available remuneration datum follow market datum review undertake february company base salary garni yamada increase respectively heslops base provide context information reference salary increase bytofollowe committee tower perrin annual global pharmaceutical pay survey review performance cfo appointment role pharmaceutical human resource association phra ensure april salary increase effect april global pharmaceutical industry benchmark subject scrutiny review committee consider pay datum global annual bonus business primarily consumer manufacturing sector bonus determine basis formal review annual performance stretch financial target base profit prior determine annual longterm incentive opportunity interest tax subject detailed assessment committee consider range vest level achieve individual business unit andgroup achievement objective base different assumption share price growth bonus payable financial performance performance level etc performance line expectation target performance individual performance objective total remuneration target median comparator group increase decrease bonus level factor range longterm incentive opportunity set way provide zero bonus subject upper limit position total remuneration median executive ceo range ensure stable benchmark develop reduce base salary ceo limit impact shortterm fluctuation incentive policy global annual bonus pay basis ontarget business performance pharmaceutical company assess number year base salary provide annual cash line median valuation method pay comparator group project value method benchmark total remuneration case ceothe bonus target set board method project future value remuneration package set objective ceo board take account different performance scenarioswhilst moderate impact strategy develop companyand set market fluctuation short term strengthen focus pageof annual report performanceremuneration report continue objective set focussed particular building well historically performance period award fourth product pipeline industry deliver commercial operational quarter start january follow date award lti excellence addition formulate update strategic award performance periodstart plan vaccine business january year award january award february reason commercial sensitivity specific objective set strategic business driver keep confidential follow end compensation provide change awards cycle financial year board review ceos performance disclosure ltiaward executive director generally againsttheset objectivesand committee february remunerationreport determine bonus payable ceo make recommendation summary detail ltiaward executive director committee performance level achieve february set outon pageof remunerationreport objective executive recommendation consider committee determine resultant bonus performance share award share option deliver resident executive form adss award deliver determine bonus award committeetook form ordinary share executive resident account excellent financial performance year country award plan incorporate dilution encourage progress build pipeline new product limit consistent guideline provide association light low level response concern express british insurers national association pension fund institutional investor relation nonperformance shareholder representative body current estimate dilution relate match provide theannual incentive plan aip exist award glaxosmithkline employee share scheme committee decide discontinue theaip aip merger approximately company share equivalent eligible employee elect invest bonus gsk capital december share adss minimum period year end committee assisted deloitte undertake review threeyear hold period participant include executive current performance measure gskltiplan entitle matching award defer shareholde extensive careful consideration committee conclude match subject performance condition thisaip measure currently lti plan remain open approximately senior executive participate appropriate relevant case share option term deferral election theaipwere plan agree annualise growth eps achieve respect bonus earn theaip vest award grant increase closed gsk continue manage ongoing rpi rpi administration subsist award require theaiprule performance share longterm incentive executive level performance share vest base executive eligible performance share award share company total shareholder return tsr relative option remuneration policy provide annual longterm performance comparator group threeyear incentive lti award normally performance measurement period tsr choose appropriate share award share option award comparative measure focus return shareholder committee consider performance share provide strong wellunderstood test mechanism measure performance alignment shareholder value remuneration policy allow comparison company operate different place great emphasis use performance sharesltiaward country determine ontarget performance half tsr measure sterling performance period longterm incentive reward derive performance share represent change value share value annual grant ltiaward plan consistent reinveste dividend pay order remove impact practice pay comparator group lead vary tax treatment dividend different jurisdiction companiesltisfor cet provide basis dividend reinveste gross executive director level annual lti opportunity result change lti award cycle eligible consider carefully yearonyear committee context employee performance share award market practice executive respect performance share award grant align award cycle closely gsk financial year december february performance periods budgeting process committee decide change annual january december january grant date forltiaward eligible employee fourth december respectivelyif gskis rank position seven quarter year quarter year midpoint performance comparator group share vest ranking point result share change take effect lti award vest gskis company fourth quarter share vest determine vest level committee instead february change award cycle affect regard company underlie financial performance performance period gsk annual report srotcerid eht troperremuneration report continue tsr rank company percentage follow introduction international financial reporting glaxosmithkline award vest standard ifrs january committee consider eps measurement basis ifrsor ukgaap share option performance share plan award prior eps performance condition performance period straddle ifrs conversion date committee agree purpose measuring eps growth determine vest target achieve ukgaap grant performance period january december year report tsr measure prorata basis glaxosmithkline performance ukgaapthis require cergrowth restate fall comparator level vest determined ukgaap basis ifrs grant actual relative level tsr simple rank performance period january stdecember year report ifrs provide close link shareholder return payment executive notional dividend reinveste pay result change lti award cycle eligible proportion vest award receipt dividend employee share option grant executive incorporate benchmarking award level addition forshare option grantsin vest increase straightline performance share earn executive sell basis ep performance hurdle set meet relate tax liability year follow end followinggraph vest period committee believe align interest executive longterm interest shareholder vest table performance share award grant december performance period january december give page share option share option allow holder buy share future date share price prevail time grant share option grant manager glaxosmithkline include executive thevestingof share option grant executive link achievement compound annual eps growth performance period committee consider eps key measure performance business fully reflect business measure extend group ensure organisational alignment setting eps target committee consider company internal projection analyst forecast glaxosmithkline ep performance condition substantially consistent performance analyst forecast pharmaceutical shareholder guideline expectation demand industry compare operate global pharmaceutical follow key principle govern use eps performance company consistent policy provide pay measure performance performance adjustment consider major item performance measure overperiod ofthree financial yearswhich adjustment judgement committee commence basis set page performance purpose adjustment ensure performance retesting performance condition meet measurement fair reasonable participant year period option lapse shareholder pension discretion exercise committee disclose executive participate glaxosmithkline senior executive pension shareholder annual report plan pension arrangement structure accordance committee set basis decision consider plan operate executive country appropriate adjustment executive likely retire benefit normally payable age detail individual arrangement executive director set page response future pension regime committee carefully consider impact change legislation decide follow gsk annual report srotcerid eht troper rpi egatnecrep gnitsev exceptional superior baseline threshold rpi rpi rpi eps targetremuneration report continue company continue fulfil obligation exist sharesave plan sharereward plan inland revenue pension arrangement approve plan open employee term compensation provide participant adversely heslop member sharesave plan contribute affected new pension regime month provide option buy share end threeyear saving period line opportunity come decision committee take account available employee follow heslop contribute monthto buy share new executive hire benefit plus match sharereward plan company match number share opportunity base pay define contribution plan buy month contribution equal base salary plus bonus cash balance plan usa executive receive benefit include healthcare uklegacy final salary plan grandfathere exist medical dental personal financial advice life assurance employee new entrant allow cap cash value benefit receive executive director employee benefit excess cap currently provide show page unfunded arrangement cap employee usa benefit cap executive director term condition provide nonqualified plan remuneration share ownership requirement executive director contract align interest executive shareholder policy executive director contract subject executive require maintain significant holding share extensive review change policy provide glaxosmithkline requirement important framework contract executive director appoint align interest executive shareholder ceo go forward require hold share value time base salary key aspect glaxosmithkline contractual framework executive director require build shareholding value time base salary member cet require build aspect policy shareholding value time base salary notice period calendar month executive group require build shareholding value termination time base salary executive require continue satisfy employ company shareholding requirement minimum month executive follow retirement company termination payment annual salary order share qualify share ownership requirement annual ontarget bonus hold personally executive spouse mitigation require minor child earn defer benefit govern benefit policy share programme operate company unexercised share include option include calculation december healthcare medical dental garniersholde wasadssdr yamada personal financial advice adss heslops ordinary share life assurance contribution garnier yamadas holding excess share vest longterm rule relevant equity incentive ownership requirement heslop december build hold value time base salarymrcoombe incentive plan shareholdingat december excess share pension base exist arrangement ownership requirement follow retirement board term relevant pension plan march noncompete clause month termination remuneration element notice date executive participate legacy glaxo wellcome garniers target bonus salarydr yamada salaryand smithkline beecham allemployee share plan heslop salary usa glaxosmithkline plan replace imposition month noncompete period executive consider vitally important company order protect group intellectual property light noncompete clause competitor practice committee believe appropriate provide mitigation contract review level severance payment committee consider investor dti guidance determine line competitive practice appropriate provide payment salary target bonus termination approve shareholder glaxosmithkline glaxo wellcome smithkline beecham appropriate gsk annual report srotcerid eht troperremuneration report continue follow independent review remuneration undertaken glaxosmithkline make annual contribution garniers garniermr coombeand yamada agree change annual salary bonus yamadas annual salary previous contractual term compensation come bonus fund increase interest rate base yield broadly line new contractual framework include year treasury bond company liability make reduction contractual notice period calendar month annual contribution order honour certain aspect old contractual prior usemployee include garni yamada term number individual feature move final salary pension arrangement current retain cash balance structure employee cash balance plan garniers casethese include entitlement reimbursement contribution base combined annual salary annual bonus excise tax change control relate payment life insurance heslop participate glaxo wellcome define benefit plan benefit fund company age follow provision accrual rate finalpensionable salary annum relate vest longterm incentive benefit accrue glaxo wellcome pension pre awards arrangement augment trustee plan termination company cause reflect distribution surplus augmentation apply retirement resignation good reason resignation element heslops pension earning march elect retain director company merge company result change control provide entitlement resignation occur day addition contractual provision outline event anniversary change control option vest thatexecutive directorsservice agreement terminate remain exercisable option termand performance share employ company follow apply vest end performance period subject case award glaxosmithkline annual investment performance timeapportione plan provide agreement terminate cause defer income gain automatically distribute soon administratively practicable award provision applybut option subject termination resign retire termination cause performance testing circumstancesand option defer distribute end performance share award month prior termination minimum threeyear deferral period notice date lapse line policy applicable senior executive garni additiondr garnier yamadaare entitle receive yamada entitle receive continue medical dental year worth pension contribution termination insurance garniers contract execute march take follow merger participant legacy share option effect january contract expire october scheme elect exchange legacy option option day month reach glaxosmithkline share receive additional cash benefit birthday yamadas contract execute july equal grant price original option take effect january yamada retire additional benefit trigger new option exercise board company june coombes contract lapse qualify additional cash benefit participant execute march take effect january retain option second anniversary expire march effective date merger heslops contract execute march take outside appointment executive director effect april heslops contract expire outside appointment approve chairman january day month reach behalf board company policy remuneration birthday earn appointment keep individual termination payment respect executive director notice period extend contract expiry date individual pension arrangement plan provide pension base twothird final salary age cash balance plan provide annual contribution interest sum accumulate cash balance plan contractual promise provide specific level retirement income gsk annual report srotcerid eht troperremuneration report continue nonexecutive director term condition fee nonexecutive director appointment nonexecutive director provide letter nonexecutive director glaxosmithkline service appointment agree serve company contract instead letter appointment company aim nonexecutive director conclusion annual general provide nonexecutive director fee competitive meeting follow anniversary appointment company equivalent size complexity fee structure case extend term year mutual nonexecutive director follow agreement nodirector serve term long year annum offering reelection shareholder standard annual cash retainer fee follow table show date letter appointment supplemental fee nonexecutive director senior independent directorthe auditcommittee nonexecutive date letter chairmanand scientificmedical expert director appointment chairman remuneration mrl culp corporate responsibility committee sir crispin davis nonexecutive director undertake sir deryck maughan intercontinental travel meeting meet sir ian prosser automatic share allocation schmitz enhance link directors shareholders shapiro glaxosmithkline require nonexecutive director receive swaan significant fee form share effect sir robert wilson october nonexecutive director total fee exclude chairmanare pay form share tsrperformance graph allocate share account nonexecutive director follow graph set performance company relative opportunity invest balance fee ftse index company constituent share account performance comparator group merger exchange rate december graph prepare accordance fee pay usdollar convert rate regulation indication likely vest award usbee exchange rate apply july grant company incentive plan new fee arrangement approve board nonexecutive director entitle compensation appointment terminate chairman sir christopher hogg retire chairman effect december sir christopher gents letter appointment board date agree serve company deputy chairman december january chairman conclusion annual general meeting follow anniversary appointment extend term year mutual agreement receive fee rate annum plus allocation glaxosmithkline share value annum whilst deputy chairmanand receive annum plus allocation glaxosmithkline share value annum chairman director senior management remuneration follow table set director glaxosmithkline plc remuneration earn interest share glaxosmithkline plctheir interest share option incentive plan pension benefit member cet company secretary know senior management participate remuneration plan executive director aggregate remuneration interest director senior management provide gsk annual report srotcerid eht troper gsk total return index gsk pharma peer return index ftse total return indexremuneration report continue annual remuneration total total fee annual defer annual fee annual annual salary benefit bonus bonus remuneration salary benefit bonus remuneration footnote current executive director garnier abc heslop yamada abc totalcurrent executive director executive director coombe bcd total executive director current nonexecutive director culp sir crispin davis sir christopher gent sir deryck maughan sir ian prosser schmitz shapiro sir robert wilson total current nonexecutive director nonexecutive director barzach sir christopher hogg sir roger hurn sir peter job mcarthur mchenry sir richard syke total nonexecutive director total nonexecutive director totalremuneration remuneration director payroll report dollar amount convert sterling average rate foreachyear follow merger participant legacy share option scheme elect exchange legacy option option glaxosmithkline share grant additional cash benefit equal grant price original option additional benefit know exchange offer incentive eoi payable new option exercise lapse market value qualify additional cash benefit participant retain option second anniversary effective date merger yeardr garni receive yamada receive nil relate option exercise page garni nonexecutive director united technologies corporation respect receive form defer stock unit stock option grant price yamada member advisory board quaker bioventures inc respect receive yamada previously member board director diadexus inc respect receive stock appreciation right grant price amount exclude table retain executive director coombe member supervisory board siemen anonexecutive director hsbc holdings plc period january retirement glaxosmithkline march receive stock appreciation right grant price nil respectively follow merger garni coombe yamada award oneoff special defer bonus member cet award equivalent annual salary december notionally invest glaxosmithkline share adss february defer year defer bonus vest february amount pay equivalent value glaxosmithkline share adss notionally acquire february plus dividend reinveste period garni receive yamada receive coombe waive deferred bonus company contribution pension plan enhance pension entitlement include table gsk annual report srotcerid eht troperremuneration report continue gsk annual report srotcerid eht troper coombe waive prorate bonus annual bonus company contribution pension plan enhance pension entitlementsthese amount arenot include fee salary shapiro member glaxosmithkline scientific advisory board receive fee form adss include fee salary barzach receive fee glaxosmithkline france healthcare consultancy provide include fee salary director receive expense year require separate disclosure require regulation swaan join board nonexecutive director january remuneration show table nonexecutive director remuneration total cash sharesadss total cash sharesadss fee salary current nonexecutive director lculp sir crispin davis sir christopher gent sir deryck maughan sir ian prosser schmitz shapiro sir robert wilson nonexecutive director barzach sir christopher hogg sir peter job jmcarthur mchenry total table set remuneration receive nonexecutive director glaxosmithkline accordingly include barzachs fee receive glaxosmithkline france healthcare consultancy providedor shapiros fee receive member glaxosmithkline scientific advisory board formation gsk nonexecutive directorshave require total fee form share allocate share account october nonexecutive director fee chairman detailsmust take fee allocation arrangementnonexecutive directorscan elect receive remain cash payment form share adss total value share adss date award cash payment form total fee include annual remuneration table fee salary table set value fee receive form cash share adss share adss notionally award nonexecutive director allocate interest account include director interest table page accumulate balance share adss notional dividend subsequently reinveste pay nonexecutive director retirement retirement nonexecutive director receive share adss cash equal value share adss date retirementremuneration report continue table set accumulate number share adss hold nonexecutive director relation fee receive board member december movement account year number share adss dividend nonexecutive director share arrangement footnote elect reinveste pay current nonexecutive director share sir crispin davis sir christopher gent sir ian prosser schmitz shapiro sir robert wilson ads lculp sir deryck maughan shapiro nonexecutive director share sir christopher hogg sir roger hurn sir peter job dividend notionally reinveste end financial year payment table set settlement nonexecutive director share arrangement leave board value award value award payment date leave allocation leave prior year sir christopher hogg sir roger hurn sir peter job awards sir christopher hogg sir peter job nonexecutive director share arrangement settle transfer share january change value award allocation leave attributable dividend reinveste change share price date award date leave leave board sir roger hurn elect receive settlement nonexecutive directorsshare arrangement quarterly cash payment gsk annual report srotcerid eht troperremuneration report continue director interest follow beneficial interest director company show register maintain company accordance company act share adss february december january february december january footnote current executive director garnier heslop yamada executive director coombe cde current nonexecutive director culp sir crispin davis sir christopher gent sir deryck maughan sir ian prosser schmitz shapiro swaan sir robert wilson glaxosmithkline ad represent glaxosmithkline share include equivalent number adss purchase glaxosmithkline stock fund plan case heslop opening number share show april case coombe closing number share show march include share purchase glaxosmithkline sharereward plan heslop totalling share december april shares february coombe shares march january coombe leave board march interest company onth february include table finclude share adss receive fee describe nonexecutive director share arrangement page dividend receive share adss convert share adss december include director interest interest abovementione director february reflect change end financial year date gsk annual report srotcerid eht troperremuneration report continue share option option adss grant footnote date grant exercise period grant price number exercise garni yamada option share grant date grant exercise period grant price number exercise jheslop jcoombe aas main option grant occur february vestingperiod ofst january tost december garnier award ad option grant price grant heslop award share option grant price yamada receive agrantof option impend retirement glaxosmithkline heslop join theboard april details cover period april december grant include table relate thesharesave plan cmr coomberetire onst march detail cover period january march option outstanding december early late vesting lapse date market price glaxosmithkline share year end give table coombe follow vest date lapse date weight average jpgarnier grant price number early latest early late market price underwater year end vested option market price year end vest option unvested option total ad option december vest date lapse date weight average tyamada grant price number early latest early late market price underwater year end vested option market price year end vest option unvested option total ad option december vest date lapse date weight average jheslop grant price number early latest early late market price underwater year end vested option market price year end vest option unvested option total share option december gsk annual report srotcerid eht troperremuneration report continue vest date lapse date weight average jcoombeto march grant price number early latest early late market price underwater period endvested option unvested option market price period end unvested option total share option march lapse date coombe option modify reflect retirement gskgrant share option executive director senior manager annual basis initial grant follow completion merger march measurement period option grant march commence january measurement period option grant november december commence january respectively director hold option share option plan refer noteto theffinancial statement employee share scheme measurement period option grant february commence january director interest option company share follow merger director elect exchange outstanding option legacy share option plan option overgskshare director participant legacy scheme election receive additional benefit cash sum equal grant price original option additional benefit give new option exercise lapse prior share option grant executive director subject performance condition order option vest business performance ep growth exclude currency exceptional item average percentage point annum increase retail price index threeyear performance period share option grant vest increase straightline basis eps performance hurdle set follow table annualise growth ep percentage award vest rpi rpi rpi rpi respect grant performance condition meet threeyear measurement period performance measure financial year follow date grant option performance condition meet end year option lapse option grant executive director subject performance condition set extent performance condition meet end threeyear performance period option lapse reteste permit grant market option exercise date number price price gain gain jpgarnier yamada heslop average exchange rate year gain garni amount eoi benefit pay garni exercise option benefit include table page average rate year gain yamada amount eoi benefit pay yamada exercise option benefit include table page coombe exercise share option highest low closing price year end december glaxosmithkline share respectively high low price glaxosmithkline adss year end december respectively market price glaxosmithkline share december december glaxosmithkline ad december price onth february glaxosmithkline share glaxosmithkline ad gsk annual report srotcerid eht troperremuneration report continue incentive plan performance share plan awards garnier adss market additional vested price vest exercise ad vest number unvested defer date market dividend unvested defer grant performance period grant number price gain lapse reinveste value award defer garnier vest tyamada adss market additional vested price vest exercise ad vest number unvested defer date market dividend unvested defer grant performance period grant number price gain lapse reinveste jheslop shares market additional vested price vest exercise share vest number unvested defer date market dividend unvested defer grant performance period grant number price gain lapse reinveste jcoombe share market additional vested price vest exercise share vest number unvested defer date market dividend unvested defer grant performance period grant number price gain lapse reinveste april total number performance share plan psp award grant coombe performance period january december prorate reflect retirement end performance periodthepspaward performance period january december february market price share ad garni awardedadssand heslopshares unveste average exchange rate year gain garni yamada amount respectively thepspis mediumterm incentive scheme introduce psp replace ltiplan midterm incentive plan operate respectivelyby glaxo wellcome smithkline beecham term psp number share actually vest determined following end relevant threeyear measurement period dependent gsk performance period describe page share award previously grant annually november december theyaregrante february follow year measurement period commence january year grant end year december threeyear measurement period award performance period commence january end december base performance gskdure period award vest february forawardswith performance period commence january subsequent award dividend reinveste psp award member cet dividend reinveste quarter payment term psp participant defer receipt vested award prior performance period begin january awards part half earn reference gsk tsr performance compare ftse company constituent half awardwill earnedif company business performance ep growth exclude currency exceptional item average percentage point peryearmore increase retail price index threeyear performance period awards gskis rank ftse base tsr performance share award vest position ftse share vest gskis rank position sharessubject awardwill vest position vest occur slide scale gsk annual report srotcerid eht troperremuneration report continue follow vest table apply award withperformance periodsfrom january december january december apply award february tsr rank company glaxosmithkline percentage award vest median median vest additional ad vest defer dividend defer participation reinveste participation midterm incentive plan adss garni midterm incentive plan mtip share award scheme operate smithkline beecham plan close new entrant completion merger participation grant final award adss receipt award defer director garnier defer receipt amount vest deferred award additional adss subsequently receive dividend reinvestment arenot include director interest table pagesince retain mtip pay average stock appreciation right sar adss grant price shapiro option exercise date number grant price market price gain gain shapiro sar hold shapiro hada grant price market price glaxosmithkline ad atst december shapiro member glaxosmithkline scientific advisory board sab shapiro member smithkline beecham sab completion merger glaxo wellcome member sab receive annual grant smithkline beecham sars general vest year date grant expire year date grant grant sars sab member cease sar entitle holder cash sum future date base share price growth date grant date exercise provision financial statement accrue gain sar date grant connection merger previously grant sar immediately exercisable gsk annual report srotcerid eht troper performance comparator group theseawardscomprised company glaxosmithkline aventis sanofisynthelabo comparator groupprior merger form sanofiaventis purpose calculate tsrover performance period award grant december start price share individual company compare price merge company end performance period adjust merger ratio dividend treat reinveste performance period tsr measure prorata basis glaxosmithkline performance fall comparator level vest determined actual relative level tsr simple rankingremuneration report continue pension accrue annual pension benefit transfer value executive director retirement set regulation require disclosure accrue benefit end year change accrue benefit year transfer value beginning end year change transfer value year listing rule require additional disclosure change accrue benefit net inflation transfer value changepension executive director disclose currency pension payable personal change change contribution accrue transfer value accrue accrue accrue transfer transfer change benefit change benefit benefit benefit scheme value value transfer year net accrue year year value inflation benefit current executive director garnier jheslop tyamada executive director coombe adr yamadastransfer value december hasincreased previously disclose result adjustment employment contract yamadas accrue benefit december decrease reflect adjustment retirement age change transfer value transfer value change accrue benefit show net contribution individual garni yamada members employee cash balance pension plan glaxosmithkline make annual contribution calculate percentage employee base salary bonusthe fund increase interest rate set annually advance base year treasury bond rate provide cash sum retirement cash sum purchase pension retirement base annuity rate applicable time entitlement spouse pension pension increase reduce initial pension normal retirement age plan year age drgarnier pension arrangement bring line term service agreement assume retirement age reduce similarly yamadas assume retirement age hadbeen reduce transfer value cash sum garnier plan increase year result phase transfer previous scheme accumulation interest contribution pay company transfer value cash sum yamadas plan increase year result accumulation interest contribution pay company garni yamada member usretirement saving plan saving scheme open usemployee executive supplemental saving plan saving scheme open executive restore government limit impose retirement saving plan contribution plan invest range fund value accumulate fund pay retirement contribution pay scheme company respect garni invest gsk share stock ownership account respect yamada contribution pay scheme invest gsk share stock ownership account share hold account include director interest table page heslops transfer value calculate basis actuarial advice accordance actuarial guidance note transfer value represent present value future payment pension plan heslops annual accrue benefit increase exclude effect inflation transfer value personal contribution increase year increase heslops pensionable salary primary reason increase transfer value coombe transfer value calculate basis actuarial advice accordance actuarial guidance note transfer value represent present value future payment pension plan coombe transfer value increase accrue benefit fall decline coombe opting receive lumpsum retirement coombe waive bonus company contribution pension plan enhance pension benefit bonus special defer bonus bonus gsk annual report srotcerid eht troperremuneration report continue director senior management report purpose necessary provide information compensation interest director senior management asagroup group purpose disclosure group define director members cet company secretary respect financial year total compensation pay member group period serve capacity aggregate increase accrue pension benefit net inflationwa aggregate payment define contribution scheme member group grant option sharesave scheme award share adss reinvestment dividend performance share plan atth february thencurrent member group comprisingperson ownedshare andadss constitute issue share capital company group hold date option purchaseshare andadss share andadss award performance share plan include share adss vest deferred share andadss legacy smithkline beecham midterm incentive plan include share adss vest deferredadss award legacy smithkline beecham stock appreciation right andshare award restrict share plan holding issue executive share option plan describe noteto thefifnancial statement employee share scheme director interest contract describe noteto thefifnancial statement relate party transaction end financial year director connect person material interest contract significance relation group business group company director remuneration report approve board director sign behalf sir christopher gent chairman march gsk annual report srotcerid eht tropergsk annual report srotcerid eht troper operate financial review prospect operate financial review prospect discuss operate financial performance financial outlook financial resource group result year prepare ifrs adopt use european union compare primarily result precede year follow heading financial trend ratio year result year december compare year december financial position resource december outlookand risk factor year result year december compare year december reconciliation accounting principle set note financial statement accounting presentation effect january gsk move report financial result accordance international financial reporting standard ifrs require european union regulation issue report prepare ifrs adopt use european union comparative figure present basis gsk take advantage exemption permit financial instrument account present gaap basis accordance ias ias january detail major difference ukgaap apply gsk give innoteto financial statement ifrs transitioninformation prepare ifrs directly comparable prepare ukgaap data market share market growth rate gsk estimate base recent datum independent external source appropriate value sterle relevant exchange rate figure quote product market share reflect sale gsk licensee order illustrate underlying performance group practice discuss result term constant exchange rate cer growth represent growth calculate exchange rate determine result overseas company sterling remain unchanged previous year cer represent growth constant exchange rate represent growth actual exchange rate annual report form purpose usreporting requirement applicable firsttime adopter ifrs gsk incorporate reference annual report form year record select financial information page thereof discussion year page operate financial review prospect section thereof financial statement support note page thereofgsk annual report srotcerid eht troper operate financial review prospect financial trend ratio growth growth cer cer turnover pharmaceutical consumer healthcare total cost sale sell general administration research development operating income operate profit profit taxation profitafter taxation year profit attributable minority interest profit attributable shareholder earning share penny dilute earning share penny research development pharmaceutical consumer healthcare total net finance costcover netfinance cost cover time time time net finance cost cover profit tax plus net finance costsdivide net finance cost tax rate borrowing net debt gearing gearing ratio calculate net debt percentage oftotalequity exchange rate group multinational business operate countriesand earn revenue incur cost currency result report sterling affect bymovement exchange rate sterling othercurrencie average exchange rate prevail period translate result cash flow overseas subsidiary associate undertaking joint venture sterling period end rate translate net asset undertaking currency influence translation usdollar euro japanese yengsk annual report srotcerid eht troper operate financial review prospect year world economy world market pharmaceutical gdp growth pick year impact global pharmaceutical sale increase billion high oil price later year see lead indicator turn world market value growth downward business confidence weaken major country geographic region total manufacturing trade strengthen year initial usa dip modest globalexpansion continue lead usa europe china wheremomentum maintain contrast germany region exclude japan indiahoweverus gdp growth slow france fourth quarter annual rate compare reflect slow consumer spending italy federal government spend interest rate japan increase series rise asia pacific mixed view outlook economy latin america gdp growth china exceed expectation atand middle east africa robust india continue expansion services canada information technology remain strong global trade arrangement total include china spotlight agreement china usaand growth market slow tobutit stillrepresent china textile import world trade organisation global prescription pharmaceutical market comparedwith ministerial talk hong kong end yearmade decade ago modest progress agreement reduction trade september gsk heldsecondposition world barrier pharmaceutical market market share pfizer japanese economy expand strongly particularly fourth market share gsk hadeightofthe world quarter drive recovery domestic demand underpin pharmaceutical product avandia flixonase strengthen labour market see fulltime employment expand imigranimitrex lamictal seretideadvair seroxatpaxil wellbutrin time seven yearsboth business confidence export zofran grow year confidence stem continue reform banking sector gdp growth year world market value growth similar rise forecast nikkei share index therapeutic class total cer rise fouryear high strength betterthanexpecte gdp cardiovascular datum central nervous system alimentary tract metabolic oil price high commodity price slow growth antiinfective bacterial eurozone nation economic forecast zone viral fungal exclude downgrade yearwith increase concern rise vaccine inflationthe european central bankraise interest rate respiratory changein rate june weak domestic demand theeuro lack resilience external event note datum base month thseptember feature theeurozone gdp growth record rate ofaround predict bank pharmaceutical turnover england cut interest rate middle year growth rate include review turnover constant ground economic growth subduedbut predict growth exchange rate cer state sterling growth pick reflect recovery domestic demand rate find table pharmaceutical turnover foreign trade therapeutic area pageand geographic region page exchange total pharmaceutical turnover million compare million increase cer sterling term currency influence group result turnoverincreasedprincipally thestrengthof theeuro dollar euro japanese yen international currencieswithin group portfolio turnover dollar strengthen pound new product launch major market rise yearend follow year ofweakness year account total turnover grow euro japanese yen yearend rate weaken million turnover establish franchise product pound amount millionrepresente total turnover increase compare year turnover old product actively promote million decline represent total turnover year continue pharmaceutical turnover therapeutic area total wellbutrinturnoverfell million wellbutrin irand srsales fall million generic competitionbut gsk ability continue deliver pharmaceutical turnover growth largely offset strong performance wellbutrin xlup primarily exceptionally broad product portfolio fast million grow highvalue product sale gsk large product seretideadvairwere billion continue gain strong growth gsk epilepsy bipolar disorder treatment market shareacross region market shareby value anti lamictalcontinue sale million drive asthma copd therapy class europe indication maintenance treatment bipolar disorder usa increase percentage point case compare requipsale rise million weekly new sale diabetes treatment strong prescription product quadruple usa avandiaavandametup billion gsk launch avandia launch forrestlesslegssyndrome rls final treatment type diabete combination approval requip adartrel rls expect product avandamet blood sugar control theproduct groupwa expand february launch antiviral usa fixeddose combination treatment avandaryl global hiv product sale grow billion sale combine avandiawith sulfonylurea approval expect new product epzicomkivexa lexiva avandiaavandametachieve market share value double million offset performance trizivirdown oral antidiabetics europe usa million epivir million sale percentage pointsrespectively herpe treatment valtrex grow million performance drive usa million product clear market leader treatment genital herpe antibacterial antibacterial sale decline worldwide usa decline wasreflecte increase generic competition metabolic diabete treatment avandiaavandametcontinuedto perform strongly overall sale billionup usa sale grow million avandiaavandamet establishingstrong positionsin europe sale rise millionhelpe launch avandamet sale international market rise million major outcome study fast grow product lamictal epilepsybipolar involve avandiaare report end adopt disorder billion valtrexfor herpesup investigate line use avandiain type diabetesand dream billion coregfor heart disease billion vaccine early use avandiato delay prevent disease progression billion bonivabonviva new oncemonthly oral bisphosphonate addition rapid uptake number high treatment osteoporosis develop roche potential product requip restless leg syndrome sale strong launch usa andin february hada share million avodartfor benign prostatic hyperplasia sale new prescription oral bisphosphonate boniva injection double million bonivabonvivafor treatment quarterly treatment osteoporosis approve usa osteoporosis waslaunche andcaptured share january receive positive opinion chmp new prescription oral bisphosphonate market europe january respiratory vaccine gsk continue global leader respiratory pharmaceutical vaccine business perform wellwith total sale rise sale key product seretideadvair flixotideflovent billion lead infanrix vaccine sale particularly strong sereventamounting billion seretideadvair usa turnover rise million help sale rise billionin usa sales werealso strong launch new productsfluarix boostrix european international marketswhich billion billionrespectively july gsk acquire corixa corporation million decembercomplete acquisition biomedical corporation central nervous system cns billion approval idbs fluviralflu vaccine expect time cns sale decline billion sale decline usaand flu season europewitha small gain internationaltotal paxilsale fall million generic competition interruption december gsk submit mockup dossier emea supply paxil crdure year product supply accelerate approval potential pandemic influenza vaccine gsk partially mitigate decline strong performance ofpaxil expect begin clinical trial come week prototype japan million pandemic vaccine different adjuvant alum newly develop adjuvant thegroupis discussion government world plan prime population stockpile vaccine gsk expect complete filing europe gsk annual report srotcerid eht troper operate financial review prospect market share value seretideadvair avandiaavandamet europe usa europe usa september september year continue pharmaceutical turnover therapeutic area total usa europe international therapeutic area growth growth growth growth major product total cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxilir paxil wellbutrin wellbutrin wellbutrin imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen retrovir agenerase lexiva epzicomkivexa herpe valtrex zovirax zeffix antibacterials augmentin augmentin augmentin zinnatceftin metabolic avandia avandamet bonvivaboniva vaccine hepatitis infanrix pediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart arixtra fraxiparine vesicare zantac cer representsgrowth constant exchange rate represent growth actual exchange ratesturnover quarter give financial recordonpage gsk annual report srotcerid eht troper operate financial review prospect year continue oncology emesis pharmaceutical turnover europe region sale zofrangrew million drive market turnover create basis million region invoice adjustment create invoice adjustment create cardiovascular urogenital major market sale ofcoregfor heart diseasegrew million europe france avodartfor benign prostatic hyperplasia enlarge prostate strong yearwith salesdouble millionby january italy product account new prescription germany alpha reductase inhibitor market spain therapeutic area poland sale zantacfell millionwith decline region europe regional analysis adjustment gsk estimate base recent datum pharmaceutical turnover geographic region independent external source value sterling relevant invoice basis exchange rate management believe turnover create basis turnover report table represent sale invoice report turnover market provide well reflection gsk local entity customer local market plus performance business market europe promotion income market total turnover europe region unaffected restatement region growth major market total cer parallel trade occur occasionally worldbut usa sufficiently material affect significantly turnover datum market europe present invoice basis france pharmaceutical turnover geographic region turnover create basis italy turnover market europe adjust effect germany parallel trade turnover basis country spain product finally consume product sell poland gsk europe international region growth major market total cer asia pacific japan usa middle east africa europe latin america france canada italy germany cer representsgrowth constant exchange rate represent growth spain actual exchange rate poland individual government determine pricing medicine europe country europe result wide price variation international product parallel trade occur party exploit price asia pacific differential purchasing product inmarketswhere low price japan enforce selling government purchaser middle east africa markets high price agree parallel trade latin america permit single market rule european union gsk canada derive benefit profit resale high price result management believe european region cer representsgrowth constant exchange rate represent growth turnover market invoice basis present actual exchange ratesturnover quarter give financial record properly represent consumption product pagesto market gsk employee base market instrumental promotion group product market create product sale final consumption market follow table give adjustment order restate turnover market europe turnover create basis gsk annual report srotcerid eht troper operate financial review prospect year continued usa international usa report turnover growth year despite international region report year year turnover growth impact generic competition paxil wellbutrin irsr strong growth japanup chinahong kongup exclude sale product turnover grow asia pacificupwas partly offset broadly flat sale business represent total pharmaceutical turnover canada australia canadian sale performance reflect generic competition paxil whilst australian business advairmaintaine strong growth sale million negatively impact government pricing reform adversely affect sale constituent product flovent serevent collectively decline flonase strong performance japan drive sale paxil indicate treatment perennial rhinitis grow serevent antiviralsup partially offset decline zantac zoviraxand tagamet sale wellbutrinproduct fall million wellbutrin irsr sale fall million result generic competition market international key product drive growth impact partially offset exceptionally strong seretide grow record sale million performance wellbutrin new oncedaily product avandiaavandamet grow million achieve sale million vaccine franchise record growth achieve sale million total sale ofpaxilwere million result generic competition paxil sale decline product supply million paxil crgenerate sale million follow fda inspection october november supply issue cidra plant puerto rico identify possible deficiency manufacturing practice group facility cidra puerto rico fda halt distribution sale antiviral therapeutic area grow hiv product supplies paxil avandamet march site valtrex herpe grow drive patient switch engaged tablete packaging range gsk product suppression therapy primarily market include paxil paxil coregavandia sale avandiaavandamet increase antibacterial sale avandamet april group reach agreement decline result generic competition begin fda consent decree provide independent quarter coregsale increase million expert review manufacturing process site compliance continue benefit wide range indication fda good manufacturing practice requirement decree allow potential future penalty maximum vaccine grew reflect good performance pediarixand million year ifgsk fail meet term launch boostrixand fluarix june group begin resupplye markets europe paxil crand avandamet sale product discussion individual market performance europe region significantly impact interruption supply turnover create basis impact avandametwa mitigate switch patient europe region contribute pharmaceutical turnoverand avandia group establish provision grow reflect strong growth number country external cost require rectify manufacturing issue plant year impact acquisition fraxiparineand arixtra detail risk factor page noteto acquire exclude fraxiparineand arixtra financial statement legal proceeding growth marketswhich recorded strong growth include consumer healthcare sale germany italypolandcentral europeandsouthern eastern growth europe government healthcare reform include pricing cer reimbursement restriction generic competition otc medicine adversely affect turnover france spain analgesic major growth driver seretide gsk large selling product dermatological europewith growth oftheavandiaavandametfranchise gastrointestinal grow hiv thevaccine franchise respiratory tract smoke control sale herpe franchise flat comparedwith mainly natural wellness support result generic competition zovirax offset patient switch new product valtrex oral care nutritional healthcare seroxat sale reflect generic competitioninthe majority market region antibacterial sale increaseddue strong normal flu growth consumer healthcare sale billion season number southern european market comprise otc medicine sale increase nutritional healthcare sale increase oral care sale increase gsk annual report srotcerid eht troper operate financial review prospectsotcmedicine low charge relate legal mattersequal overthecounter medicine sale million growth reduction total sgaandlower sharebase payment charge analgesic respiratory tract helped offset equal decrease total sgapartly offset high cost loss sale dermatological product divest related programme deliver future cost savingsequal panadol growth international market key driver increase total sga growth analgesic research development january fda advisory committee recommend expenditure percentage turnover line alli orlistat approve overthecounter use usa increase comparedwiththe previous yearpartly promote weight loss overweight adult result somewriteoffsofintangibleasset exclude thesewrite reduce calorie lowfat diet approve alli fda off expenditure grow slightly turnover growth approve weightloss drug available overthecounter pharmaceutical expenditure represent pharmaceutical turnover oral care oral care sale grow million sale sensodyneand operating income denture care brand polident poligripand corega grow operating income include royalty income equity investment respectively helping offset low sale toothpaste disposal impairment product disposal fair value product adjustment quest collar theravance option operating income million compare nutritional healthcare million increase income predominantly nutritional healthcare product sale grow million increase product asset disposal gain compare lucozade continue grow strongly europe favourable fair value movement million quest operating profit collar theravance option analysis operate profit subsequent discussion operating profit compare result result overall operate profit margin increase percentage point operate profit million increase sterling term growth constant exchange rate operating profit increase cer margin increase percentage pointsreflecte low charge turnover relate legal mattersand sharebased paymentshigher product cost sale asset disposal increase advertising promotion selling sell general rate turnover growth partially offset administration item high cost relate programme deliver future cost research saving increase expenditure development operating profit taxation income thediscussion compare result result operate profit gain asset disposal include associate million million cost legal matter million cost sale million charge relate costsave programme cost sale percentage turnover increase percentage million millionsharebase payment point constant exchange rate increase million million percentage pointsreflecte high cost relate ongoing rectification manufacturing issue cidra site puerto rico share profitslosse joint venture associate partly offset operating efficiency compare undertaking previous year share profit associate arise principally group hold quest diagnostic inc sell general administration sell general administration sga percentage disposal interest associate turnover decrease percentage point constant exchange disposal interestsin associate rate decrease percentage point reflect flat group dispose million share investment expenditurecomparedwith theprior year turnover increase quest diagnostic inc cash proceed millionaprofit sga cost line overall high million recognise group shareholde quest advertising promotion sell expense offset low december general administrationexpenditure advertising promotion selling expense increase account increase total sga general administration cost decline account areduction total sga gsk annual report srotcerid eht troper operate financial review prospect year continue year continue net finance cost continue wide difference view group irs hmrc relevant taxation authority financeincome open issue exist ultimate liability matter vary amount provide dependent outcome interestincome litigation proceeding negotiation relevant tax unwind discount asset authority fair value adjustment profit year growth finance cost cer interest cost profitafter taxation year unwind discount liability profit attributable fair value adjustment shareholder earning sharepence earning adsus finance income increase compare predominantly weighted average number high interest rate high cash balancesfinance costsincrease share million high interest ratesa high interest cost result issue million bond dilute earning sharepence dilute earning adsus taxation weight average number share million corporation tax profit year million increase overseas taxation sterling term profit attributable minority interest million profit attributable shareholder current taxation million increase sterling term defer taxation total earning share increase reflect high profit reduction weight average number share result charge taxation profit amount million group share buyback programme interest cost represent effective tax rate tax rate programme impact group earning benefit high tax relief actual actual rate exchangeearning share increase potential exercise share option employee arise favourable currency impact ep percentage point reflect increase share price year strengthen dollar euro average exchange rate integrate nature group worldwide operation involve relative compare afavourable currency impact significant investment research strategic manufacture turnover difference principally arise different mix limit number location consequential crossborder supply currency profit compare turnover route numerous endmarket give rise complexity delay dividend negotiation revenue authority profit board declare fourth interim dividend penny individual group company liable taxdisagreement share result dividend year pence pence revenue authority intragroup transaction increase dividend penny share particular price good transfer equivalent fourth interim dividend receivable adr holders group company different tax jurisdiction produce conflict cent ad base exchange rate claim revenue authority profit tax dividend exdividend date february record individual territory resolution issue continue fact date february pay april life gsk group hassignificant open issue revenue authority usa japan canada details ifrs interim dividend recognise account set note financial statement taxation pay declare gsk normally pay dividend quarter quarter relate quarter group total current tax payable liability december declare consequentlythe financial statement recognise million million respect transfer dividend pay fourth interim dividend price tax matter second interim dividend total gsk use good advice determine transfer pricing million methodology seeking manage transfer pricing issue satisfactory conclusion basis external professional advice continue believe adequate provision liability likely arise open assessment gsk annual report srotcerid eht troper operate financial review prospectscritical accounting policy customer rebate offer key manage care group purchasing organisation direct indirect customer consolidate financial statement prepare accordance arrangement require customer achieve certain international financial reporting standard adopt use performance target relate value product purchase european union follow accounting policy approve formulary status predetermine market share relative board describe noteto theffinancial statement accounting competitor theaccrualfor rebate estimate base policy management require estimate assumption specific term agreement historical experience affect amount asset liability revenue expense product growth rate report financial statement actual amount result differ estimate follow consider cash discount offer customer encourage prompt critical accounting policy adopt payment accrue time invoicing adjust subsequently reflect actual experience turnover revenue recognise title risk loss pass historical experience customer return gsk customer reliable estimate relevant deduction record accrualfor estimate sale return apply historical gross turnover reduce rebate discount allowance experience customer return amounts invoice product return give expect give vary product market relate information stock level arrangement buy group arrangement wholesaler anticipate price increase competitor activity purchasing organisation dependent submission reconciliation gross turnover net turnover claim time initial recognition saleaccrualsare pharmaceuticals businessisas follows time sale estimate rebate discount allowance payable return base available market information historical experience amount estimate fully reflect final outcome gross turnover amount subject change dependent chargeback thing type buy group product sale mix level usgovernment accrualis review adjust quarterly light historical state programme experience actual rebate discount allowance give manage care return change arrangement future event group purchasing cause assumption theaccrualsare base change organisation rebate affect future result group cash discount group large business pharmaceutical market customer return complex arrangement rebate discount prioryear adjustment allowance follow briefly describe nature item arrangement existence group pharmaceutical business total deduction medicaid programme stateadministere programme net turnover provide assistance certain poor vulnerable patient increase customer return arosefrom product recall medicaid drug rebate program establish reduce state follow manufacturing issue cidra plant increase federal expenditure prescription drug gsk participate generic competition provide rebate state accrual medicaid rebate calculate base specific term individual state agreement totalaccrualsfor rebate discount allowance return combination historical experience product pharmaceuticals business december population growth anticipate price increase impact december follow contracting strategy impact medicaid arrangement see expect affect december december level discount give gskha arrangement certain key party party chargeback able buy product wholesaler low price usgovernment state programme chargeback represent difference invoice price manage care group purchase wholesaler indirect customer contractual discount organisation rebate priceaccrualsfor estimate chargeback calculate base cash discount term agreement historical experience product customer return growth rate total gsk annual report srotcerid eht troper operate financial review prospect year continue year continue monthly process operate monitor inventory level intangible asset wholesaler abnormal movement process use gross intangible asset acquire glaxosmithkline sale volume prescription volume base party datum source party cost acquisition capitalise licence compound information receive key wholesaler aim development amortise point maintaininventoriesat consistent level year year base available use estimate useful livesup toyear pattern consumption basis pharmaceutical estimate useful life review annually impairment review inventorylevel wholesaler distribution channel undertake event occur question carry december estimate value asset brand acquire business capitalise month turnover calculation use party information independently separable longterm value accuracy totally verify believe group brand amortise estimate useful life sufficiently reliable purpose exceeding year end useful economic life foresee brand amortise taxation subject annual impairment review impairment review base current tax provide amount expect pay riskadjuste future cash flow discount appropriate defer tax temporary difference tax basis asset interest rate future cash flow base business forecast liability carry amount rate inherently judgemental future event cause enact substantially enact balance sheet date value intangible asset impair group open tax issue number revenue authority adverse effect future result group principally relation transfer pricing dispute gsk use good pension postemploymentbenefit advice determine transfer pricing methodology seek cost provide pension postretirement benefit manage transfer pricing issue satisfactory conclusion charge theincome statementin accordance withias rover basis external professional advice continue believe period benefit derive employee service adequate provision liability likely arise open cost assess accordance advice receive assessment continue wide difference independent actuary basis assumption select view open issue exist ultimate liability matter management use ifrs usgaap vary amount provide dependent assumption include future earning pension increase discount outcome litigation proceeding negotiation relevant rate expect long term rate return asset tax authority disclose innoteto thefinancial statementspension legal dispute postemployment benefit expect long term rate return gsk provide anticipate settlement cost reasonable onbondsare determine base onthe portfolio mix indexlinke estimate likely outcome dispute legal governmentand corporatebondsan equity risk premium add expense arise claim group equity discount rate arebase appropriate longterm company director take legal advice establish index include theiboxxover year aaindexfor ukand provision take account insurance agreement moodys indexfor usa sensitivity analysis provide note regard relevant fact circumstance areductionin discount rate lead matter accordance accounting requirement provision increasein net pension deficitof approximately million product liability claim certain product anincreasein annual pension cost approximately million incur report basis sufficient history claim selection different assumption affect future result settlement available provision group unasserted claim claim reasonable estimate product right goodwill likely outcome ultimate liability addition critical accounting policy outline pende unasserted claim vary amount provide accounting policy product right goodwill deem dependent outcome litigation proceeding important respect balance sheet prepare accordance investigation possible settlement negotiation accounting principle gaap merger glaxo impairment fix asset wellcome smithkline beecham account carry value fix asset subject depreciation acquisition give rise product right billion amortisation review impairment indication goodwill billion recognisedgoodwill product value asset impaired impairment right determine indefinite life amortise determine reference high net realisable value review annually impairment impairment review assess value use measure reference riskadjuste future cashflow business projection prepare group annual discount appropriateinter rate future cashflow budgeting planning process determine base business forecast inherently impairment invalueha occur business projection include judgemental future event cause assumption assumption future event change future event impairment review change consequent adverse effect cause assumption business projection change future result group consequent adverse effect future result group report gaap gsk annual report srotcerid eht troper operate financial review prospectsfinancial position property plant equipment total cost group property plant equipment december billion net book value asset billion land building represent billion plant noncurrent asset equipment billion asset construction billion property plant equipment glaxosmithkline invest million new renewal goodwill property plant equipment mainly relate large intangible asset number project renewal improvement expansion investment associate facility worldwide site property mainly hold freehold joint venture new investment finance group liquid resource investment december group capital contractual commitment defer tax asset future expenditure million operating lease noncurrent asset commitment million total noncurrent asset gsk business sciencebase technologyintensive highly regulate governmental authoritiesthe groupallocate significant current asset financial resource renewal maintenance property inventory plant equipment minimise risk interruption production current tax recoverable achieve compliance regulatory standard number trade receivables process use chemical hazardous material liquid investment cash cash equivalent group observe stringent procedure use specialist skill asset hold sale manage environmental risk activity environmental issue date operation modify total current asset discontinue report responsibility environment total asset health safety note ffinancial statement legal proceeding gsk believe facility liability adequate current need current liability shortterm borrowing intangible asset trade payable intangible asset include cost intangible acquire current tax payable party computer software cost intangible shortterm provision asset december million million increase include addition total current liability million arise fromthe acquisition ofcorixa corporation noncurrent liability biomedicalcorporation longterm borrowing investment defer tax provision gsk hold investmentsincludingassociate joint ventureswith pension post carry value december million employment benefit millionthe market value december million provision million investmentsare mainly equity share noncurrent liability hold derive directly group business total noncurrent liability large investment associate quest diagnostics inc total liability book value december million million theinvestment include stake company net asset group research collaboration provide access equity biotechnology development potential interest interest share capital company arise business divestment share premium account trade receivables retain earning trade receivablesinclude million million reserve derivative financial instrument hold fair value shareholder equity remain increase reflectsincrease sale impact strengthen overseas currency translation foreign minority interest currency receivable total equity trade payable trade payable include million million derivative financial instrument hold fair value remainingincreasereflect increase customer return rebate accrual andstrengthene foreign currency gsk annual report srotcerid eht troper operate financial review prospect financial position resourcesfinancial position resource continue provision share purchase group carry defer tax provision shortterm esop trust market purchase share noncurrent provision million december gsk plc nil share hold trust satisfy future million respect estimate future liability exercise option award group share option million relate legal dispute award scheme proportion share hold trust respect award rule scheme require company provision tax legal dispute indemnify satisfy exercise market purchase issue disposal liability cost manufacture restructure new sharesthe share hold trust match option merger integration extent balance sheet date award grant diminish dilutive effect new share issue actual constructive obligation exist reasonably shareholdersequityand earning estimate december esop trust hold million gsk pension postemployment benefit sharesagainst future exercise share option share awards group account pension postemployment thecarrying value low cost expect proceed arrangement accordance iasrthe net deficitbefore million deduct reserve allow defer taxationwasmillion market valueof share wasmillion million special cash contribution million million reduce funding deficit gsk repurchase billion share treasury share plan expect repurchase billion exact time future purchase depend market condition net debt factor december gsk hold million share treasury share cost million deduct retain earning cash cash equivalentsand liquid investment commitment contingent liability borrowing repayable year financial commitment summarise innoteto theffinancial borrowing repayable year statement commitment contingent liability net debt obligation respect short longterm debt set innote thefifnancial statement contingent liability andnoteto net debt reduce million millionprimarily theffinancial statement net debt increase operating profit partly offset acquisition amount provide pension postretirement benefit corixaand idbiomedicalfor total consideration billion restructuring integration plan legal environmental total equity dispute set innoteto theffinancial statement summary movement equityis set provision contractual obligation commitment follow table set group contractual obligation total equity beginning year commitment december fall payment implementation accounting total yrs yrs yrs financial instrument ias total equity beginning year adjust loan total recognise income expense interest loan year finance lease obligation dividend shareholder operating lease ordinary share issue commitment ordinary share purchase cancel intangibleasset ordinary share purchase held property plant treasury share equipment ordinary share issue esoptrust pension sharebase payment commitment change minority interest shareholding total minority interest total equity atend year commitment respect future interest payable loan disclose take account effect interest rate swap gsk annual report srotcerid eht troper operate financial review prospectsthe group enter number research collaboration cash flow develop new compound pharmaceutical company asummary consolidated cash flow statement set term arrangement include upfront fee equity investment loan commitment fund specify level research addition group agree net cash inflow operating activity payment future milestone achieve net cash outflow investing activity agreement relate compound early stage development net cash outflow financing activity milestone payment continue number year compound successfully development process increase cash bank overdraft generally close product marketing approval great exchange adjustment possibility success payment show intangible cash bank overdraft begin year asset represent maximum pay milestone achieve number commitment cash bank overdraft end year licensing agreement principallywithvertex pharmaceuticals cash bank overdraft end year inc comprise gskhas agree trustee pension scheme cash cash equivalent additionalcontribution approximately million overdraft year fiveyear period end december orderto eliminate pension deficitson ias basisby pointthe table show commitment basis deficit net cash inflow operating activity taxation pay december amount total contribution normal plus million increase million arise additional approximately million year commitment principally high operating profit past december net cash outflow investing activity million contingent liability increase million reflect purchase corixa follow table set contingent liability comprise idbiomedical billion purchase business discount bill performance guarantee item arise billion reflect purchase fraxiparineand normal course business expect expire arixtrafrom sanofi total yrs yrs yrs free cash flow million increase free cash flow cash generate business guarantee meet obligation interest tax dividend pay minority contingent liability interest capital expenditure noncurrent tangible intangible asset total free cash flow gsk management plan normal course business group provide reporting purpose discussion presentation indemnification guarantee respect business disposal investment analyst gsk free cash flow present basis legal dispute subsequently arise provision accordance ifrs measure directly reasonable estimate likely outcome comparable similarly describe measure dispute include noteto theffinancial statement company reconciliation net cash inflow operating provision activity close equivalent ifrs measure free cash group policy provide settlement cost assert flow show claim environmental dispute reasonable estimate reconciliation free cash flow prior point liability record legal environmental cost discuss risk factor pagesto gsk use good advice determine transfer pricing net cash inflow operating activity methodology basis external professional advice purchase noncurrent intangible asset continue believe adequate provision purchase noncurrent tangible asset liability likely arise open taxation assessment ultimate disposal noncurrent tangible fix asset liability matter vary significantly amount provide interest pay dependent outcome litigation proceeding interest receive negotiation relevant tax authority discuss dividend receive joint venture noteto theffinancial statement taxation associate undertaking dividend pay minority interest free cash flow gsk annual report srotcerid eht troper operate financial review prospect financial position resource continuedfinancial position resource continue reconciliation net cash flow movement net debt payment performance december average number day purchase represent trade fix asset creditor parent company net debt begin year nil nil respect company increasein cash year subsidiary aggregate wasday day cash outflowinflowfrom management liquid resource treasury policy net increase longterm loan glaxosmithklineplc report sterling pay dividend net repayment shortterm loan sterling profit role corporate treasury gskis manage exchange movement monitor group external internal funding requirement net debt end year financial risk support group corporate objective treasury activity govern policy procedure approve investment appraisal board monitor treasury management group gskha formal process assess potential investment proposal order ensure decision align group overall gsk maintain treasury control system procedure monitor strategy process include analysis impact profit foreign exchange interest rate liquidity credit financial risk assessment return base discount cash flow liquidity discount rate perform financial analysis decide internally gsk operate globally primarily subsidiary company allow determination extent investment cover established market group trade group cost capital specific investment discount rate nature ofgsk business patent protection adjust account country risk weighting product initsportfolio group product compete largely capital expenditure financial investment product efficacy price selling margin sufficient cash payment tangible intangible fix asset amount cover normal operating cost group operating subsidiary million million disposal realise million substantially cash generative million cash payment acquire equity investment operate cash flow fund investment research million million year sale development new product routine outflow capital equity investment realise million million expenditure tax dividend repayment mature debt future cash flow group time time additional demand finance group expect future operating cash flow sufficient share purchase acquisition fund operate debt service cost satisfy normal level gsk operate high level interest cover low level capital expenditure meet obligation exist licensing net debt relative market capitalisation addition strong agreement meet routine outflow include tax positive cash flow normal trading activity additional liquidity dividend subject risk factor discuss pagesto readily available commercial paper programme short group time time additional demand term investment group aeuropeanmedium term note finance acquisition group access programme billion billion issue source liquidity bank financial institution december group establish shelf addition cash flow operation forsuch need registration billion december billion billionwa issue payment policy treasury operation group company responsible monitoring manage objective treasury activity manage posttax net work capital term sale collection supplier payment costincome financial operation benefit group earning reflect local commercial practice corporate treasury operate profit centregsk use company subsidiarie policy variety financial instrument include derivative finance ensure supplier pay time particular operation manage market risk operation company seek derivative principally comprise forward foreign currency contract settle term payment supplier agree term interest rate currency swap swap borrowing transaction liquid asset currency require group purpose ensure supplier aware agree term manage exposure funding risk change foreign exchange ofpayment rate interest rate abide term payment policy include arrangement accelerate payment small supplier gsk annual report srotcerid eht troper operate financial review prospectsfinancial position resource continue gsk balance use borrowing liquid asset regard borrowing denominate swap foreign currency cash flow operating activity thecurrencie match investment overseas group asset treat hedge earn tax cost intragroup distribution currency relevant net asset business asset denominate posttax cost base composition net debt december borrowing compare totheposttax return liquid asset appreciation sterle major currency result liquid asset surplus immediate operating requirement reduction group net debt approximately million group company generally invest manage centrally weaken sterle major currency result corporate treasury requirement group company operate increase group net debt approximately million finance meet possible central resource interest rate risk management external borrowing mainly manage centrally corporate treasury gsk policy interest rate risk management require comprise portfolio long mediumterm instrument short net borrowing fix rate increase ratio term finance forecast net interest payable trading profit gsk hold issue derivative financial instrument trading group use limited number interest rate swap purpose group treasury policy specifically prohibit redenominate external borrowing interest rate coupon activity transaction financial instrument undertake require group purpose duration swap match manage risk arise underlie business activity duration theprincipal instrument interest rate derivative speculation instrument account fair value cash flow hedge relevant asset liability fund maturity counterparty risk group invest centrally manage liquid asset government group manage centrally shortterm cash surplus bond shortterm corporate debt instrument minimum borrowing requirement subsidiary company use forward shortterm credit rating money market fund credit contract hedge future repayment originate rating aaaaaa andother structure investmentscredit rating currency show standard poor moodys investor service sensitivity analysis consider sensitivity group net debt respectively hypothetical change market rate assume group manage net borrowing requirement variable remain constant base composition net debt portfolio longterm borrowing include bond finance arrangement december take shortterm finance billion commercial paper consideration fix rate borrowing place percentage programme intwo bond issue european point basis pointsdecrease average interest rate result medium term note programme millionsevenyear increase group annual net interest charge coupon bondand million yearcoupon bond approximately million groupslongterm borrowing mature date equity risk management includea private financing mature equity investment classify current asset availableforsale redeem gsk time particular group manage disposal meet overall business event accelerate event increase cost requirement arise group regularly monitor value funding group gsk longterm debt rating equity investment enter hedge selectively standard poor moodys investor service approval board agency shortterm rating paper issue group financial asset liability commercial paper programme respectively analysis net debt give noteto theffinancial statement foreign exchange risk management net debt analysis financial asset liability carry gskforeign currency transaction exposure arise normal trade value fair value reconciliation net debt give note flow respect external intragroup trade theffinancial statement financial instrument relate hedgedthepolicy minimise exposure overseas operating disclosure discussion derivative financial subsidiary transaction risk match local currency income instrument quantitative disclosure market risk local currency cost purpose intragroup trading transaction accordance requirement ias ias match centrally intragroup payment term manage group continue benefit strong positive cash flow group reduce risk exceptional foreign currency cash flow hedge net debt decrease significantly year selectively management corporate treasury december group purchase share significant proportion group borrowing include market billion acquisition approximately billion commercial paper programme dollar benefit financial asset liability december liquidity dollar denominate capital market certain representative treasury policy strategy gsk apply borrowing swap currency require consistently year significant change group purpose group seek denominate borrowing policy year currency principal assetsand cash flow gsk annual report srotcerid eht troper operate financial review prospectsoutlook risk factor outlook new product candidate appear promise development significant investment fail reach market limited sale growth exist product launch new product commercial success result efficacy safety concern inability key driver gsk business performance strong growth see obtain necessary regulatory approval difficulty excessive cost key product seretideadvair avandiaavandametand manufacture infringement patent intellectual property gsk vaccine business expect continue right inability differentiate product adequately major development project schedule enter phase iii compete include oncology product casopitant pazopanibas product alzheimer disease hiv meningitis lupus risk loss expiration patent marketing exclusivity diabete seven product filing plan patent infringement litigation include vaccine cervarix cervical cancer potential flu effort generic manufacturer involve challenge validity pandemic vaccine allermistfor allergic rhinitis eltrombopag low patent assertion alternative compound platelet count help patient suffer thrombocytopenia infringe group patent group successful tykerbfor breast cancer mepolizumab hypereosinophilic syndrome patent protection datum exclusivity period maintain exclusive lamictal oncedaily formulation epilepsy right market major product particularly usa group high turnover margin seven product expect launchedapproved group turnover margin adversely affect note include rotarix rotavirus entereg postoperative bowel thefifnancial statement legal proceeding discussion disorder trexmiafor migraine avandaryl diabete coreg crfor patentrelate proceeding group involve heart failure arranonfor cancer altabaxfor infection generic drug manufacturer seek market generic version typically sale exist product decline dramatically generic group important product include avandia competition introduce patent expiry early zofran wellbutrin imitrexlamictal valtrex andpaxil prior successful challenge group patent glaxosmithkline expiration group patent exhibit readiness engage legal proceeding validity infringement product future generic product competitive group patent relate product paxil wellbutrin launch usa discuss risk factor note ffinancial respectively significant impact group overall statement legal proceeding turnover earning gsk publish earning guidance earning weakness intellectual property protection certain share growth expect constant exchange country rate term country group operate patent group net debt billion low relative protection significantly weak usa market capitalisation position advantage european union addition effort control public health opportunity arise build business crisis develop country south africa brazil consider plan substantial reduction scope patent risk uncertaintie inherent business protection pharmaceutical product particular country affect future performance include project anticipate sale facilitate competition market generic growth expect earning growth discuss risk manufacturer unable introduce factor compete product number year risk factor loss patent protection include abrogation patent right compulsory licensing likely affect adversely group risk uncertaintie relevant group business operating result national market expect factor list group think material group overall absence adequate patent protection cause group actual result differ materially expect limit opportunity look market future sale historical result growth risk deliver commercially successful new product continue development commercially viable new product critical group ability replace sale old product decline expiration exclusive right increase overall sale develop new product costly lengthy uncertain process new product candidate fail stage process latestage product candidate fail receive regulatory approval gsk annual report srotcerid eht troper operate financial review prospectsoutlook risk factor continue risk substantial adverse outcome litigation antitrust litigation government investigation usa increasingly common follow noteto fifnancial statement legal proceeding adverse outcome prosecution patent infringement action discussion proceeding governmental investigation defendant direct indirect purchaser payer initiate group currently involve unfavourable resolution antitrust action claim direct indirect purchaser similar future proceeding investigation material payer typically file class action relief seek adverse effect group financial result group include treble damage restitution claim damage material provision relate legal adverse antitrust verdict subject automatic trebling usa proceeding investigation reduce earning group sale marketing regulation additional significant provision relate legal group operate globally complex legal regulatory proceeding investigation future reduce environment vary jurisdiction failure earning case practice plaintiff bar claim comply applicable law rule regulation jurisdiction damage compensatory punitive statutory amount result civil criminal legal proceeding usa bear relationship underlie harm accordingly example group respond federal state governmental potentially mislead quantify potential exposure claim investigation pricing marketing reimbursement proceeding investigation type describe note prescription drug product investigation result related recent insurance loss experience include pharmaceutical product restitution civil false claim act litigation behalf federal liability exposure increase cost narrow state government relate proceeding initiate coverage afford insurance pharmaceutical company group behalf consumer private payer generally include group proceeding result trebling damage award fine respect violation law criminal proceeding order contain insurance cost inrecent yearsthe group initiate group company individual continue adjust coverage profile accept great degree uninsured exposure addition whereclaims risk competition price control limitation sale insurance policy insurer reserve right deny coverage party competition ground denial coverage ultimately uphold group operate highly competitive business claim result material additional charge group pharmaceutical business face competition proprietary earning product large international manufacturer producer generic pharmaceutical significant product innovation technical product liability litigation advance intensification price competition competitor preclinical clinical trial conduct development adversely affect group operating result continue potential product determine safety efficacy product consolidation pharmaceutical industry adversely affect use human follow approval regulatory body group competitive position continue consolidation notwithstanding effort drug vaccine group customer increase pricing pressuresthe introduce marketplace unanticipated effect group hadproduct million annual global sale evident group currently defendant number product liability lawsuit include class action involve substantial claim damage relate group pharmaceutical productsisaugmentin respect towhich productslitigation particularly usa inherently unpredictable groupalready generic competition zofran imitrex valtrex excessive verdict justify evidence occur avandia wellbutrin respect group class action sweep person prescribe intellectual property right usaare currently subject group product inflate potential liability force litigation flonase fdaapprovedthe firstgeneric number claim pain suffer punitive damage versionin february frequently assert product liability action allow represent potentially openende exposure gsk annual report srotcerid eht troper operate financial review prospectsoutlook risk factor continue group major product regulatory control subject problem loss patent protection unexpected group comply broad range regulatory control effect regulatory proceeding publicity affect doctor testing approval manufacturing marketing patient confidence pressure competitive product new pharmaceutical consumer healthcare product particularly effective treatment introduce adverse impact usa countries european union affect group revenue operating result significant cost product development time require reach particular group face intense competition manufacturer market uncertainty successfully sostricter regulatory generic pharmaceutical product major marketsgeneric control heighten risk withdrawal regulatorson product enter market expiration patent datum basis postapproval concern product safety exclusivity period group product introduction generic reduce revenue result product recall product liability product typically lead dramatic loss sale reduce lawsuit group revenue margin proprietary product addition case group voluntarily cease marketing expiration date patent group major product set product example withdrawal lotronexin shortly pageand legal proceeding involve patent challenge set initial launch usa face decline sale base noteto fifnancial statement legal proceeding concern efficacy safety scientifically justify governmental payer control absence regulatory action development pharmaceutical product subject price control pressure postapproval adverse event profile product product class restriction market include japan germany france major impact marketing sale product italy government intervene directly set price risk interruption product supply addition market major purchaser pharmaceutical manufacture pharmaceutical product constituent product governmental agency private health care material require compliance good manufacturing practice provider economic power exert substantial pressure regulation group manufacture site subject review price term access formulary approval fda regulatory agency compliance group predict exist control increase failure supplier key material group manufacture new control introduce reduce group margin facility lead product recall seizure interruption affect adversely ability introduce new product profitably production delay approval new product pende resolution manufacturing issue noncompliance result example usa group high margin fine disgorgement profit interruption supply fine sale country pricing pressure significantly disgorgement remedy materially adversely affect increasefollowingimplementation pharmaceutical benefit group financial result group cidra puerto rico facility medicare event state programme work resolution fda observation deficiency control cost ofprescription drugsare adoptedas experience manufacturing practice subject compliance consent develop underthe medicare programoutpatient pharmaceutical decree enter fda refer note coverage beneficiarie government theffinancial statement legal proceeding consequence private insurer coverage offer discussion supply certain product manufacture enormous purchasing power program demand cidra curtail constrictedwhich adverse impact discount implicitly create price control prescription sale drugsadditionally number state propose implement scheme control price senior citizen group undertake business continuity plan single program include importation country bulk source certain component bulk active material finish purchase drug growth number patient cover product create risk failure supply event regulatory large manage care institution usa likely noncompliance physical disruption manufacturing site increase implementation medicarebenefit increase pricing pressure group productsthese trend adversely affect group revenue margin sales usa gsk annual report srotcerid eht troper operate financial review prospectsoutlook risk factor continue risk concentration sale wholesaler global political economic condition usa line pharmaceutical company group group conduct substantial portion operation outside sell product small number wholesaler addition group management foreign exchange rate discuss hospital pharmacie physician group sale operate financial review prospect foreign exchange large amount approximately risk management fluctuation exchange rate sterle group pharmaceutical sale december group currency especially dollar euro trade receivablesdue wholesaler total japanese yen materially affect group financial result million december million group group control change inflation interest rate expose concentration credit risk respect foreign currency exchange rate control economic wholesaler affect financial factor affect business possibility political unrest difficulty materially adversely affect group financial legal regulatory change nationalisation jurisdiction result group operate factor materially affect group environmental liability future result operation environmental law jurisdiction impose actual accounting standard potential obligation group remediate contaminate site new revise accounting standard rule promulgate group identify potentially responsible party time time byus international accounting standard setting board comprehensive environmental response compensation material adverse impact group report financial liability act number site remediation cost relate result adoption international financial reporting group use ownership site failure manage properly standard ifrs change market valuation certain financial environmental risk result additional remedial cost instrument equity collar link group investment materially adversely affect group operation note quest diagnostic option link group theffinancial statement legal proceeding discussion strategic alliance theravance impairment equity environmentalrelate proceeding group involve investment reflect group report result reliance information technology gain loss actually realise significant impact group increasingly dependent information technology theresult give period group believe complie system include internetbased system internal communication appropriate regulatory requirement concern financial communication customer supplier statement disclosure company significant disruption system computer experience investigation potential noncompliance virus outside incursion materially adversely account disclosure requirement result affect group operation significant penalty taxation human resource effective tax rate group earning benefit fact group approximately employee world portion earning tax favourable rate subject law regulation concern employee jurisdiction outside change tax law application range discrimination harassment personal privacy respect matter transfer pricing risk double labour relation vary significantly jurisdiction jurisdiction taxation relate portion group earning tax failure continue recruit retain right people maintain favourable rate increase group effective tax rate culture compliance significant adverse affect adversely affect financial resultsthe group open issue group revenue authority usa japan canada far large relate glaxo heritage product respect internal revenue service inland revenue compete contradictory claim matter discuss noteto theffinancial statement taxation disruption pandemic influenza event pandemic influenza group subject disruption range factor national government willing abrogate intellectual property right medicine short supply country afflict pandemic flu risk employee family affect consequence sale distribution manufacturing activity shut supply continuity active ingredient finish good affect gsk annual report srotcerid eht troper operate financial review prospect year accordance ussec disclosure requirement follow pharmaceutical turnover discussion compare result year december growth rate include review turnover constant result year december information exchange rate cer state sterling growth prepare ifrs rate find table pharmaceutical turnover growth rate constant exchange rate cer therapeutic area page state sterling growth rate turnover product total pharmaceutical turnover million compare find table pharmaceutical sale therapeutic area million increase cer sterling term page turnover decline principally weakness dollar exchange currency influence group result pharmaceutical turnover therapeutic area dollar euro japanese yen gsk ability continue deliver pharmaceutical turnover growth pound hit high level dollar despite generic competition product primarily year climb yearend euro gain exceptionally broad product portfolio fastgrowe high sterling dollar value product second consecutive year dollar fall value include respiratory product seretideadvairup euro impact continue unrest iraq tension billion diabete treatment avandiaavandametup world concern economy billion lamictalfor epilepsybipolar disorder billion valtrexfor herpe billioncoregfor heart disease world market pharmaceuticals billion vaccine billion global pharmaceutical sale increase billion gsk product sale million world market value growth geographic region total cer respiratory usa gsk continuedto global leader respiratory pharmaceutical europe sale key product seretideadvair flixotideflovent germany serevent amount billion sale france seretideadvair group large productgrew billion contribute decline sereventand flixotide italy constituent products japan usa advairsales grow billion growth seretide asia pacific europe strong million international latin america sale grow reflect good growth geographic area middle east africa canada old respiratory product ventolinand becotidecontinued decline patient convert new product total central nervous system cns growth market slow remain double digit cns sale decline billion sale decline region represent global prescription pharmaceutical market compare decade ago total sale ofpaxilwere billion result generic competition paxil sale decline million september gsk hold second position world mitigate decline strong performance product pharmaceutical market market share pfizer japan million performance paxil market share gsk eightofthe world generate sale million pharmaceutical product augmentin avandia imigranimitrex lamictal seretideadvair seroxatpaxil wellbutrin total sale wellbutrinproduct fall million wellbutrin zofran sale fall million result generic competition impact partially offset world market value growth exceptionally strong performance wellbutrin new therapeutic class total cer daily product achieve sale million year cardiovascular market central nervous system strong growth gsk epilepsy bipolar disorder treatment alimentary tract metabolic lamictalcontinue sale million ongoing antiinfective bacterial viral growth million drive indication fungal exclude vaccine maintenance treatment bipolar disorder receive respiratory note datum base month thseptember gsk annual report srotcerid eht troper operate financial review prospectsantiviral total sale ofpaxil million result global hiv product sale rise billion sale usa generic competition paxil irsale decline increase million gsk continue grow hiv million mitigating decline performance paxil franchise despite launch new product competitor generate sale million hiv performance enhance launch epzicom new sale antiviral therapeutic area grow hiv product combination product epivirziagen usa august valtrex herpe grow drive patient switch suppression therapy sale herpe treatment valtrex exceed million time million performancewasdriven sale ofavandiaavandamet increase antibacterial sale usa million product clear decline result generic competition begin market leader treatment genital herpe quarter coregsale increase continued benefit wide range indication antibacterial antibacterial sale decline worldwide usa vaccine grew reflect good performance pediarix reflect generic competition region europe metabolic discussion individual market performance europe region turnover create basis turnover invoice basis diabetes treatment avandiaavandametcontinuedto perform year explanation adjustment strongly overall sale billion sale usa grow million encouragingly avandia europe region contribute pharmaceutical turnover avandamet grow strongly europe international overall turnover growth region good growth market sale respectively strong record spain southern eastern europe government performance marketswasdriven grow acceptance healthcare reform include price reimbursement restriction opinion leader physicians benefit new adversely affect turnover france italy germany product improve control diabetic patient seretide gsk large selling product europe grow vaccine report notable growth spain seretide vaccine business strong year sale constituent product sereventand flixotidegrew billion key productsdrovegrowth pediarixinfanrixup million priorix million fluarix decline sale herpe franchise mainly result million generic competition zovirax partially offset patient switch new product valtrex oncology emesis sale zofran grow million drive seroxatsale reflect generic competition performance million france cardiovascular urogenital antibacterial sale decline generic competition coregfor heart disease sale grow million region therapeutic area vaccine grew drive hepatitis franchise infanrix sale zantac fall millionwith decline region international usa international region report year year turnover growth usa report flat turnover indespite significant impact strong growth asia pacificup latin americaup generic competition paxiland wellbutrin exclude sale offset flat sale australia decline subsaharan product turnover grow business represent africa middle eastnorth africa canada total pharmaceutical turnover canada sale decline generic erosion paxil exclude element canada grow advairmaintaine strong growth sale million adversely affect sale constituent japan record turnover growth despite routine government product floventand sereventwhich show decline flonase price reduction implement paxil serevent indicate treatment perennial rhinitis grow valtrex perform particularly welloffsette small decline zantacand zovirax sale wellbutrinproduct fall million wellbutrin sale fall million result generic market international key product drive growth competition impact partially offset seretide grow record sale million exceptionally strong performance wellbutrin new avandiaavandamet grow million daily product achieve sale million year vaccine franchise record growth achieve sale market million gsk annual report srotcerid eht troper operate financial review prospect year continue year continue gsk annual report srotcerid eht troper operate financial review prospect pharmaceutical turnover therapeutic area total usa europe international therapeutic area growth growth growth growth major product total cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxilir paxil wellbutrin wellbutrin wellbutrin imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen retrovir agenerase lexiva herpe valtrex zovirax zeffix antibacterials augmentin augmentin augmentin augmentin zinnatceftin metabolic avandiaavandamet vaccine hepatitis infanrix pediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart zantac cer represent turnover growth constant exchange rate represent growth actual exchange ratesconsumer healthcare sale operatingprofit growth analysis ofoperatingprofit subsequent discussion cer compare result result otc medicine growth analgesic cer dermatological turnover gastrointestinal respiratory tract cost sale smoking control sell general natural wellness support administration research oral care development nutritional healthcare operating income operatingprofit growth consumer healthcare sale billion comprise otc medicine sale increase oral care sale increase nutritional healthcare sale increase cost sale cost sale percentage turnover remain broadly line otcmedicine prior year reduce merger manufacturing otc medicine sale billion sale growth restructuring cost offset significant weakening smoke control products usa europe dollar relative loss high margin paxil irand wellbutrin helped offset decline dermatological product sale generic adverse product mix merger generic competition cutivate usa manufacturing restructuring cost nil million expansion panadol brand international market help analgesic grow sell general administration july gsk obtain otc marketing right usa orlistat sell general administration sga cost decline fdaapprove prescription product obesity management decline sterling term reflect saving general market roche xenical administration partly offset increase advertising oral care promotion selling cost cost increase oral care sale billion strong growth account percentage point increase total sga international lead sensodyne polidentand poligrip general administration cost decline account brand asixpercentage point reduction total sga low charge relate programme deliver future cost saving equal nutritional healthcare percentage point reduction total sga general sale nutritional healthcare product grow billion expense reduction equal afourpercentage point decline total lucozade grow million sganet currency movement overall reduction ofpercentage point relative expense express percentage turnover research development expenditure increase reflect increase clinical trial activity pharmaceutical expenditure represent pharmaceutical turnover year operatingincome operating income include royalty income equity investment disposal impairment product disposal operate income million compare million reflect low product asset disposal gsk annual report srotcerid eht troper operate financial review prospect year continue year continue operatingprofit taxation overall theoperate profitmarginincreasedpercentage point asoperatingprofit million decline sterling termson corporation tax turnover decline constant exchange ratesoperatingprofit overseas taxation increase reflect completion merger manufacturing restructure programme andlower charge current taxation relate programme deliver future cost saving partly offset defer taxation increase expenditureand low product asset disposal total share tax profitslosse associate joint charge taxation profit amounting million venture represent effective tax rate share profit associate arise principally group hold inquest diagnostic inc integrate nature group worldwide operation involve significant investment research strategic manufacture disposal interest associates limit number location consequential crossborder supply group dispose million share route numerous endmarket give rise complexity delay investment quest diagnostic inc cash proceed million negotiation revenue authority profit reduce group shareholde december individual group company liable taxdisagreement recognise charge million goodwill previously revenue authority intragroup transaction write reserve profit million recognise particular price good transfer group company different tax jurisdiction produce finance income conflict claim revenue authority profit interest income tax individual territory resolution issue continue unwind discount asset fact life gsk group open issue revenue authority usa japan canada far large relate glaxo heritage product respect internal revenue service irs inland revenue compete financecost contradictory claim interestcost unwind discount onprovision late position taxation taxation year operate financial review prospect page profit taxation take account finance income financecost thecontribution associate business disposal profit tax million compare million anincrease decline sterlingterm gsk annual report srotcerid eht troper operate financial review prospectsprofit year growth cer profit taxation year profit attributable shareholder earning share penny earning ad weight average number share million diluted earning share penny dilute earning ad weight average number share million profit year million increase decline sterling term net profit attributable minority interest profit attributable shareholder million increase decline sterling term ep pence compare pence sterling base decline eps reflect significant weakening dollar exclude effect currency statutory eps grow reflect completion group merger restructuring programme underlie business growth partly offset high tax rate dividend board declare fourth interim dividend penny share make total year penny share compare total dividend penny share gsk annual report srotcerid eht troper operate financial review prospect year continuedfinancial statement section comprise director statement responsibility independent auditor report financial statementsandthe consolidated financial statement consist principal financial statement support note prepare ifrsa adopt use european union presentedi balance sheetof glaxosmithkline plcwhich hasbeen prepare ukgaap director statement responsibility independent auditor report financial statement consolidated income statement consolidate balance sheet consolidate cash flow statement consolidate statement recognise income expense note financial statement presentation financial statement accounting policy new accounting policy future requirement exchange rate segment information operating income operating profit employee cost finance income financecost associate joint venture taxation earning share dividend property plant equipment goodwill intangible asset investment associate joint venture investment noncurrent asset inventory trade receivables cash cash equivalent asset hold sale trade payable pension postemployment benefit provision noncurrent liability contingent liability net debt share capital share premium account movementsin equity relate party transaction acquisition disposal commitment financial instrument relate disclosure employee share scheme reconciliation accounting principle principal group company transition ifrs legal proceeding balance sheetof glaxosmithkline plc prepare ukgaap gsk annual report stnemetat laicnanifdirector statement responsibility director statement responsibility relation internal control consolidated financialstatements board audit committee review director areresponsible assessment risk internal control framework operate glaxosmithkline consider effectiveness system ensure maintenance proper accounting record internal control operation inthegroup year cover disclose reasonable accuracy financial position group report date approval board director time financial statement beprepare comply company actand article ia combine code regulation board consider glaxosmithkline plc apply principle preparingfinancial statement financial period combine code corporate governance financial true fair view accordance ifrs adopt use reporting council asdescribe corporate governanceon european unionof state affairs thegroup page comply provision end financial period ofthe profit loss period describe page ensure operation system internalcontrol take require listing rule financial service authority reasonable step safeguard asset group auditor haveconsidere director statement compliance prevent detect fraud irregularity relation point combine code specify financialstatement year end december theirreview comprise principal statement support note set infinancial statement page report annual report director confirm suitable accounting policy annual report year end december consistently apply preparation financialstatement comprise report director remuneration report support reasonable prudent judgement estimate financial statement additional information investor asnecessary approve board director sign behalf responsibility auditor relation financial statement set independent auditor report page opposite financialstatement year end december include annual report publish hardcopy print form available website director sir christopher gent responsible maintenance integrity annual report chairman website accordance legislation govern stmarch preparation dissemination financial statement access website available outside comparable legislation different director remuneration remuneration report page set remuneration policy operate glaxosmithkline disclosure director remuneration disclosable information relate director officer interest prepare accordance company act complie section combine code corporate governance go concern basis make enquiry director reasonable expectationthat grouphasadequate resource continue operational existence foreseeable future forthis reason continue adopt go concern basis inprepare financial statement gsk annual report stnemetat laicnanifindependent auditor report members glaxosmithkline plc audit group financial statement glaxosmithkline basis audit opinion plc year end stdecember comprise conduct audit accordance international standard consolidate balance sheet consolidated income statement audit ireland issue auditing practice board consolidated cash flow statement consolidate statement audit include examination test basis evidence relevant recognise income expense relate note group amount disclosure group financial statement financial statement prepare accounting policy include assessment significant estimate set judgment director preparation group report separately parent company financial financial statement accounting policy statement glaxosmithkline plc year end stdecember appropriate group circumstance consistently apply information director remuneration report adequately disclose describe audit plan perform audit obtain information explanation consider necessary order respective responsibility director provide sufficient evidence reasonable assurance auditor group financial statement free material director responsibility prepare annual report misstatement cause fraud irregularity error group financial statement accordance applicable law form opinion evaluate overall adequacy international financial reporting standard ifrss adoptedbythe presentation information group financial statement european union set director statement responsibility opinion responsibility audit group financial statement opinion accordance relevant legal regulatory requirement group financial statement true fair view international standard audit ireland report accordance ifrss adopt bythe european union include opinion prepare state group affair stdecember company member body accordance section profit cash flow year end company act purpose give opinion accept assume responsibility purpose group financial statement properly prepared person report show accordance company act article ias hand come save expressly agree prior consent regulation write separate opinion relation ifrss report opinion group financial statement true fair view group financial explain note group financial statement group statement properly prepare accordance addition comply legal obligation comply ifrss company act article ias regulation adopt bythe european union comply ifrss report opinion director report consistent issue international accounting standard board group financial statement receive opinion group financial statement true fair view information explanation require audit accordance ifrss state group affair information specify law director remuneration december profit cash flow year transaction disclose end review corporate governance statement reflect company compliance provision frc combine code specify review list rule financial service authority report require consider board statement internal control cover risk control form opinion effectiveness group corporate governance procedure pricewaterhousecooper llp risk control procedure charter accountant register auditor read information contain annual report london consider consistent audit group financial stmarch statement information comprise onlythe joint statement chairman chief executive financial summary description business corporate governance statement operate financial review prospect consider implication report aware apparent misstatement material inconsistency group financial statement responsibility extend information gsk annual report stnemetat laicnanifconsolidate income statement year end december note turnover cost sale gross profit sell general administration research development operating income operate profit finance income financecost share tax profit associate joint venture profit disposal interest associates profit taxation taxation profit disposalof business profit taxation year profit attributable minority interest profit attributable shareholder basic earning share penny dilute earning share penny gsk annual report stnemetat laicnanifconsolidate balance sheet december note noncurrent asset property plant equipment goodwill intangible asset investment associate joint venture otherinvestment defer tax asset noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing trade payable current tax payable shortterm provision total current liability noncurrent liability longterm borrowing defer tax provision pension postemployment benefit provision noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity minority interest total equity approve board onstmarch sir christopher gent chairman gsk annual report stnemetat laicnanifconsolidate cash flow statement year end december note cash flow operating activity cash generate operation taxation pay net cash inflow operating activity cash flow investing activity purchase property plant equipment proceed sale property plant equipment proceed sale intangible asset purchase intangible asset purchase equity investment proceed sale equity investment share transaction minority shareholder purchase business net cash acquire disposal business interest associate investment associate joint venture interest receive dividend associate joint venture net cash outflow investing activity cash flow financing activity decreaseincrease liquidinvestment proceed share employee share option issue share capital share capital purchase cancellation purchase treasury share redemption preference share issue subsidiary increase longterm loan repayment longterm loan net repayment shortterm loan net repayment obligation finance lease interest pay dividend pay shareholder dividend pay minority interest dividend pay preference share finance cash flow net cash outflow financing activity increase cash bank overdraft exchange adjustment cash bank overdraft begin year cash bank overdraft end year cash bank overdraft end year comprise cash cash equivalent overdraft gsk annual report stnemetat laicnanifsupplementary information cash flow year end december reconciliation operating profit operating cash flow note operate profit adjustment depreciation impairment asset write amortisation intangible asset profitlosson sale property plant equipment profitlosson sale intangible asset profiton sale equity investment fair value loss inventory sell change work capital decreaseincreasein inventory increase trade receivables increasedecreasein trade payable decreaseincreasein pension provision sharebase incentive plan net cash inflow operating activity reconciliation net cash flow movement net debt net debt begin year implementation account financial instrument ia increasein cash bank overdraft cashinflowoutflowfrom liquid investment net increase longterm loan net repayment shortterm loan net repayment obligation finance lease net noncash fund subsidiary undertaking acquire exchange adjustment noncash movement movement net debt net debt end year previously adjust analysis change net debt report ias exchange acquisition cash flow liquid investment cash cash equivalent overdraft debt year commercial paper eurobond mediumterm note debt year eurobond mediumterm note private financing net debt information significant change net debt notenet debt gsk annual report stnemetat laicnanifstnemetat laicnanif consolidated statement recognise income expense year end december exchange movement overseas net asset tax exchange movement fair value movement availableforsale investment defer tax fair value movement revaluation goodwill exchange actuarial lossesgain define benefit plan defer tax actuarial movementsin define benefit plan fair value movement cash flow hedge defer tax fair value movement cash flow hedge net loss recognise directly equity profit year total recognise income expense year implementation account financial instrument ias total recognise income expense total recognise income expense year attributable shareholder minority interest implementation account financial instrument ias attributable shareholder minority interest gsk annual report note financial statement presentation financial statement financial statement prepare accordance group accounting policy approve board describe description business note glaxosmithkline major global healthcare group engage creation discovery development manufacture conversion ifrs marketing pharmaceutical product include vaccine overthe year glaxosmithkline produce financial counter otc medicine healthrelate consumer product statement ifrs adoption ifrs result number glaxosmithkline principal pharmaceutical product include significant adjustment previously report result equity medicine follow therapeutic area central nervous system shareholder fund present generally accept respiratory antiviral antibacterial vaccine oncology emesis accounting principle ukgaap main change relation metabolic cardiovascular urogenital sharebase payment pension intangible asset defer taxation financial instrument compliance applicable law ifrs financial statement prepare accordance ifrs firsttime adoption international financial reporting company act article ias regulation standard permit company adopt ifrsfor time international accounting standard ias international financial exemption requirement ifrs reporting standard ifrs relate interpretation adopt transition period glaxosmithkline adopt follow key use european union exemptions gsk therearenodifferencesbetween ifrs adopt use business combination business combination prior transition european union ifrs publish international date january restate ifrs basis accounting standard board sharebase payment ifrs sharebase payment apply financial period equity instrument share option grant financial statement cover financial year january november glaxosmithkline elect adopt stdecember comparative figure financial retrospective application standard year january december january financial instruments financial instrument comparative tost december period present annual report composition group record theukgaap basisapplicable year list subsidiary associate undertaking opinion accordance ias financial instrument disclosure director principally affect profit net presentation ias financial instrument recognition asset group give principal group company note measurement composition financial statement note detail consolidate financial statement draw accordance parent company financial statement ifrs ifrs accounting presentation financial financial statement parent company glaxosmithkline statement comprise plc prepare accordance ukgaap consolidated income statement accounting presentation thecompany balance sheet ispresente consolidated balance sheet page consolidate cash flow statement consolidate statement recognise income expense accounting policy note financial statement consolidation additional information accordance requirement consolidated financial statement include usgenerally accept accounting principle gaap include asset liability result cash flow note financial statement notea statement company subsidiary include esop trust difference reconciliation net income shareholder equity ifrs gaap provide group share net asset result associate joint ventures accounting convention financial statement prepare historical cost financial statement entity consolidate convention modify certain item carry fair value state december accounting policy entity group ability exercise control accounting principle policy account subsidiary group ability preparation financial statement conformity exercise joint control account joint venture generally accept accounting principle require management group ability exercise significant influence estimate assumption affect report amount account associate asset liability disclosure contingent asset liability interest acquire entity consolidate effective date date financial statement report amount acquisition interest sell consolidated upto date revenue expense report period actual result disposal differ estimate stnemetat laicnanif gsk annual report stnemetat laicnanif note financial statement continue accounting policiescontinue expenditure expenditure recognise respect good service receive transaction balance subsidiary eliminate supply accordance contractual term provision profit tax take sale subsidiary sale obligation exist future liability respect past joint venture associate product sell customer event obligation reliably outside group defer tax relief unrealise intragroup profit estimate advertising promotion expenditure charge account extent consider recoverable income statement incur shipment cost intercompany goodwill arise acquisition interestsin subsidiary joint transfer charge cost sale distribution cost sale venture associate represent excess purchase customer include sell general administrative consideration group share fair value expenditure restructuring cost recognise respect direct identifiable asset liability contingent liability acquire expenditure business reorganisation plan capitalise asa separate item case subsidiarie sufficiently detail advanced appropriate cost investment case joint venture associate communication affect undertaken goodwill denominate currency operation acquire research development case acquisition prior goodwill write research development expenditure charge income directly equity subsequent disposal asset statement period incur development acquisition relate goodwill remain equity charge expenditure capitalise criterion recognise asset consolidated income statement business combination meet usuallywhen aregulatory filing major restate marketand approval consider highly probable property plant result asset liability associate joint venture equipment research development depreciate incorporate consolidated financial statement accordance group policy equity method account environmental expenditure asset liability include related goodwill overseas environmental expenditure relate exist condition result subsidiary associate joint venture translate sterling past current operation current future rate exchange rule balance sheet date result benefit discernible charge income statement group cash flow overseas subsidiary associate joint venture recognise liability sitebysite basis reliably translate sterling average rate exchange exchange estimate liability include group portion total cost adjustment arise open net asset profit portion potentially responsible party cost theyear retain overseas subsidiary associate joint venture probable able satisfy respective share translate sterling exchange difference arise related cleanup obligation recovery reimbursement record foreign currency borrowing hedge group net investment asset virtually certain operation take separate component equity pension postemployment benefit translate sterling asset liability result cash cost provide pension define benefit scheme flow overseas subsidiary associate joint venture calculate project unit credit method spread report currency hyperinflationary economy adjustment period benefit expect derive aremade reflect current price level loss net monetary employee service accordance advice qualified assetsis charge consolidated income statement actuarie pension obligation measure present value estimate future cash flow discount rate reflect yield foreign currency transaction high quality corporate bond foreign currency transaction group company book inlocal currency exchange rate ruling date transaction pension scheme asset measure fair value balance sheet foreign currency asset liability retranslate local date actuarial gain loss difference expect currency rate exchange rule balance sheet date actual return effect change actuarial assumption exchange difference areinclude income statement recognise statement recognise income expense year arise group contribution define revenue contribution plan charge income statement incur revenue recognise income statement good service supply available external customer cost postemployment liability calculate similar order receive title risk loss pass customer way define benefit pension scheme spread period turnover represent net invoice value deduction discount benefit expect derived employee allowance give accrual estimate future rebate service accordance advice qualified actuary return methodology assumption estimate rebate legal dispute return monitor adjust regularly light provision anticipate settlement cost reasonable contractual historical information past experience turnover estimate likely outcome legal dispute include copromotion income group records share group addition provision legal revenue relate cost sale value add tax expense arise claim receive dispute sale taxis exclude revenue gsk annual report note financial statement continue accounting policy continue goodwill goodwill state cost impairment goodwill deem respect product liability claim relate product indefinite useful life test impairment annually sufficient history claim settlement incur report ibnr actuarial technique determine fair value interest acquire entitys asset reasonable estimate group exposure unasserted claim liabilitie contingent liability exceed consideration pay product provision basis excess recognise immediately gain income statement provision unasserted claim intangible asset obligation exist dispute possible intangible asset state cost provision amortisation reasonable estimate cost associate claim group impairment party charge income statement licence patent knowhow marketing right separately incur acquire acquire business combination amortise employee share plan estimate useful life time available incentive form share provide employee use estimate useful life determine amortisation share option share award scheme option award charge review annually andtake account estimate fair value grant date cost charge income time takes bring compound product market statement relevant vesting period apply anydevelopment cost incur group associate fully retrospective basis acquire licence patent knowhow marketing right write income statement whenincurre criterion group provide finance esoptrust purchase company recognition internally generate intangible asset meet share open market meet obligation provide share employee exercise option award cost run brand value independently fair value business esop trust charge income statement share hold acquire party brand value esoptrust deduct reserve hold substantial longterm brand sell value proceed receivable employee exercise separately rest business acquire brand deem permanent impairment value reflect areamortise estimated useful life transfer retain earning consider useful economic life indefinite property plant equipment prior acquire minor brand similar intangible property plant equipment ppe state cost purchase eliminate group balance sheet reserve year construction provision depreciation impairment acquisition financing cost capitalise cost acquire develop computer software internal depreciation calculate write cost ppe exclude use internet site external use capitalise intangible freehold land straightline basis expect useful fix asset software site support significant business life normal expect useful life major category ppe system expenditure lead creation durable asset review annually erp system software amortise seven year computer software year freehold building year impairment noncurrent asset leasehold land lease term year carry value noncurrent asset review building impairment indication asset plant machinery year impair additionally goodwill intangible asset indefinite fixture equipment year useful live intangible asset available use ondisposal ppe cost relate accumulate depreciation test impairment annually provision impairment impairment remove financial statement charge income statement year concern net proceed take income statement investment associate joint venture lease investment associate joint venture carry leasing agreement transfer group substantially consolidate balance sheet group share oftheir net asset benefit risk ownership asset treat finance date acquisition postacquisition retain profit lease asset purchase outright asset loss goodwill arise acquisition include inppe computer software capital element availableforsale investment leasing commitment show obligation finance availableforsale investment initially record cost lease asset hold finance lease depreciate basis remeasure subsequent reporting date fair value unrealise consistent similar own asset lease term short gain loss availableforsale investment recognise interest element lease rental include income directly equity disposal impairment investment statement lease operating lease annual rental gain loss equity recycle income statement include income statement straightline basis equity investment record noncurrent asset lease term expect sell year stnemetat laicnanif gsk annual report stnemetat laicnanif note financial statement continue accounting policy continue derivative financial instrument hedge ias adopt group january purchase sale equity investment account information relate financial instrument remain trade date purchase sale availableforsale report ukgaap applying follow policy investment account settlement date derivative contract treat inception economic hedge equity investment record cost underlie financial instrument matching accounting inventory treatment cash flow derivative instrument long inventory include financial statement low cost designate hedge restate market value future include raw material direct labour direct cost relate change value take directly profit loss account production overhead net realisable value cost generally currency swap forward exchange contract fix value determine basis relate asset liability contract currency taxation contract rate accrue profit loss account life current tax provide amount expect pay apply contract tax rate enact substantially enact gain loss foreign exchange contract designate hedge balance sheet date forecast foreign exchange transaction defer include defer tax provide liability method measurement relate foreign currency transaction temporary difference arise tax basis asset period occur gain loss balance sheet hedge liability carry amount financial statement accrue take directly reserve forward defer tax asset recognise extent probable premiumsdiscount recognise interest life future taxable profit available temporary contract difference utilise interest differential interest swap agreement recognise defer tax provide temporary difference arise profit loss account adjustment interest expense investment subsidiary associate joint venture life agreement time reversal temporary difference control probable temporary difference new accounting policy future requirement reverse foreseeable future follow ifrs ifric interpretation issue deferred tax provide rate tax enact iasb likely affect future annual report substantively enact balance sheet date defer tax liability ifrs financial instrument disclosure issue august asset discount require implement gskfrom january derivative financial instrument hedge new standard incorporate disclosure requirement ias derivative financial instrument manage exposure supersede add quantitative qualitative market risk treasury operation principal derivative disclosure relation financial instrument instrument glaxosmithkline foreign currency swap ifric determine arrangement contain lease interest rate swap forward foreign exchange contract issue december require implement gsk group hold issue derivative financial instrument january interpretation require arrangement trade speculative purpose nature legal form lease derivative financial instrument initially recognise balance account accordance ias lease interpretation sheet cost remeasure subsequent reporting date expect material impact group fair value hedge derivative classify inception fair value hedge cash flow hedge net investment hedge change exchange rate fair value derivative designate fair value hedge record group use average exchange rate prevail income statement change fair value period translate result cash flow overseas subsidiary hedge asset liability joint venture associate undertaking sterling period change fair value derivative designate cash flow hedge end rate translate net asset undertaking recognise equity amount defer equity transfer currency influence translation income statement line hedge forecast transaction relevant exchange rate hedge net investment foreign entity account average rate similar way cash flow hedge change fair value derivative instrument euro qualify hedge accounting recognise immediately yen income statement period end rate euro yen gsk annual report note financial statement continue segment information group primary segment report business sector geographical report secondary format business sector consist pharmaceutical prescription pharmaceutical vaccine consumer healthcare oral care otc medicine nutritional healthcare geographical sectors usa europe international rest world market reflect group significant regional market consistent group regional market management reporting structure business sector datum include allocation corporate cost sector appropriate basis sale business sectorsthe group activity organise global basis geographical sector figure influence location group operate resource particular manufacturing research variation time intragroup trading funding arrangementsturnover show business sector location customer geographic information give location subsidiary segment information give turnover location customer location subsidiary operating profit total asset net asset shownwhere group copromote product party record sale group record share revenue copromotion income turnover nature copromotion activity group record cost sale pharmaceutical turnover include copromotionrevenueof million million million turnover business sector pharmaceutical consumer healthcare turnover profit business sector pharmaceutical consumer healthcare operate profit finance income finance cost share profit tax associate joint venture pharmaceutical consumerhealthcare profit disposal interest associates profit taxation taxation profit disposal business profit taxation year investment associate joint venture business sector pharmaceutical consumer healthcare investment associate joint venture property plant equipment intangible asset business sector addition pharmaceutical consumer healthcare total addition depreciationamortisation pharmaceutical consumer healthcare total depreciationamortisation impairment pharmaceutical consumer healthcare total impairment impairment reversal pharmaceutical consumer healthcare total impairment reversal stnemetat laicnanif gsk annual report stnemetat laicnanif note financial statement continue segment information continue total asset business sector pharmaceutical consumerhealthcare total operating asset investment associate liquid investment derivative financial instrument cash cash equivalent current defer taxation tangible asset hold sale total asset total liability business sector pharmaceutical consumer healthcare total operating liability shortterm borrowing longterm borrowing derivative financial instrument current defer taxation total liability turnover location customer usa europe international turnover property plant equipment intangible asset addition location usa europe international total addition total asset location usa europe international intersegment trading balance total operating asset investment associate liquid investment derivative financial instrument cash cash equivalent current defer taxation tangible asset hold sale total asset gsk annual report note financial statement continue segment information continue segment purpose usgaap information give separately respect include group europe market region consider group home segment purpose segmental reporting turnover location customer turnover include intersegment turnover intersegment turnover turnover location subsidiary operating profit total asset net operating asset operate income royalty asset disposal profit income include fair value adjustment royaltiesareprincipally core recur incomefrom outlicense intellectual property asset disposal profit include product divestment disposal equity investment intellectual property tangible property income include equity investment carry value adjustment arise stock market change fair value adjustment arise quest collar theravance option operating profit follow item charge operating profit employee cost note advertising distribution cost depreciation property plant equipment amortisation intangibleasset net foreign exchange gainslosse inventory cost inventory include cost sale writedown inventory reversal ofprior yearwritedown inventory operate lease rental minimum lease payment contingent rent sublease payment audit fee fee auditor work auditor ukfirm auditor overseas firm stnemetat laicnanif gsk annual report stnemetat laicnanif note financial statement continue operating profit continue analysis fee auditor work advisory service relate section sarbanesoxley act nonstatutory assurance service tax compliance service tax planning advice service include audit fee fee relate company audit glaxosmithkline plc include nonstatutory assurance service amount related group preparation adoption international financial reporting standard service include human resource advisory compliance treasury relate services december pricewaterhousecooper fee invoice million comprise statutory audit million assurance million taxation service million employee cost wage salary social security cost pension postemployment costssee note cost sharebase incentive plan severance cost integration restructuring activity group provide benefit employee commensurate local practice individual country include market healthcare insurance subsidise car scheme personal life assurance average number person employ group include director year number number number manufacturing sell general administration research development average number group employee exclude temporary contract staff number group employee end financial year give financial recordonpagethe average number person employ glaxosmithkline plc nil nil compensation director cet company secretary aggregatewa follow wage salary social security cost pension postemployment cost cost sharebase incentive plan information director remuneration give remuneration report pagesto gsk annual report note financial statement continue finance income interest income unwind discount asset interest extend credit receivables net investment hedge fair value adjustment nonhedge derivative finance cost interest bank loan overdraft interest loan interest respect finance lease realise loss financial instrument unwind discount provision fair value hedge fair value adjustment nonhedge derivative associate joint ventures associate share tax profit quest diagnostic inc share tax loss associate share tax profitslosse joint venture share turnover joint venture sale joint ventures associate summarise income statement information respect group associate set total turnover total profitloss taxation taxation charge base profit year corporation tax statutory rate double taxation relief overseas taxation current taxation defer taxation stnemetat laicnanif gsk annual report stnemetat laicnanif note financial statement continue taxation continue reconciliation taxation rate group profit ukstatutoryrate taxation overseas taxis benefit ofspecial tax status credit intercompany stock profit impact share base payment tax profit associate difference prior year item tax rate group operate country tax rate differ uktax rate profit arise fromcertainoperation singapore puerto ricoireland belgium accord special status tax reduce rate compare normal rate tax territory effect reduction taxation charge increase earning share byp andp group require ifrs create defer tax asset respect unrealise intercompany profit arise stock hold group year end apply tax rate country stock hold tax rate country profit originally tax paidwhich practice ukand usgaapthe group tax rate increase decrease result reduction workinprogress finished good integrate nature group worldwide operation involve significant investment research strategic manufacture limited number location consequential crossborder supply route numerous endmarket give rise complexity delay negotiation revenue authority profit individual group company liable tax disagreement revenue authority intragroup transaction particular price good transfer group company different tax jurisdiction produce conflict claim revenue authority profit tax individual territory resolution issue continue fact life gsk group open issue revenue authority usa japan canada far large relate glaxo heritage product respect internal revenue service irs revenue customs hmrc compete contradictory claim gsk attempt settle dispute direct discussion irs subsequently discussion authority term double tax convention country thesediscussion terminate july january irs issue notice deficiency year claim additional taxis billion april group file petition tax court dispute irs claim seek refund billion taxis january irs issue notice deficiency year claim additional federal taxis billionwhich group contest filing petition tax court april irs file statutory answer june september court agree consolidate irs claim single trial total claim period billion additional federal taxis relate interest december billion net federal tax relief give total billion group petition irs claim include counterclaim repayment federal taxis total billion base partly reference advance pricing agreement apa smithkline beecham irs cover transfer pricing tagamet december irs file motion summary judgement exclude evidence relate apas court proceeding march trial judge deny irs motion reserve ruling admissibility apa evidence trial schedule commence october decision expect mid similar tax issue remain open date gsk expect receive substantial claim irs year gsk continue believe profit report subsidiary period date pay taxis usa sufficient reflect activity operation group tax creditor balance december billion billion include provision estimate amountat irs dispute ultimately settle irs follow methodology apply previously respect later year gsk estimate potential unprovided exposure respect dispute irs year amountedto approximately billion december billion gsk continue discussion hmrc respect transfer pricing matter dispute year date little progress past year consequently matter subject litigation course gsk annual report note financial statement continue taxation continue gsk use good advice determine transfer pricing methodology seek manage transfer pricing issue satisfactory conclusion basis external professional advice continue believe adequate provision liability likely arise open assessment continue wide difference view group irs hmrc relevant taxation authority open issue exist ultimate liability matter vary amount provide dependent outcome litigation proceeding negotiation relevant tax authority show annual report provision taxation arise distribution profit retain overseas subsidiary associate undertaking ground remittance profit retain december require way incremental tax arise aggregate unremitte profit balance sheet date approximately billion december group recognise defer tax asset million million respect income tax loss approximately million million loss million million expire million million expire million million available indefinitely december group recognise defer tax asset respect income tax loss approximately million million million million expire million nil expire million million available indefinitely group capital loss december estimate excess billion respect defer tax asset recognise defer tax asset recognise insufficient evidence loss utilise payable recoverable net movement current tax account january exchange adjustment charge profit loss account cash pay movement december movement defer tax asset liability pension share accelerate product post legal manu stock option net defer taxation capital intragroup business retirement tax facture valuation award temporary assetliability allowance intangible profit disposal benefit loss dispute restructuring adjustment scheme difference total defer tax asset january defer tax liability january january ias adjustment january adjust exchange adjustment creditchargeto income creditchargeto equity transfer tofrom current tax acquisition movement december defer tax asset december defer tax liability december defer taxation provide stock valuation adjustment intragroup profit temporary difference show arecurrent defer taxation movement arise origination reversal temporary difference net temporary difference include accrue expense provision stnemetat laicnanif gsk annual report stnemetat laicnanif note financial statement continue earning share basic earning share dilute earning share earning share calculate divide profit attributable shareholder weight average number ofshare issue period numberof share calculate basic diluted earning share reconciledbelow weight average number share issue million million million basic dilution share option dilute share hold esop trust exclude trustee waive right dividend share hold esop trust dividend interim second interim interim fourth interim total total dividend dividend share penny paidpayable july october january april total dividend dividend share penny pay july september january april total dividend dividend share penny pay july october january april ifrs interim dividend recognise financial statement pay declare gsknormally pays dividend quarter quarter relate quarter declare financial statement recognise dividend pay fourth interim dividend second interim dividend amount recognise year follow dividend shareholder gsk annual report note financial statement continue property plant equipment plant land equipment asset building vehicle construction total cost january exchange adjustment addition addition business combination disposal reclassification transfer asset hold sale cost atstdecember exchange adjustment addition addition business combination disposal reclassification transfer asset hold sale cost december depreciation january exchange adjustment provision year disposal reclassification transfer asset hold sale depreciation atstdecember exchange adjustment provision year disposal reclassification transfer asset hold sale depreciation december impairment january exchange adjustment disposal impairment loss reversal impairment impairment atstdecember exchange adjustment disposal impairment loss reversal impairment transfer asset hold sale impairment december total depreciation impairment atstdecember total depreciation impairment december net book value january net book value december net book value december gsk annual report stnemetat laicnanifnote financial statement continue property plant equipmentcontinue net book value december group land building comprise freehold property million million property lease year million million property lease year million million include land building december lease asset cost million million accumulate amortisationof million million net book value million million include plant equipment vehicle december lease asset cost million million accumulate amortisationof million million net book value million january million impairment loss principally arise decision rationalise facility calculate base fair value cost sellor value use value use calculation determine net present value project riskadjuste posttax cash flow relevant asset cash generating unit apply discount rate group posttax weight average cost capital adjust appropriate country specific risksthis approximate apply pretax discount rate pretax cash flow loss charge cost sale million research development million sell general andadministration million goodwill cost january exchange adjustment addition business combination disposal asset write cost december net book value january net book value december addition year comprisemilliononthe acquisitionof biomedical corporationand million acquisition corixa corporationseenotefor detail goodwill amortise tested impairment annually value use calculation generally utilise calculate recoverable value use calculate net present value project riskadjuste posttax cash flow cash generating unit goodwill contain apply discount rate group posttax weight average cost capital adjust appropriate country specific risk approximate apply pretax discount rate pretax cash flow gsk annual report stnemetat laicnanifgsk annual report stnemetat laicnanif note financial statement continue computer licence intangible asset software patent etc brand total cost january exchange adjustment addition disposal asset write reclassificationsfrom property plant equipment cost stdecember exchange adjustment addition addition business combination disposal asset write reclassificationsfrom property plant equipment cost december amortisation january exchange adjustment provision year disposal asset write reclassificationsfrom property plant equipment amortisation stdecember exchange adjustment provision year disposal asset write reclassificationsfrom property plant equipment amortisation december impairment january exchange adjustment impairment loss disposal impairment stdecember exchange adjustment impairment loss asset writtenoff impairment december total amortisation impairment december total amortisation impairment december net book value january net book value stdecember net book value december note financial statement continue intangible asset continue amortisation impairment charge research development sell general administration december net book value computer software include million internally generate addition business combination year million comprise million acquisition idbiomedical corporation million acquisition corixa corporation noteother addition licence patent year relate purchase ofdevelopment commercialisation rightsforbotox certain territoriesacquire allergan andvarious compound right note brand comprise portfolio product acquire acquisition sterling winthrop inc block drug company net book value major brand follow panadol sensodyne polident corega poligrip solpadeine brand consider indefinite life give strength durability brand level marketing support brand relatively stable profitable market sector size diversification market share mean risk market relate factor cause shortening brand life consider relatively low group aware material legal regulatory contractual competitive economic factor limit useful life accordingly amortisedeach brand istestedannually impairment apply fair value cost sell methodology year posttax cash flow forecast terminal value calculation apply discount rate group posttax weight average cost capitalof adjust appropriate countryspecific risksthis approximate apply pretax discount rate pretax cash flow main assumption include future sale price volume product contribution future development expenditure require maintain product marketability registration relevant jurisdiction product life assumption review management budget strategic planning cycle change market condition product erosion generic competition investment associate joint venture joint associated venture undertaking total total january implementation account financial instrument ia january adjust exchange adjustment addition transfer disposal retain profit year december principal associate undertaking quest diagnostic inc clinical laboratory business list new york stock exchange investment book value december million million market value million million december group own quest group hold ownership interest voting control quest group ability exercise significant influence active participationon quest board directorsand board subcommittees gsk annual report stnemetat laicnanifnote financial statement continue investment associate joint venture continue summarise balance sheet information respect group associate set total asset total liability net asset group share associate net asset investment joint venture comprise million share gross asset million million share gross liability million principally arise interest joint venture shionogiglaxosmithkline holding develop specify chemical compound glaxosmithkline shire biochem primarily comarket combivir trizivirand epivirin certain territory investment total total january implementation account financial instrument ia january adjust exchange adjustment addition fair value movement impairment transfer disposal december investment comprise noncurrent equity investment availableforsale investment record fair value balance sheet date investment trade active market fair value determine reference relevantstockexchange quote bid price investment fair value estimate reference current market value similar instrument reference discount cash flow underlie net asset group hold number equity investment frequently entity group enter research collaboration equity investment record noncurrent asset expect sell year case record current asset noncurrent equity investment include list investment million million offer group opportunity return dividend income fair value gain disposal investment fair value movement reclassify reserve income statement base average cost impairment loss record table recognise income statement year operate income amount recycle fair value reserve note recognition impairment impairment initially result prolonged significant decline fair value equity investment acquisition cost subsequent decline fair value immediately take income statement noncurrent asset noncurrent asset comprise sundry receivable year include insurance recovery receivable discount riskfree rate returnand derivative financial instrument inventory raw material consumable work progress finish good gsk annual report stnemetat laicnanifgsk annual report stnemetat laicnanif note financial statement continue trade receivable trade receivables prepay pension contribution prepayment accrue income interest receivable employee loan advance derivative financial instrument receivable trade receivable include million million associate joint venture show deduct provision bad doubtful debt million million cash cash equivalent cash bank hand shortterm deposit commercial paper cash cash equivalent include highly liquid investment maturity month asset hold sale land building plant equipment vehicle trade payable trade payable wage salary social security payable defer income customer return rebate accrual accrual derivative financial instrument dividend payable customer return rebate accrual provide group point sale respect estimate rebate discount allowance payable customer principally usa provision time sale actual amount pay base claim time initial recognition sale amount estimate fully reflect final outcome amount subject change dependent thing type buy group product sale mix level provision review adjust quarterly light historical experience actual rebate discount allowance give return change arrangement future event cause assumption provision base change affect future result groupgsk annual report stnemetat laicnanif note financial statement continue pension postemployment benefit pension postemployment cost pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme postemployment cost analyse fund define benefithybrid scheme unfunded define benefit scheme define contribution scheme unfunded postretirement healthcare scheme postemployment cost cost define benefit pension postretirement healthcare scheme charge income statement follow cost sale sell general administration research development gsk entity operate pension arrangement cover group material obligation provide pension retire employee thesearrangement develop accordance local practice country concern pension benefit provide state scheme define contribution scheme retirement benefit determine value fund arise contribution pay respect employee define benefit scheme retirement benefit base employee pensionable remuneration length ofservice hybrid define benefit scheme include define contribution section contribution define benefit scheme determine accordance advice independent professionally qualified actuary pension cost define benefit scheme accounting purpose assess accordance independent actuarial advice project unit method certain country pension benefit provide unfunded basis administer trustee company liability generally assess annually accordance advice independent actuary formal independent actuarial valuation group main plan undertake regularly normally year theasset fund scheme generally hold separately administer trust insured asset invest different class order maintain balance risk return investment diversify limit financial effect failure individual investment target asset allocation scheme equity bond scheme equity bond property long term aim increase property element consequent reduction equity actuarial movement year recognise statement recognise income expense discount rate base iboxx year aaindex discount rate base moodys index expect return bond reflect portfolio mix indexlinke government corporate bond equity risk premium add equity project inflation rate pension increase long term prediction base yield gap long term index link fix interest gilt mortality rate calculate standard mortality table project plan obligation increase depend individual scheme mortality experience allowance future improvement life expectancy usa mortality rate calculate fully generational table project scale white collar adjustment build allowance future improvement life expectancy group special funding contribution pension scheme totalling million gsk agree trustee define benefit pension scheme group additional contribution approximately million year fiveyear period end december order eliminate deficit ias basisby point define benefit pension scheme operate benefit glaxo wellcome employee smithkline beecham employee remain separate scheme close new entrant subsequent employee entitle join define contribution scheme usa glaxo wellcome smithkline beecham define benefitscheme merge addition group operate number postretirement healthcare scheme principal usa follow information relate group define benefit pension postretirement healthcare schemesnote financial statement continue gsk annual report stnemetat laicnanif pension postemployment benefit continue group apply follow assumption assess liability usa rest world rate increase future earning discount rate expect pension increase cash balance creditconversion rate inflation rate amount record income statement statement recognise income expense year end december relation define benefit pension postretirement healthcare scheme follow postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial loss record statement recognise income expense postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial gainslosse record statement recognise income expense postretirement pension benefit usa rest world group group amount charge operating profit current service cost past service cost expect return pension scheme asset interest scheme liability settlement curtailment actuarial lossesgainsrecorde statement recognise income expense total actuarial loss record statement recognise income expense january milliongsk annual report stnemetat laicnanif note financial statement continue pension postemployment benefit continue fair value asset liability define benefit scheme aggregate datum define benefit scheme group follow usa rest world group average december expect rate fair expect rate fair expect rate fair fair return value return value return value value equitie property bond asset fair value asset present value schemeobligation include noncurrent asset include pension postemployment benefit actual return plan asset usa rest world group average december expect rate fair expect rate fair expect rate fair fair return value return value return value value equitie property bond asset fair value asset present value schemeobligation include noncurrent asset include pension postemployment benefit actual return plan asset usa rest world group average december expect rate fair expect rate fair expect rate fair fair return value return value return value value equitie property bond asset fair value asset present value schemeobligation include noncurrent asset include pension postemployment benefit actual return plan asset note financial statement continue pension postemployment benefit continue postretirement pension benefit movement define benefit obligation usa rest world group group obligation january exchange adjustment service cost interest cost actuarial loss scheme participant contribution benefit pay settlement curtailment obligation december exchange adjustment service cost interest cost actuarial loss scheme participant contribution benefit pay settlement curtailment obligation december exchange adjustment service cost interest cost actuarial loss scheme participant contribution benefit pay settlement curtailment obligation december liability postretirement healthcare scheme assess assumption pension scheme assumption future medical inflation reduce year basis liability usscheme assess million million million define benefit pension obligation analyse follow fund unfunded postretirement benefit unfunded gsk annual report stnemetat laicnanifnote financial statement continue pension postemployment benefit continue postretirement pension benefit movement fair value asset usa rest world group group assets january exchange adjustment expect return asset actuarialgain employer contribution scheme participant contribution benefit pay asset december exchange adjustment expect return asset actuarialgain employer contribution scheme participant contribution benefit pay asset december exchange adjustment expect return asset actuarial gain employer contribution scheme participant contribution benefit pay asset december define benefit scheme include define contribution section account balance total million december million million information scheme asset gaap give note employercontribution estimate approximately million respect defer benefit pension scheme million respect postretirement benefit transition date conversion ifrsfor gsk january follow historical datum present date build roll year record year postretirement pension benefit history actuarial gain loss usa rest world group group actuarial gain scheme asset percentage scheme asset december actuarial loss scheme liability percentage scheme obligationsat december fair value asset present value scheme obligation deficit scheme gsk annual report stnemetat laicnanifnote financial statement continue pension postemployment benefit continue postretirement pension benefit history ofactuarialgain loss usa rest world group group actuarialgainsof scheme asset percentage scheme asset december actuariallossesgain scheme liability percentage ofof schemeobligationsat december fair value asset present value schemeobligation deficit scheme actuarialgainslosse scheme asset percentage scheme asset december actuariallossesgain scheme liability percentage ofschemeobligationsat december fair value asset present value schemeobligation deficit scheme sensitivity analysis change assumption material impact annual define benefit pensionandpostretirement cost benefit obligation decrease discount rate follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation year increase life expectancy follow approximate effect increase annual pension cost increase annual postretirement benefit cost increase pension obligation increase postretirement benefit obligation decrease expect rate return asset follow approximate effect increase annual pension cost increase rate future healthcare inflation follow approximate effect increase annual postretirementbenefitscost increase postretirement benefit obligation gsk annual report stnemetat laicnanifnote financial statement continue provision legal manufacturing merger restructure integration dispute provision total january exchange adjustment addition business combination charge year unwind discount apply reverse unused reclassification movement december settle year settle year december group recognise cost previous year respect plan manufacturingandother restructuring initiate follow merger glaxo wellcome smithkline beecham acquisition block drug plan largely complete cost recognise provision principally respect identify severance site announce manufacturing activity ceaseand site closure cleaning costsare expect incur mainlywithin yearscost asset writedown recognise impairment property plant equipment group recognise cost previous year respect plan integration glaxo wellcome smithkline beecham business implementation integration follow merger substantially completecost recognise provision respect identify severance expect incur respect programme encourage staff convert glaxo wellcome smithkline beecham share option glaxosmithkline share option employee exercise option discount provision increase million million calculate riskfree rate return glaxosmithkline involve number legal dispute include notification possible claim provision legal dispute include amount relate antitrust product liability contract termination selfinsurance environmental cleanup property rental company director take legal advice establish provision take account insurance agreement regard relevant fact circumstance matter accordance accounting requirement provision discount million million riskfree rate return effect change discount rate increase discount december million number product history claim settlement make possible use ibnr incur report actuarial technique determine reasonable estimate group exposure unasserted claim relation product apart ibnr provision provision unasserted claim ultimate liability matter vary amount provide dependent outcome litigation proceeding investigation possible settlement negotiation nature group business number matter include provide ibnr actuarial technique subject negotiation litigation year large individual amount provide expect settle year december expect million million provision legal dispute reimburse include noncurrent asset discussion legal issue refer notelegal proceeding noncurrent liability accrual defer income derivative financial instrument payable gsk annual report stnemetat laicnanifnote financial statement continue contingent liability december contingent liability comprise guarantee discount bill item arise normal course business amount million million december million million financial asset pledge collateral contingent liability discussion tax issue refer note taxation legal issue refer note legal proceeding net debt current asset liquid investment cash cash equivalent shortterm borrowing medium term note eurobond note commercial paper bank loan overdraft loan obligation finance lease longterm borrowing note medium term note european medium term note european medium term note european medium term note european medium term note medium term note european medium term note european medium term note medium term note loan stock bank loan loan private financing obligation finance lease net debt current asset liquid investment classify availableforsale investment atst december theyincludedredeemableshareswhichwerefully collateralise highly rate bond billion millionthe billion redeemable preference share hold december redeem yearthe effective interest rate liquid investment december wasapproximately effective interest rate cash cash equivalent december wasapproximately gsk annual report stnemetat laicnanifnote financial statement continue net debt continue shortterm borrowing commercial paper comprise billion programme million million issue december million million back committed facility day duration million million million million renewable annually liquid investment cash cash equivalentsa show table weight average interest rate commercial paper borrowing december weight average interest rate current bank loan overdraft december longterm borrowing bond issue european medium term note programme million year coupon bondand million year coupon bond loan yearare repayable period follow year year year year year loan repayable year carry interest effective rate betweenand repayment date range fromto average effective interest rate ofall notesatst december wasapproximately secure loan loan amount million million secure charge noncurrent current asset finance lease obligation rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total future rental payment future finance charge total finance lease obligation gsk annual report stnemetat laicnanifnote financial statement continue share capital share premium account share ordinary share premium number share capital authorise december december december share capital issue fully pay january issue share option scheme purchase cancel december issue share option scheme purchase cancel december issue share option scheme december december december december number share issuable outstanding optionsnote number unissue share option december issue share capitalshare hold esop trustshare hold treasury share andshare free issue issue share fully pay atotal billion spend company buy share cancellation hold treasury share whichbillion spend exact time future purchase extent repurchase share hold treasury share cancel determine company dependent market condition factor share purchase period january february period february february furthermillion share purchase cost millionall purchase publicly announce buyback programme table set monthly purchase share buyback programme average share price exclude number share commission stamp duty month january nil february march april nil june july nil august september october november december total share purchasedin hold treasury share detail substantial shareholding refer substantial shareholding gsk annual report stnemetat laicnanifnote financial statement continue movementsin equity shareholders equity share share retain minority total capital premium earning reserve total interest equity january recognise income expense year distribution minority shareholder dividend shareholder ordinary share issue ordinary share purchase cancel ordinary sharestransferredby esop trust writedownof share hold esoptrust sharebase incentive plan atst december recognise income expense year change minority shareholding distribution minority shareholder dividend shareholder ordinary share issue ordinary share purchase cancel ordinary share purchase held treasury share ordinary sharestransferredby esoptrust writedownof share hold esoptrust sharebase incentive plan december implementation account financial instrument ia january adjust recognise income expense year change minority shareholding distribution minority shareholder dividend shareholder ordinary share issue ordinary share purchase held treasury share ordinary sharestransferredby esoptrust writedownof share hold esop trust sharebase incentive plan tax sharebase incentive plan december retain earning reservesamounte million december million million million million million relate company million million million relate joint venture associate undertakingsthe cumulative translation exchange equityat december sincest january million million million share base incentive plan million include million relate associate undertaking gsk annual report stnemetat laicnanifnote financial statement continue movementsin equity continue reserve analyse follow cash flow esop trust fair value hedge share reserve reserve reserve total january ordinary share purchase cancel ordinary share transfer esop trust writedown share hold esop trust atstdecember ordinary share purchase cancel ordinary share transfer esop trust writedown share hold esop trust sharebasedincentive plan december implementation account financial instrumentsunder ias january adjust recognise income expense year ordinary share transfer esop trust writedown share hold esop trust december reserve include merger reserve create merger glaxo wellcome smithkline beecham amounting million december million million reserve include capital redemption reserve create result share buyback programme amount million december million million relate party transaction glaxosmithkline hold aninter quest diagnostics inc december group quest diagnostic party longterm contractual relationship quest diagnostic primary provider clinical laboratory testing support group clinical trial testing requirement worldwide quest diagnostic provide service million million group december balance payable glaxosmithkline quest diagnostic million million group shionogi ltd enter transaction usjoint venture company support research development activity conduct joint venture company glaxosmithkline provide service joint venture million million december balance glaxosmithkline joint venture million million shapiro nonexecutive director glaxosmithkline plc receive fee form adss subsidiary company membership group scientific advisory board fee include annual remuneration remuneration report pagesto barzach nonexecutive director glaxosmithkline plc receive fee subsidiary company healthcare consultancy provide include annual remuneration remuneration report aggregate compensation director cet company secretary give note employee cost gsk annual report stnemetat laicnanifnote financial statement continue acquisition disposal detail acquisition disposal subsidiary associate undertaking joint venture business give acquisition december group acquire issue share capital idbiomedical corporation biotechnology company base canada specialise development manufacture vaccine particularly influenza vaccine cash consideration million transaction account purchase method accountingthe goodwill arise acquisition result benefit separately quantify record include immediate access additional flu vaccine manufacturing capacity particularly event pandemic skilled workforce good relation canadian government supply flu vaccine idbiomedical corporation turnover million million loss million loss millionfor year million turnover million loss relate period acquisition andareinclude group account book fair value fair value adjustment value net asset acquire intangible asset property plant equipment asset defer tax provision liability goodwill total consideration total consideration include directly attributable cost million july group acquire issue share capital corixa corporation biotechnology company specialise develop vaccine adjuvant immunology base product cash consideration million investment increase group hold corixa group number business relationship corixa prior acquisition date principally relation adjuvant developed corixa group vaccine transaction account purchase method account exist investment corixawith book value million previously classify availableforsale investmentand nowform investment subsidiarythe exist issue share capital acquire previous year cash consideration million corixa corporation turnover million loss million year million turnover million loss relate period acquisition andareinclude thegroup account book fair value fair value adjustment value net asset acquire intangible asset asset liability goodwill exist investment total consideration total consideration include directly attributable cost million gsk annual report stnemetat laicnanifnote financial statement continue acquisition disposal continue euclid partner additional million invest euclid srpartner associatein group interest glaxosmithkline consumer healthcare limited april anindiansubsidiary grouppurchase share capital hold byminorityshareholder cash consideration million glaxosmithkline pharmaceutical limited june anindiansubsidiary grouppurchased share capital hold byminorityshareholder cash consideration million glaxosmithkline biological shanghailimite achinese subsidiary grouppurchase share capital hold minority shareholdersfor cash consideration million disposal ideapharm december group dispose ofideapharm subsidiary locate romania cash proceed million receive january net asset dispose inthe yearinclude cash million aseptic technology april group dispose aseptic technology societe regionale dinvestissement wallonie cash proceed million gsk gsk gsk biological aseptic pharma consumer euclid shanghai tech ceutical healthcare ideapharm corixa biomedical cash flow total cash consideration cash cash equivalent acquire net cash payment acquisition cash cash equivalent dispose net cash proceed disposal gsk annual report stnemetat laicnanifnote financial statement continue acquisition disposal continue acquisition fraxiparine fraxodi arixtra september group acquire fraxiparine fraxodiand arixtra andrelate asset include manufacture facility cash consideration million book fair value net asset value adjustment acquire intangible asset tangible fix asset inventory provision onerous contract euclid partner additional million invest euclid partner associate company group interest disposal quest diagnostics inc group dispose million share investment quest diagnostic inc cash proceed million reduce group shareholde december aprofit million recognise glaxosmithkline vehicle finance ltd group dispose employee vehicle financing subsidiary result loss million glaxosmithkline pharmaceutical chongqing ltd group dispose glaxosmithkline pharmaceutical chongqing ltd group subsidiary locate china million profit disposal million realise beeyar investments pty ltd july group disposed beeyar investments pty ltd subsidiary locate south africa cash proceed million realise profit million optilead srl year group hold associate undertake optilead srl sell result loss million fraxiparine gsk gsk fraxodi quest vehicle pharmaceutical beeyar arixtra euclid diagnostic finance chongqe investment total cash flow cash consideration pay net cash proceed disposal gsk annual report stnemetat laicnanifnote financial statement continue acquisition disposal continue acquisition europharm group complete buyout minority interest europharm holding group subsidiary locate romania million give rise goodwill million capitalise book fair value net asset goodwill cost value adjustment acquire capitalise acquisition europharm iterfi sterilyo payment million pursuant acquisition agreement base financial performance acquire company include defer compensation disposal clinical laboratory additional cash refund million receive respect indemnify liability arise clinical laboratory disposal occur refund follow successful outcome case uscourt appeal iterfi clinical sterilyo europharm laboratory total cash flow cash consideration pay net cash proceed disposal commitment contractual obligation commitment contract provide financial statement intangible asset plant property equipment pension commitment interest loan number commitment licensing agreement principally vertex pharmaceuticals inc commitment relate intangible asset include milestone payment dependent successful clinical development represent maximum pay milestone achieve gsk agree trustee ukand uspension scheme additional contribution approximately million year fiveyear period end december order eliminate pension deficit ias basis point table show commitment basis deficit december amount total contribution normal plus additional approximately million year commitment past december group commitment relate revenue payment licence alliance principally exelixis inc commitment respect future interest payable loan disclose take account effect interest rate swap commitment operating lease rental payment year rental payment year rental payment year rental payment year rental payment year rental payment year total commitment operate lease gsk annual report stnemetat laicnaniffinancial instrument relate disclosure borrowing denominate swap foreign currency match investment overseas group asset treat hedge financial risk management relevant net assets glaxosmithkline plc report sterling pay dividend sterling profit role corporate treasury gsk manage december group outstanding contract sell monitor group external internal funding requirement purchase foreign currency total gross notional principal financial risk support group corporate objective treasury million million majority activity govern policy procedure approve contract period month board monitor treasury management group base composition net debt december gsk maintain treasury control system procedure monitor appreciation sterle major currency result foreign exchange interest rate liquidity credit financial risk reduction group net debt approximately million weaken sterle major currency result gsk use variety financial instrument include derivative increase group net debt approximately million finance operation manage market risk operation financial instrumentsincludecash liquid resource interest rate risk management borrowing spot foreign exchange contract gsk policy interest rate risk management require net borrowing fix rate increase ratio number derivative financial instrument manage forecast net interest payable trading profit market risk treasury operation derivative instrument principally comprise forward foreign currency contractsandinter group use limited number interest rate swap rate currency swap swap borrowing liquid redenominate external borrowing interest rate coupon asset currency require group purpose manage require group purpose duration swap match exposure funding risk change foreign exchange rate duration principal instrument interest rate derivative interest rate instrument account fair value cash flow hedge relevant asset liability gsk balance use borrowing liquid asset regard tothe cash flow operating activity thecurrencie group manage centrally shortterm cash surplus earn tax cost intragroup distribution currency borrowing requirement subsidiary company use forward business asset denominate posttax cost contract hedge future repayment originate currency borrowing compare totheposttax return liquid asset sensitivity analysis consider sensitivity group net debt liquid asset surplus immediate operating requirement hypothetical change market rate assume group company generally invest manage centrally variable remain constant base composition net debt corporate treasury requirement group company operate financing arrangement december take finance meet possible central resource consideration fix rate borrowing placea percentage point basis pointsdecreasein average interest rate result external borrowing mainly manage centrally corporate treasury increase group annual net interest charge comprise portfolio long mediumterm instrument short approximately million term finance market risk financial asset gsk hold issue derivative financial instrument group invest centrally manage liquid asset government trading purpose group treasury policy specifically bond shortterm corporate debt instrument minimum prohibit activity transaction financial instrument shortterm credit rating money market fund undertake manage risk arise underlie business credit rating aaaaaa structure investmentscredit activity speculation rating show standard poor moodys investor foreign exchange risk management servicesrespectively theseinvestment classify available gsk foreign currency transaction exposure arise normal trade forsale flow respect external intragroup trade equity investment classify availableforsale investment hedge gsk policy minimise exposure overseas group manage disposal meet overall business requirement operating subsidiary transaction risk match local currency arise group regularly monitor value equity income local currency cost purpose intragroup trading investment enter hedge selectively approval transaction match centrally intragroup payment term board manage reduce risk exceptional foreign currency cash flow hedge selectively management corporate treasury credit risk usa line pharmaceutical company group significant proportion group borrowing include sell product small number wholesaler addition commercial paper programme dollar benefit hospital pharmacie physician group sale liquidity dollar denominate capital market certain largestwholesalersamounte approximately borrowing swap currency require group pharmaceutical sale december group group purpose group seek denominate borrowing trade receivable wholesaler total currency principal assetsand cash flow million december million gsk annual report stnemetat laicnanif note financial statement continuedfinancial instrument relate disclosure equity investment investment trade active market continue determine reference relevant stock exchange quote bid price investmentsdeterminedby reference current group expose concentration credit risk respect market value similar instrument reference discount wholesaler affect cash flow underlie net asset financial difficulty materially adversely affect group cash cash equivalent approximate carry financial result liquid investment base quote market pricesin case group believe expose major concentration marketable security base principal amount case credit risk onother class offinancial instrument group nonmarketable security short repricing period expose creditrelate loss event nonperformance shortterm loan overdraft approximate carry counterpartie financial instrument expect short maturity instrument counterpartie fail meet obligationswhere group longterm loan base quote market price case significant investment single counterparty collateral eurobond fix rate borrowing approximate obtain order reduce risk carry case offloate rate bank loan loan group apply boardapprove limit credit forward exchange contract base market price exchange exposure counterparty employ strict minimum credit rate balance sheet date worthiness criterion choice counterparty currency swap base market valuation balance liquidity sheetdate group operate globally primarily subsidiary company quest equity collar theravance option base established market group trade option pricing model use significant assumption nature group business patent protection respect price volatility dividend yield interest rate product group portfolio group product compete interest rate instrument base net present value largely product efficacy price selling margin discount cash flow sufficient toexceednormal operating cost group operate receivable payable approximate carry subsidiary substantially cash generative provision approximate carry lease obligation approximate carry value operate cash flow fund investment research development new product routine outflow capital year end december total expenditure tax dividend repayment mature debt change fair valuesestimate usingvaluation technique refer group time time additional demand finance result credit income statement million forshare purchase acquisition fair value investment ingskshare gsk operate high level interest cover low level atst december esop trust hold gsk ordinary share net debt relative market capitalisation addition strong carry valueof million million positive cash flow normal trading activity additional liquidity fair value million million base quote readily available commercial paper programme short market price share represent purchase esop trust term investment group aeuropeanmedium term note satisfy future exercise option award employee programme billion billion issue incentive scheme thecarrying value low cost december march group establish shelf expect proceed share recognise registration billion december billion deduction reservesat december gsk hold billionwas issue treasury share cost million million deduct retain earning fair value financial asset liability table pagepresent carry amount ifrs committed facility fair value group financial asset liability group commit facility commercial paper december comparative information present table programme million million million page carry amount december million day duration renewable annually december record gaap basis applicable date undrawn commit facility total million accordance ias ias describe note million million million fair value financial asset liability include atthe instrument exchange current transaction willing party force liquidationsale follow method assumption estimate thefair value gsk annual report stnemetat laicnanif note financial statement continuedgsk annual report stnemetat laicnanif note financial statement continue financial instrument relate disclosure continue ifrs disclosure group adopt ias ias january follow disclosure include december meet requirementsof ias classification fair value financial asset liability follow table set classification financial asset liabilitiesreceivable payable include extent classify financial asset liability accordance ias provision include contractual obligation settle cash appropriate currency interest rate swap present alongside underlie principal instrument carrying amount instrument adjust effect currency interest rate swap acting hedge carry fair value value december liquid investment cash cash equivalent current asset financial instrument note bond usnotesbondsand private financing note bond swap currency swap interest rate swap notesswappe yen currency swap note interest rate swap othershorttermborrowing otherlongterm borrowing total borrowingsand relate swap equity investment receivables payable provision otherderivative asset otherderivative liabilitie financial asset financial liability total financial asset liability total financial asset total financial liability reconciliation net debt liquid investment cash cash equivalent total borrowing lessnet effect ofinter rate currency swap net debt note financial statement continue gsk annual report stnemetat laicnanif financial instrument relate disclosurescontinue interest rate profile financial asset liability follow table set exposure financial asset andliabilitie fix interest rate float interest rate orno interest rate maturity profile financial asset liability expose interest rate risk table indicate contractual repricing maturity date instrument cash december liquid cash financial investment investment equivalent receivables asset total financial asset year year year year year great year total interestearning analyse fix rate interest float rate interest total interest earn noninterestearne total effect obligation december interest rate finance financial debt swap lease payable provision liability total financial liability year year year year year great year total interest bearing analyse fix rate interest float rate interest total interest bear noninterest bear total maturity analysis interestearne financialasset maturity analysis interestearne financial asset isequivalent maturity analysispresente interest rate profile tableabove maturity analysis interest bearing financialliabilitie december finance financial debt lease payable liability total financial liability year demand year year year year year gsk annual report stnemetat laicnanif note financial statement continue financial instrument relate disclosure continue currency profile financial asset liability group currency exposure rise net currency gain loss recognise income statement arise principally company sterle functional currency table set exposure financial asset liability hold currency functional currency group company effect currency swap december sterling euro yen total financial asset investment cash cash equivalent receivables december sterling euro yen total financial liability debt obligation finance lease payable provision derivativefinancial instrument table set net principal fair value derivative contract hold gsk fair value contract underlie principal asset liability currency interest relate instrument foreign exchange contract cross currency swap interest rate swap equity relate instrument option warrant equity collar embed derivative total derivative financial instrument gskhedge equity value holding large equity investment quest diagnostic inc series variable sale forward contract contract equity collar structure series million quest share mature group enter option agreement theravance shareholder sell half theravance share gsk predetermine price give maximum number share subject option group obligation cap million december option record liability ofmillion million december maximum potential exposure gsk fair value movement option approximatelymillion expiry date august group enter option agreement purchase half outstanding theravance share issue pre determine price december option record asset ofmillion million december maximum potential exposure gsk fair value movement option thereforemillion expiry date july note financial statement continue financial instrument relate disclosure continue follow table set principal andfair value derivative contract qualify hedge accounting treatment contract underlie fair value principal derivative contract cash flow hedge cross currency swap fair value hedge foreign exchange contract interest rate swap cross currency swap net investment hedge foreign exchange contract cross currency swap cash flow hedge group enter cross currency swap designate cash flow hedge convert fix euro coupon payable annually fix yen payment bond mature risk hedged variability cash flow arise currency fluctuation fair value hedge foreign exchange contractsdesignate fair value hedgeshavebeen enteredin order hedge foreign currencyrisk associate intercompany loan deposit commercial paper borrowing andother liabilitie group designate interest rate swapsand interest element cross currency swapsa fair value hedge risk hedge variability ofthe fair value bondsarise frominter rate fluctuation net investment hedge foreign exchange contract currency element cross currency swap designate net investment hedge respect foreign currency translation risk arise consolidation group net investment usdollar euro yen foreign operation gaap disclosure group exercise ifrs exemption record financial instrument comparative period exist gaap basis follow disclosure include december meet requirement financial reporting standard derivative financial instrument disclosure gaap accounting policy derivative financial instrument group hold issue derivative financial instrument trading purpose derivative financial instrument manage exposure market risk treasury operation principal derivative instrument currency swap forward foreign exchange contract interest rate swap derivative contract treat inception economic hedge underlie financial instrument matching accounting treatment cash flow derivative contract havea high correlation specific financial instrument hedge inception hedge period derivative instrument long designate hedge restate market value future change value take directly income statement currency swap forward foreign exchange contract fix value relate asset liability contract currency contract rate accrue income statement life contract gain loss foreign forward exchange contract designate hedge forecast foreign exchange transaction defer include measurement relate foreign currency transaction period occur gain loss balance sheet hedge accrue take directly reserve forward premiumsdiscount recognise interest life contract interest differential interest swap agreement recognise income statement adjustment interest expense life agreement gsk annual report stnemetat laicnanifnote financial statement continue financial instrument relate disclosure continue classification fair value financial asset liability follow table set classification financial asset liability provide reconciliation group net debt note short term payable receivables exclude financial asset liability provision include contractual obligation settle cash appropriate currency interest rate swap present alongside underlie principal instrument carrying amount instrument adjust effect currency interest rate swap acting hedge december carry fair value value net debt liquid investment cash cash equivalent current asset financial instrument note bond usnote bond private financing note bond swap currency swap interest rate swap notesswappe yen currency swap note interest rate swap otherlongterm borrowing shortterm loan overdraft total borrowingsand relate swap total net debt equity investment receivables payable provision foreign exchange derivative nonhedge derivative total financial asset liability total financial asset total financial liability gsk annual report stnemetat laicnanifnote financial statement continue financial instrument relate disclosure continue currency interest rate risk profile financial liability financial liability take account currency interest rate swap analyse total financial liability comprise total borrowing million longterm payable millionand provision million exclude shortterm payable foreign exchange derivative million benchmark rate determine interest payment float rate financial liability table libor noninterest fix rate float rate bearing weight weight average average weight december interest year average rate rate year total currency fix maturity sterle euro yen currency currency interest rate risk profile financial asset total financial asset comprise investment million liquid investment million cash cash equivalent million longterm receivables million benchmark rate determine interest receipt float rate asset table libid noninterest fix rate float rate bearing weight weight average average december fix interest year rate rate rate total currency fix sterle euro yen currency gsk annual report stnemetat laicnanifnote financial statement continue financial instrument relate disclosure continue currency exposure net monetary assetsliabilitie group currency exposure rise net currency gain loss recognise income statement arise principally company sterle functional currency monetary asset liability denominate overseas functional currency borrowing designate hedge overseas net asset exclude table december functional currency group operation net monetary assetsliabilitie sterle euro yen total hold nonfunctional currency sterling euro yen finance total debt lease maturity financial liability year demand year year year gain loss net hedge unrecognise gain loss begin year unrecognised gain loss arise previous year recognise year unrecognised gain loss arise year total unrecognised gain loss end year expect recognise year expect recognise year total unrecognised gain loss end year unrecognised gain loss represent difference carry fair value currency swap interest rate swap equity collar foreign exchange derivative impact ias ia adoption comparative information nature main adjustment comparative information comply ias ias therecognition fair valueof financial instrumentsclassifie fair value profit loss availableforsale gsk annual report stnemetat laicnanifnote financial statement continue employee share scheme group operate share option scheme option grant employee acquire share adss glaxosmithkline plc grant price share award scheme award grant employee acquire share adss glaxosmithkline plc cost subject tothe achievement group specify performance target group introduce new share award scheme restrict share plan award grant employee acquire share adss glaxosmithkline plc cost year vest period grant restrict share award replace grant option certain employee cost schememore readily equate potential gain employee group operate share option scheme savingsrelate share option scheme grant share option scheme normally exercisable year date grant grant restrict share share award normally exercisable end year vestingperformance period grant savingsrelate share option scheme normally exercisable year save option share option scheme normally grant market price ruling date grant accordance practice majority option savingsrelate share option scheme grant price marketprice ruling date grant share option award tothe directorsand effect grant cetare subject performance criterion lay remuneration report option pricing purpose value option arrive stockbase compensation charge blackschole option pricing model assumption model follow riskfree interest rate dividend yield volatility expect life option grant share option scheme year year year savingsrelate share option scheme year year year weight average share pricefor grant year ordinary share adss volatility determine base year share price historythe fair value performance share plan grant account market conditionsexpecte life option determine base weighted average historic exercise option stockbase compensation charge record income statement follow cost sale sell general administration research development option outstanding share option share option savingsrelate scheme share scheme adss share option scheme weight weight weight weight weight weight number exercise fair number exercise fair number exercise fair price value price value price value january option grant option exercise option cancel december option grant option exercise option cancel december option grant option exercise option cancel december range exercise price average share price gsk annual report stnemetat laicnanifnote financial statement continue employee share scheme continue order encourage employee convert option exclude savingsrelate share option hold glaxo wellcome smithkline beecham share adss glaxosmithkline share adss programme establish additional cash benefit exercise price original option provide employee voluntarily leave group year date merger exercise option early month expiry date original option year date merger cash benefit pay option expire unexercised market price exercise price date expiry option outstanding share option share option savingsrelate scheme share scheme adss share option scheme december weight late weight late late number exercise exercise number exercise exercise number exercise exercise year grant price date price date price date total option exercisable option share adss grant savingsrelate share option grant change effective exercise price outstanding option year option exercisable share option share option savingsrelate scheme share scheme adss share option scheme weight weight weight number exercise number exercise number exercise price price price december december december glaxosmithkline share award scheme performance share plan group operate performance share plan award grant director senior executive cost percentage award vest base performance group year measurement period performance condition consist part apply award award grant condition compare glaxosmithkline total shareholder return tsr period tsr company ukftse index period award grant subsequent yearsthe condition compare glaxosmithkline tsr period tsr pharmaceutical company comparator group period second performance condition compare glaxosmithkline earning share growth increase ukretail price index year performance period award grant director member cet december subject single performance condition compare glaxosmithkline tsr period tsr company comparator group period gsk annual report stnemetat laicnanifnote financial statement continue employee share scheme continue share weight adss weight number share adss issuable number fair value number fair value january award grant award exercise award cancel december award grant award exercise award cancel december award grant award exercise award cancel december restrict share plan group operate restrict share plan award grantedin form share certain employee cost award vest year performance criterion attach share weight adss weight number share adss issuable number fair value number fair value atst january award grant december award grant award exercise awardscancelled december employee share ownership plan trust group sponsor employee share ownership plan esop trust acquire hold share glaxosmithkline plc satisfy award employee incentive plan option grant employee share option scheme trustee esop trust purchase share onthe open market finance provide group way loan contributionscost run esop trust charge income statement share hold esoptrust deduct reserve hold value proceed receivable employee exercise deem permanentdiminutionin value reflect transfer retain earning share hold share award scheme number share nominal value carry value market value share hold share option scheme number share nominal value carry value market value trust acquire hold share meet notional dividend reinveste deferred award smithkline beecham midterm incentive plan trustee waive right dividend share hold esoptrust gsk annual report stnemetat laicnanifreconciliation usaccounte principle like ifrs sfas require goodwillmust notbe amortise annual impairment test goodwill undertaken analysis reconciliation present note represent implementation sfas year early financial information prepare basis generally accept group transition ifrs result goodwill balance acquire accounting principle usgaap ifrs reflect year amortisation summary material difference ifrs usgaap ifrs gaap ifrscost incur integrate restructuring acquisition smithkline beecham wellcome smithkline beecham block drug business follow group exercise exemption available ifrs acquisition respectively charge timeadoption ifrs restate business combination prior income statement post acquisition similarly integration date transition group report gaap restructuring cost arise respect acquisition ofcorixa generally accept accounting principle ukgaap ifrs idbiomedical charge income statement combination glaxo wellcome plc ifrs usgaap certain ofthesecostsareconsidere smithkline beecham plc continues account merger allocation purchase consideration affect pool interest accordance withukgaapat time goodwill arise acquisition gaap business combination qualify pool interest account glaxo wellcome deemedto inprocessresearch development iprd accounting acquirer purchase business combination ifrs iprd project acquire business combination capitalise remain balance sheet subject accordingly net asset smithkline beecham recognise impairment writedownsamortisation charge asset fair valueas date acquisition result fair value estimate useful life point whenthe asset available exercise increase value smithkline beecham inventory useunder usgaap asset recognise open property plant equipment intangible asset investment balance sheet writtenoff immediately income pension obligation recognise fair market value statementa technological feasibility iprd attribute internallygenerate intangible asset mainly product establish alternative future use ifrs right inclusive patent andtrademark inprocess research defer tax provide iprd asset acquire business development appropriate defer taxation combination usgaap provide defer tax effect difference cost acquisition fair asset result reconcile adjustment defer tax value asset liability smithkline beechamisrecorde goodwill goodwill iprd acquire transaction business combination capitalise interest discuss underintangible asset ifrs group capitalise interest usgaap require interest incur cost construct fix assetto intangible asset capitalise amortise life asset ifrs certain intangible asset relate specific compound product purchase party develop goodwill commercial application capitalise subject group exercise exemption available ifrs amortisation regulatory approval obtain usgaap restate business combination prior date transition payment madein respect ofthese compound product group report gaap ukgaap ifrs ukgaap development receive regulatory approval goodwill arise acquisition account charge directly theincome statement purchase method eliminate equity ifrs futuredisposal closure business goodwill previously take ifrs intangible asset amortise estimate useful directly equity gaap charge economic life case certain acquire brand income ukgaap goodwill arise acquisition end useful economic life brand foresee capitalise amortise period exceed year gaap implementation sfas goodwill date group transition ifrs january intangible asset intangible asset include amortisation cease accordance ifrs business brand amortise finite life implementation sfas combination group instead identify value report intangible asset deem indefinite life unit purpose assess annually potential long amortise result difference accounting impairment goodwill allocate reporting unit permit treatment prior implementation sfas carry business combination exemption available ifrs valuesofindefinite live brandsare affect byamortisation charge amortisation arise prior reverse usgaap gaap goodwill arise acquisition prior june capitalise amortise period exceed year july financial accounting standard board fasb issue statement financial accounting standard sfas goodwill intangible asset gsk annual report stnemetat laicnanif note financial statement continuedreconciliation accounting principle proceed sale marketable security usgaap continue million year end december proceed include rollover liquid fund shortterm deposit gross restructuring cost gain loss reflect consolidated income statement ifrs restructuring cost incur follow acquisition respect marketable security weremillion andnil respectively charge profit loss account post acquisition usgaap purpose certain cost recognise liability pension postretirement benefit acquisition opening balance sheet key differencebetween ifrs usgaap method recognition actuarial gain loss gsk opt underifrs restructuring cost record provision ifrswhen recognise actuarial gain lossesin statement recognise restructuring plan announce usgaap provision income expense year arise usgaap recognise criterion meet liability actuarial gain loss recognise corridor incur adjustment eliminate approach defer actuarial gain loss amortise provision restructuring cost meet usgaap pension liability recognise ifrs great requirement usgaap marketable security stockbase compensation marketable security consist primarily equity security certain ifrs sharebasedpayment share option fair value liquid investment principally government bond short grant date cost charge income statement term corporate debt instrumentsunder sfas accounting relevant vest periods usgaap group apply certaininvestment indebt andequitysecuritie security sfas accounting forstockbasedcompensation relate consider availableforsaleand carry fair value accounting interpretation accounting option planswhich unrealise gain loss net tax record separate require option fair value grant date include component shareholder equity ifrstheseare account inthe income statementover vest period option availableforsale financial assetsin accordance withias difference arise result application differ financialinstrument recognition andmeasurement measurement basesin respect performance condition attach accounting treatment marketable security usgaap sharebase payment treatment lapse grant ifrs issimilar difference arise principallyas result derivative instrument category marketable security define sfas sfas accounting derivative instrument hedge small category availableforsale financial asset activity amend sfas sfas interpret define ia investment marketable security derivative implementation group adopt group sfas definition account cost effect january sfas establish accounting impairment usgaap fair value reporting standard derivative instrument include certain group adopt ia january derivative instrument embed contract collectively accordance exemption available ifrs present refer derivative hedge activity sfas require financial instrument comparativeperiod accordance entity recognise derivative asset liability ukgaap security state low consolidate balance sheet measure instrument fair cost net realisable value value change fair value period record current earning hedge accounting obtain sfas prescribe marketable security review leastevery monthsfor requirement designation documentation hedge temporary impairment equity security factor relationship ongoing assessment effectiveness order consider include qualify hedge accounting investee current financial performance future prospect group evaluate contract embed derivative general market condition geographic industry area accordance sfas requirement embed derivative investee operate clearly closely related host contract account duration extent market value separately host contract derivative cost key difference ifrs group financial gross unrealised gain loss marketable security statement prepare usgaap group application million millionrespectivelyat december respective requirement million millionrespectively fair value marketable security unrealise loss december ismillion certain derivative designate group hedge million marketable security instrument ias designate hedge continuous loss position monthsdeferre tax instrument sfas accordingly hedge accounting provide unrealised gain loss december apply usgaap respect arrangement million million gain million reclassify ofaccumulatedothercomprehensive income income statement disposal equity investment year gsk annual report stnemetat laicnanif note financial statement continuednote financial statement continue reconciliation accounting principle continue follow adjustment include reconciliation definition derivative scope sfas exclude computer software ifrs group capitalise cost incur instrument liquid market lead certain acquire develop computer software internal use item recognise balance sheet software support significant business system account derivative ifrs notably option expenditure lead creation durable asset gaap theravance share group apply sop accounting cost computer software develop obtain internal use restrict ias exemption requirement recognise category cost capitalise embed foreign currency derivative currency commonly economic environment host contract guarantor obligation usgaap group apply sfas grant similar exemption group fasbs financial interpretation fin guarantor identify separately account embed derivative accounting disclosure requirement guarantee include gaap ifrs indirect guarantee indebtedness require group recognise certain guarantee issue measure fair group exercise exemption available ifrs value ifrs guarantor obligation recognise present financial instrument comparativeperiod accordance additional criterion meet liability incur ukgaap ukgaap derivative instrument hedge recognise balance sheet matching variable interest entity fasbs interpretation principle match gain loss hedge revise fin consolidation variable interest entity certain contract foreign currency transaction profit entity know variable interest entity vie relatedgain loss relate fair value adjustment consolidate primary beneficiary entity primary derivative instrument reconcile item beneficiary generally define majority risk group designate derivative qualify hedge reward arise vie additionally vie instrument sfas significant majority variable interest hold certain disclosure require group complete review fair value book value derivative instrument potential vie consequence consolidated theravance december disclose classification fair value inc note page vie financial asset liability table note group primary beneficiary identify valuation derivative instrument fix asset inventory impairment reversal impairment fair value derivative instrument sensitive movement previously record carrying value asset permit underlie market rate variable group monitor ifrs certain circumstance usgaap permit fair value derivative instrument quarterly basis reversal impairment derivativesinclude interest rate swap crosscurrency swap value standard valuation model counterparty valuation othersmalladjustment party valuation standard valuation model consolidated summary statement cash flow group consider relevant discount rate market yield curve usgaap cash flow statement reportsthree category cash valuation date forward currency exchange rate counterparty flow operating activity include tax interest invest risk significant rate variable obtain market activity include capital expenditure acquisition disposal source valuation base remain term maturity cash flow availableforsale current asset instrument investment andfinance activity include dividend pay foreign exchange contract value forward rate observe summary statement ofcash flow present page quote price relevant market possible group comprehensive income statement assume party longterm contract economically viable requirement sfas report comprehensive income reserve right exercise early termination right economically provide comprehensive income statement meet ifrs beneficial right exist contract statement recognise income expense page dividend ifrs gsk plcs quarterly dividend recognise payment usgaap dividend recognise financial statement declare gsk annual report stnemetat laicnanifnote financial statement continue reconciliation accounting principle recent fasb pronouncement continue november fasb issue sfas inventory cost amendment arb chapter sfas clarify recent financial accounting standard board fasb abnormal amount idle facility expense freight handling cost pronouncement waste material spoilage recognise current fsp fin period charge require allocation fix production march fasb issue fasb staff position fsp fin overhead inventory base normal capacity implicit variable interest fasb interpretation production facility sfas effective fiscal year begin consolidation variable interest entity fsp require report june enterprise consider hold implicit variable interest thevieor potential vie determination implicit december fasb issue sfas exchange non variable interest exist involve determine enterprise monetary asset amendment apb opinion amend indirectly absorb receive variability entity apb opinion accounting nonmonetary transaction fsp effective reporting period begin eliminate exception nonmonetary exchange similar march adoption fsp group productive asset replace general exception impact overall result operation financial positionunder exchange nonmonetary asset commercial gaap substance sfas effective nonmonetary asset exchange occur fiscalyearsbeginne june eitf june emerge issue task force eitf reach consensus march fasb publish fasb staff position fsp fin issue determine amortisation period leasehold accounting conditional asset retirement obligation improvement purchase lease inception acquire interpretation fasb statement clarifie business combination eitf require leasehold improvement application sfas accounting obligation associate acquire business combination amortise short retirement longlive asset respect conditional asset useful life asset term include require lease retirement obligation fsp effective period begin period renewal deem reasonably assure date december acquisition additionally issue require improvement place november fasb issue fsp fsp service significantly contemplate near mean otherthantemporary impairment application begin lease term amortise short certain investment nullify certain requirement eitf useful life asset term include require lease period supersede eitf fsps provide guidance identify renewal deem reasonably assure date impair investment new disclosure requirement leasehold improvement purchase investment deem temporarily impair fsps eitf effective immediately adoption eitf effective fiscal year begin december amaterial impact group consolidate financial position november fasb issue fsp fin provide result operation cash flowsunder gaap clarification respect application fin guarantor sfas rand relate fsps accounting disclosure requirement guarantee include december fasb issue sfas revise share indirect guarantee indebtedness fsp fin include base payment sfas replace sfas supersede apb scope provide guidance concern application sfas require cost result sharebase fin guarantee grant business owner payment transaction recognise financial statement fair entitys revenue revenue specify portion entity value excess tax benefit report finance cash meet minimum refer minimum revenue inflow reduction taxis pay sfas effective guarantee group january effective date group expect adoption compensation cost recognise base requirement sfas pronouncement material impact consolidate new sharebased award base requirement financial position result operation cash flow gaap sfas award grant prior effective date sfas remain unvested effective date sfas accounting change error correction replacement apb opinion sfas issue sfas fasb issue fsp rfsp fspr change accounting reporting change accounting fsps detail aspect implementation principle require retrospective application prior period sfas rgsk process assess impact financial statement change accounting principle adoption sfas group consolidate financial position impracticable sfas effective accounting change result operation cash flow gaap fiscal year begin december group determine impact sfas depend future change accounting principle gsk annual report stnemetat laicnanifnote financial statement continue reconciliation accounting principle continue follow summary material adjustment profit shareholder fund require gaap apply instead ifrs profit note profit taxation year ifrs profit attributable minority interest profit attributable shareholder ifrs usgaap adjustment amortisation impairment intangible asset acquisition disposal product rights writeoff inprocess acquire business combination capitalise interest disposal interestsin associate subsidiarie investment pension postretirement benefit stockbased compensation derivative instrument hedge fair value option grant minority shareholder restructure tax benefit exercise stock option defer taxation net incomeunder usgaap earning share usgaap basic net income share dilute net income share earning ad usgaap basic net income ad dilute net income ad equity shareholder fund note total equity ifrs minority interest shareholdersequityunder ifrs usgaapadjustment goodwill product right pension intangible asset property plant equipment capitalise interest marketable security investment pension postretirement benefit restructuring cost derivative instrument hedge fair value option grant minority shareholder dividend defer taxation shareholder equity gaap gsk annual report stnemetat laicnanifnote financial statement continue reconciliation accounting principle continue consolidated statement cash flow usgaap net cash provide operating activity net cash investing activity net cash financing activity net increase cash cash equivalent exchange rate movement cash cash equivalent begin year cash cash equivalent end year note profit equity shareholder fund reconciliation goodwill follow table set ifrs usgaap adjustment require ifrs balance sheet respect goodwill include goodwill respect associate undertaking balance sheet goodwill ifrs goodwill usgaap ifrs usgaap adjustment million millionusgaap goodwill balance december million million respect goodwill arise acquisition smithkline beecham glaxo wellcome follow table present change goodwill allocate group reportable segment consumer pharmaceutical healthcare total atst january asset write exchange adjustment december addition disposal exchange adjustment december intangible asset follow table set ifrsto usgaap adjustment require ifrs income statement balance sheet respect intangible asset income statement amortisation charge ifrs amortisation charge usgaap ifrsto usgaap adjustment amortisation impairment charge ifrs impairment charge usgaap ifrs usgaap adjustment impairment addition adjustment amortisation impairment ifrs usgaap adjustment arise year million million million respect acquisition disposal inprocess licence patent etc capitalise ifrs charge directly research development expense usgaap nil million million nil respect disposal product right high carrying value usgaap ifrs gsk annual report stnemetat laicnanifnote financial statement continue reconciliation accounting principle continue balance sheet product right intangible asset ifrs product right intangible asset usgaap net ifrsto usgaap product right adjustment product right intangible asset usgaap analyse follow acquire license brand subject indefinite product patent etc amortisation live brand total cost accumulate amortisation impairment carrying value cost accumulate amortisation impairment carrying value acquire product pharmaceutical product principally arise acquisition smithkline beecham plc book value net accumulate amortisation impairment follow avandia seroxatpaxil augmentin fluviral havrix infanrix coreg twinrix engerixb hycamtin acquire product intangible asset usgaap indefinite live brand relate large number consumer healthcare product principally arise acquisition ofsmithkline beecham plc include product previously acquire smithkline beecham sterling winthrop inc block drug company book value follow panadol aquafresh lucozade horlick ribena nicorette odol tums sensodyne nicoderm indefinite live brand intangible asset gaap gsk annual report stnemetat laicnanifnote financial statement continue reconciliation accounting principle continue brand consider indefinite life give strength durability brand level marketing support brand relatively stable profitable market sector size diversification market share mean risk market relate factor cause shortening brand life consider relatively low group aware material legal regulatory contractual competitive economic factor limit useful life accordingly amortisedeach brand test annually impairment apply fair value cost sell methodology year posttax cash flow forecast terminal value calculation apply discount rate group posttax weight average cost capital approximate apply pretax discount rate pretax cash flow carry value certain intangible subject amortisation review impairment million million record million nil relate pharmaceutical product million million consumer healthcare product impairment charge respect consumer healthcare intangible asset subject amortisation million recognise nil discuss notelegal proceeding number distributor generic drug file application market generic version number group product prior expiration group patent generic version product launch future period early date group currently expect impairment carry value product arise estimate future amortisation expense year intangible asset subject amortisation december follow year total inprocess million nil nil arise acquisition idbiomedical corixa corporation write value basis intangible asset acquire relate development project pre approval stage technological feasibility project establish point acquisition theravance group form strategic alliance theravance inc develop commercialise novel medicine variety important therapeutic area term alliance theravance receive million significant relate group purchase theravance share group option increase ownership significant premium price pay transaction theravance shareholder option low exercise price cause glaxosmithkline acquire half outstanding stock give maximum number share subject option group obligation cap million group exclusive option license potential new medicine theravance programme august exercise option theravance programme group responsible relevant development manufacturing commercialisation activity depend success programme theravance receive clinical regulatory commercial milestone payment royaltie subsequent sale medicine base assessment perform groupwas primary beneficiary theravance define fin result theravance consolidate group gaap financial statement net asset acquire measure fair value principal adjustment carry value net asset theravance balance sheet prior acquisition recognition inprocess research development iprd valuation million iprdwa writtenoff immediately acquisition accordance usgaap purchase accounting effect consolidate theravance include reversal fair value gain record investment ifrsha decrease shareholder equity million million net income million million additionally group account theravance option discuss accordance sfas account certain financial instrument characteristic liability equity require group record fair value option liability fair value theravance option december million million accordance sfas accounting derivative instrument hedge activity option recognise financial statement readily convertible cash gsk annual report stnemetat laicnanifnote financial statement continue reconciliation accounting principle continue taxation total tax expense ifrs current tax expense defer taxcreditexpense total tax expense gaap current tax expense defer tax credit total tax expense ifrsto usgaap adjustment current tax expense defer tax credit total tax expense ifrs usgaap adjustment respect current tax expense include million million million group share tax expense associate recognise taxation charge income statement usgaap record share tax profit associate income statement present accordance ifrs defer taxation usgaap classification gsk defer taxation liability asset gaap follow liability stock valuation adjustment time difference current defer taxation liability accelerate capital allowance product right product business disposal pension postretirement benefit time difference total defer taxation liability asset intragroup profit stock valuation adjustment time difference current defer taxation asset accelerate capital allowance product business disposal pension postretirement benefit tax loss restructure legal dispute share option award scheme time difference valuation allowance total defer taxation asset net defer taxation gaap net defer taxation ifrs ifrs usgaap adjustment gsk annual report stnemetat laicnanifnote financial statement continue reconciliation accounting principle continue pension postretirement cost usgaap pension scheme pension scheme overseas pension scheme unfunded postretirement healthcare scheme postemployment cost analyse fund define benefithybrid scheme unfunded define benefit scheme define contribution scheme unfunded postretirement healthcare scheme postemployment cost disclosure include additional information require sfas pension cost major overseas define benefit pension plan restate follow table accordance gaap minor retirement plan pension cost million million million recalculate accordance requirement sfas exclude net periodic pension cost major retirement plan service cost interest cost expect return plan asset amortisation prior service cost amortisation transition obligation amortisation net actuarial loss net periodic pension cost gaap termination benefit curtailment cost major assumption compute pension cost rates future pay increase discount rate expect longterm rate return plan asset aggregate average international plan assumption vary significantly assumption estimate future benefit payment gsk annual report stnemetat laicnanifnote financial statement continue reconciliation accounting principle continue change benefit obligation benefit obligation atst january amendments service cost interest cost plan participant contribution actuarial loss benefit pay termination benefit curtailment cost exchange adjustment benefit obligation atst december benefit obligation atst decemberfor pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation december million december million change plan asset fair value plan asset atst january actual return plan asset employer contribution plan participant contribution benefit pay exchange adjustment fair value plan asset atst december fair value plan asset end year pension plan accumulate benefit obligation excess plan asset plan asset consist primarily investment overseas equity fix interest security indexlinke security property december equity include million gsk share million share market value million million analysis percentage total plan asset major category disclose note analysis include asset value million minor retirement plan exclude table fund status fund status unrecognise net actuarial loss unrecognise prior service cost unrecognised transition obligation net recognise amount recognise statement financial position prepay benefit cost accrue pension liability intangible asset accumulate comprehensive income net recognise gsk annual report stnemetat laicnanifnote financial statement continue reconciliation accounting principle continue postretirement healthcare usgaap postretirement healthcare cost major overseas postretirement healthcare scheme restate follow table accordance usgaap minor healthcare plan cost million nil million recalculate exclude net healthcare cost service cost interest cost amortisation prior service cost amortisation net actuarial loss net healthcare cost major assumption calculate net healthcare cost rate future healthcare inflation discount rate rate future healthcare inflation reflect fact benefit certain group participant cap change benefit obligation benefit obligation atst january service cost interest cost plan participant contribution actuarial loss benefit pay exchange benefit obligation atst december change plan asset fair value plan asset atst january employer plan participant contribution benefit pay fair value plan asset atst december fund status fund status unrecognise net actuarial loss unrecognise prior service cost accrue postretirement healthcare cost decrease increase impact variation rate future healthcare inflation effect total service interest cost postretirement healthcare effect obligation postretirement healthcare medicare gross subsidy net estimate future benefit payment gsk annual report stnemetat laicnanifstnemetat laicnanif note financial statement continue principal group company follow represent principal subsidiary associated undertakings glaxosmithkline group stdecember detail give principal country operation location headquarters business segment business activity equity share capital undertaking wholly own group percentage interest show company incorporate principal country operation state europe location subsidiary undertaking segment activity england brentford glaxosmithkline holdings onelimite phch brentford glaxosmithkline service unlimited phch brentford glaxosmithkline finance plc phch brentford glaxosmithkline capital plc brentford smithkline beecham plc phch brentford wellcome limited phch greenford glaxo group limit greenford glaxo operation limit brentford glaxo wellcome international bvi phch brentford glaxo wellcome investment bvi phch stockley park glaxo wellcome limit brentford glaxosmithkline export limit brentford glaxosmithkline research development limit brentford glaxosmithkline uklimited brentford smithkline beecham investments limited phch brentford smithkline beecham swg limited brentford smithkline beecham research limit brentford staffordmiller limited greenford wellcome foundation limit austria vienna glaxosmithkline pharma gmbh belgium genval glaxosmithkline rixensart glaxosmithkline biological rixensart glaxosmithkline biological manufacture guernsey peter port smithkline beecham limited phch denmark ballerup glaxosmithkline consumer healthcare brndby glaxosmithkline pharma finland espoo glaxosmithkline france marly roi groupe glaxosmithkline sas marly roi laboratoire glaxosmithkline sas marly roi glaxo wellcome production sas marly roi glaxosmithkline sante grand public sas germany buehl glaxosmithkline consumer healthcare gmbh cokg munich glaxosmithklinepharmagmbh greece athens glaxosmithkline aebe phch hungary budapest glaxosmithklinemedicine healthcare product limited phch italy verona glaxosmithkline spa milan glaxosmithkline consumer healthcare luxembourg mamer glaxosmithkline international luxembourg phch gsk annual report stnemetat laicnanif note financial statement continue principal group company continue europe location subsidiary undertaking segment activity netherlands zeist glaxosmithkline zeist glaxosmithkline consumer healthcare norway oslo glaxosmithkline poland poznan glaxosmithkline pharmaceuticals warsaw glaxosmithkline consumer healthcare spzoo portugal lisbon glaxosmithklineprodutos farmaceuticos limitada republic dublin glaxosmithkline consumer healthcare ireland limitedii ireland carrigaline smithkline beecham cork limitedii carrigaline smithkline beecham manufacturinglimitedii spain tre cantos glaxosmithklinesa alcala henares smithkline beecham sweden solna glaxosmithkline switzerland muenchenbuchsee glaxosmithkline investments switzerland gmbh phch muenchenbuchsee glaxosmithkline zug adechsa gmbh usa usa philadelphia smithkline beecham corporation phch pittsburgh glaxosmithkline consumer healthcare pittsburgh block drug company inc wilmington glaxosmithkline financial inc wilmington glaxosmithkline holdings americas inc phch americas bermuda hamilton glaxosmithkline insurance ltd phch canada mississauga glaxosmithkline inc phch vancouver idbiomedical corporation asia pacific australia boronia glaxo wellcome australia pty ltd phch china hong kong glaxosmithkline limited phch tianjin sinoamerican tianjin smith kline french laboratories ltd india mumbai glaxosmithkline pharmaceutical limit nabha glaxosmithkline consumer healthcare limitediii malaysia petale jaya glaxosmithkline pharmaceutical sdn bhd new zealand auckland glaxosmithkline limited phch pakistan karachi glaxosmithkline pakistan limited phch philippines makati glaxosmithkline philippines inc phch singapore singapore glaxo wellcome manufacturing pte ltd singapore glaxosmithkline pte ltd south korea seoul glaxosmithkline korea taiwan taipei glaxo wellcome taiwan limit gsk annual report note financial statement continue principal group company continue japan location subsidiary undertaking segment activity japan tokyo glaxosmithkline phch latin america argentina buenos aires glaxosmithkline argentina phch brazil rio janeiro glaxosmithkline brasil ltda phch colombia bogota glaxosmithkline colombia phch mexico delegacion tlalpan glaxosmithkline mexicosade phch puerto rico guaynabo glaxosmithkline puerto rico inc san juan pharmco puerto rico inc venezuela caracas glaxosmithkline venezuela phch middle east africa egypt cairo glaxosmithkline sae south africa bryanston glaxosmithkline south africa pty ltd phch turkey istanbul glaxosmithkline ilaclari sanayi ticaret usa location associate undertaking business usa teterboro quest diagnostic incorporatediv clinical testing incorporate netherlands exempt provision section company amendmentact ireland iii consolidated subsidiary undertaking accordance section company act ground dominant influence equity account ground significant influence directly hold wholly own subsidiary glaxosmithkline plc key business segment pharmaceutical consumer healthcare business activity development export finance hold company insurance marketing production researchs service detail group subsidiary associate undertaking attach company annual return file registrar ofcompanie stnemetat laicnanif gsk annual report note financial statement continue transition ifrs ifrs adjustment summary principal difference gaap ifrs background apply togski set financial effect show ifrs project pagesto june council european union adopt customer allowance regulation require list company member state prepare adjustment reclassification turnover expense consolidate financial statement accordance profit cash flow effect ifrs detailed rule relation international financial reporting standard ifrs certain marketing promotional expenditure glaxosmithkline annual report year end deduct turnover record expense december annual report prepare ifrs rule exist gaap eitf account consideration give vendor customer require early year ifrs financial statementsare marketing advertising promotion payment customer present annual report transition date ifrs deduct turnover significant impact glaxosmithkline january normallyaccounte change consumer healthcare business payment large retailer nature require retrospective application gsk instore advertise preferential shelfspace product listing etc take advantage exemption available ifrs transitional commonplace rulesto applycertainrequirementsonlywith effect transition date january case financial instrument gskbelieve reflect good practice revenue recognition january absence detailed guidance ifrs decide adopt revenue recognition policy ifrs line financial instrument eitf thereforethereis expect anydifference gsk adopt ias endorse european union turnover report ifrs turnover report exemption available ifrs relax gaap adjustment impact profit tax eps requirement comparative information present annual report comply ias ias glaxosmithkline sharebase payment take advantage exemption financial thepreviousuk gaap approach sharebase paymentswasto instrument account present gaap basis record intrinsic loss grant suffer company mean share option grant market price therewasno january adjustment million charge income statement share option open balance sheet reflect movement gaap grant cost employee longterm incentive carry value ias value financial plan income statementwascharge equal instrument fair value market price date award spread financial instrument concern performance period usually year hold fair value ifrs movement record equity ifrs sharebase payment ukgaap equivalent frs equity investment sharebase payment come force liquid investment require fair value equity instrument issue charge derivative classify cash flow hedging instrument income statementthe grouphas choose recognise unvested option award retrospectively hold fair value ifrs movement record income statement gsk receive tax credit appropriate relate share equity collar link group investment quest diagnostic option award exercise base gain holders inc dependent tax rule country option link group strategic alliance deduction claim defer tax asset represent estimate theravance inc future tax relief gain base potential gain derivative classify hedge instrument include available option award holder balance sheet date embed derivative movement defer tax asset balance sheet derivative classify fair value hedge result tax credit tax charge record hedge element relevant asset liability income statementthe tax credit recognise income statement cap cumulative tax presentation difference effect sharebased payment charge excess credit take nonequity minority interest repay equity ias valuation rule apply adjustment reducedprofit tax million charge profit tax large element million earning million million arise quest collar million million eps pence pence theravance option million nil valuation inherently unpredictable change fair value financial instrument material impact future result financial position gsk stnemetat laicnanif gsk annual report note financial statement continue transition ifrs continue pension postemployment benefit glaxosmithkline accountedunder gaap pension thesharebase payment chargereducedtoamore normal level postemployment benefit opebs accordance ssap millionin considerably high charge spreadthe cost provide benefit estimate average arise main factor relatively share option service live employee grant gwsb merger finalise catchup grant early year ias employee benefitsrecognise surplus deficit follow normal annual grant november addition account accordance transitional provision ifrs grant average share price excess surplus deficit recognise balance share optionsbecame exercisable sheet transition date january addition follow fellout charge nowreflectsmore current share amendment ias issue iasb december price normal grant level permit recognise movement surplus deficit immediately balance sheet outside income statement coreg capitalisation amortisation statement recognise income expensethis mean north american right coregwere acquire time case balance sheet reflect surplus deficit gwsb merger partial consideration require disposal position fund kytril roche gaap account exchange asset value attribute coregon group policy charge operating business balance sheet ifrs require acquire right coregto service cost element pension charge get report add intangible asset fair value date cost sale sell general administrative expenditure acquisition million amortise remain research development appropriate charge useful life year adjustment reduce profit element relate funding deficit report inselle tax million million eps pence general administrative expenditure ias service penny cost element total charge considerably high ssap funding deficit element low thisha ledto intangible asset amortisation additional reclassification adjustment income statement gaap gskamortisedintangible asset estimate expense heading expect useful life acquisition whichwasup maximum year ifrs permit amortisation commence overall impact adjustment pension opebs asset available use annual impairment testing wasa decrease profit tax million increase require point gskha determine point million decrease ep pence nil amortisation productrelate asset commence ifrs share profit associate normally regulatory approval majority group ukgaap share profit associateswasreporte intangible asset relate acquisition right compound profit tax group ifrs require share development reach point amortisation profit net profit attributable group interest commence lead reduction amortisation charge tax minority interest associate lead likely reverse future compound reach reclassification adjustment remove share associate regulatory approval amortisation charge short interest tax minority interest line income period profit tax increasedby million statement net share profit million ep pence pence associates line adjustment reduce profit tax goodwill amortisation million million butdidnot affect eps gaap require goodwill amortise estimate defer tax intercompany profit expect useful life gskhad determine normally gaap defer tax provision intercompany profit long year ifrs goodwill consider hold inventory calculate supply company effective tax indefinite life amortise subject annual rate ifrs take balance sheet approach recognition impairment testing adjustment reverse goodwill defer tax result tax rate company hold amortisation charge gaap include record inventory balance sheet date apply provision profit share associate line relate acquisition proportion group inventory hold specific location group interest quest diagnostic inc business change significantly balance sheet date combination exemption ifrs goodwill previously write significant change value defer tax asset direct reserve gaap recycle income reflect tax charge year statement disposal partdisposal subsidiary associate gaap adjustment increase profit tax million million eps pence penny stnemetat laicnanif gsk annual report stnemetat laicnanif note financial statement continue transition ifrs continue amortisation goodwill ukgaap prior date transition ifrs january reverse adjustment accordingly goodwill recognise ifrs balance sheet low number minor adjustment reclassification respect gsk take include advantage business combination exemption computer software record intangible asset sharebase payment ifrs sharebase payment apply form integral operate system tangible fix equity instrument share option grant asset november glaxosmithkline elect adopt defer tax brand acquire company retrospective application standard difference fair value brand acquisition financial instrument financial instrument comparative tax value taxable temporary difference arise period present annual report cash equivalent reclassification liquid investment arerecognise measuredon theuk gaap basisapplicable maturity month acquisition include year accordance ias financial cash cash equivalent instrument recognition measurementa result certain derivative instrument recognise comparative provision reclassification element provision expect period ifrs hedge accounting apply comparative pay year balance sheet date period hedge borrowing record amortise cost exception pension opebs present current fair value availableforsale financial asset liabilitie equity investment liquid investment record cost cash flow statement impairment fair value ukgaap ifrs change cash flow group ifrs cash flow format similar ukgaap present cash flow different category different order ukgaap cash flow statement ifrs accounting adjustment net cash generate operation intangible asset reclassification inclusion liquid investment maturity month acquisition relate exchange adjustment cash cash equivalent ifrs ifrs exemptionsand elections ifrs firsttime adoption international financial reporting standard permit company adopt ifrs time exemption requirement ifrs transition period election apply ifrs retrospective effect require gskha adopt follow key exemptionsand election business combination business combination prior transition date january restate ifrs basis merger glaxo wellcomeand smithkline beecham restate ifrs basis account acquisition fair value adjustment net asset acquire company require include recognition significant intangible asset balance product right relate marketed product inprocess recognise merger accounting significant goodwill balance record goodwill writtenoff reserve prior old ukgaap write goodwill business combination exemption take additional goodwill balance relate acquisition prior havebeen recognise ifrs balance sheet gsk annual report note financial statement continue transition ifrs continued ifrs consolidated income statement month month gaap adjustment ifrs ukgaap adjustment ifrs turnover cost sale gross profit sell general administration research development operating income operate profit finance income financecost share profitslosse associate joint venture profit disposal interest associate profit taxation taxation lossprofit disposal business profit taxation year profit attributable minority interest profit attributable shareholder earning sharepence dilute earning sharepence ifrs consolidated statement recognise income expense december december ukgaap adjustment ifrs ukgaap adjustment ifrs exchange movement overseas net asset tax exchange movementsand unrealise gain goodwill write revaluation goodwill exchange unrealisedlossprofiton disposal intellectual property actuarial gainslosse define benefit plan defer tax actuarial movement ondefinedbenefit plan net lossesgainsrecognise directly equity profit year total recognise income expense year gsk annual report stnemetat laicnanifnote financial statement continue transition ifrs continued ifrs consolidated balance sheet december december ukgaap adjustment ifrs ukgaap adjustment ifrs noncurrent asset property plant equipment goodwill intangible asset investment associate joint venture investment defer tax asset noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing trade payable current tax payable shortterm provision total current liability noncurrent liability longterm borrowing defer tax provision pension postemployment benefit provision noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity minority interest totalequity gsk annual report stnemetat laicnanifnote financial statement continue transition ifrs continue analysis ifrs adjustment income statement year end december share intangible share customer base coreg asset goodwill pension profit ifrs allowance payment amortisation amortisation amortisation opebs associate adjustment turnover cost sale gross profit sell general administration research development operating income operate profit finance income financecost share profitslosse associate jointventure profit disposal interest associate profit taxation taxation profit disposal business profit taxation year profit attributable minority interest profit attributable shareholder earning sharepence reconciliation opening equity component equity january share total share premium retain shareholder minority total capital account reserve earning equity interest equity gaap ifrs adjustment net tax pension defer profit stock dividend defer tax onindefinite life asset coreg intangible asset sharebase payment tax sharebase payment total ifrs adjustment ifrs gsk annual report stnemetat laicnanifnote financial statement continue transition ifrs continue analysis ifrs balance sheet adjustment december coreg capitalisation intangible goodwill dividend sharebase asset amortisation pension ifrs defer payment amortisation amortisation reversal opebs adjustment noncurrent asset property plant equipment goodwill intangible asset investment associate joint venture investment defer tax asset noncurrent asset total noncurrent asset current asset inventory current tax recoverable trade receivables liquid investment cash cash equivalent asset hold sale total current asset total asset current liability shortterm borrowing trade payable current tax payable shortterm provision total current liability noncurrent liability longterm borrowing defer tax provision pension postemployment benefit provision noncurrent liability total noncurrent liability total liability net asset equity share capital share premium account retain earning reserve shareholder equity minority interest total equity gsk annual report stnemetat laicnanifnote financial statement continue legal proceeding group hold patent relate advairwhich affect reissue application include compound patent group involve significant legal administrative relate active ingredient salmeterol afford protection proceeding principally product liability intellectual property tax anti august give effect expect grant trust governmental investigation relate private litigation paediatric exclusivity fdaandvarious patent relate group make provision proceeding regular basis diskusdevice expire period summarise notesand group additional significant provision legal proceeding require avandia avandamet event development matter consistent august group file action district court generally accept accounting principle litigation particularly district new jersey teva pharmaceuticals usa inc usa inherently unpredictable excessive award infringement group patent relate maleate salt form justify evidence occur group future rosiglitazone active ingredient avandia expire incur judgment enter settlement claim result september group file comparable action payment exceed current provision court reddys laboratory allege infringement material adverse effect group financial patent action file response condition result operation andor cash flow abbreviate new drug application anda filing fda reddys laboratories teva certification group intellectual property claim include challenge validity maleate salt patent invalid fda approval andas stay group patent product process assertion early november resolution respective noninfringement patent loss case patent infringement action result loss patent protection product issue consequence loss significant decrease sale teva subsequently file additional certification challenge product materially affect future result operation validity group basic compound patent rosiglitazone group january group commence action teva court infringement patent basic compound legal expense incur provision relate legal claim patent currently expire give effect patent term charge sell general administration cost provision restoration paediatric exclusivity take appropriate legal advice reasonable estimate likely outcome dispute january group file action district court group establish actuarially determine provision product district new jersey teva infringement liability claim incur report describe note patent basic compound maleate salt patent december group aggregate provision legal rosiglitazone teva file anda fda generic dispute include tax matter describe version avandametwith certification patent invalid taxation note billion ultimate liability infringe fda approval anda stay early legal claim vary amount provide dependent june resolution patent infringement action outcome litigation proceeding investigation avandametis protect patent avandia early possible settlement negotiation hold invalidity avandiacase dispositive avandameta significant matter describe imitrex intellectual property december group commence action district advair court southern district new york reddys september group apply patent laboratory allege infringement primary trademark office uspto reissue combination patent compound patent sumatriptan active ingredient imitrex advair inhale combination salmeterol fluticasone patent issue afford protection february propionate expire september follow give effect grant paediatric exclusivity fda internal review conclude language patent defendant file anda fda sumatriptan oral accurately describe circumstance invention tablet certification invalidity compound patent claim invention precisely objective certify invalidity noninfringement theothercompound seek reissuance strengthen protection afford patent expire june give effect paediatric patent january uspto issue final office action exclusivity reject application group seek reconsideration rejection response uspto expect half march group commence infringement action year application reissue remain pende cobalt pharmaceutical transfer patent remain force list register pharmaceutical district court southern district new york defendant patent maintain food drug administration fda file anda forsumatripan oral tablet certification orange book invalidity noninfringement compound patent issue reddys case final pretrial conference consolidated reddys cobalt case schedule gsk annual report stnemetat laicnaniflegal proceeding continue group file action apotex district court eastern district pennsylvania february group commence infringement action infringement additional group patent december district court district delaware spectrum judge grant deny summary pharmaceutical defendant file anda injectable judgment motion file apotex result issue validity sumatriptan certification invalidity noninfringement infringement fouradditionalpatent remain compound patent issue reddys cobalt trial july judge certify patent case trial date case set november hold invalid appeal tothe cafcin february cafc affirm judge rule invalidity patent lamictal august group commence action district group commence action district court court district new jersey teva pharmaceuticals usa eastern district pennsylvania geneva alphapharm andrx inc allege infringement group compound patent pharmaceutical zenith teva pharmaceutical connection lamotrigine active ingredient lamictaloral tablet patent anda filings paxiland basf sumika fine chemical afford protection january give effect grant connection supply paroxetine hydrochloride use paediatric exclusivity fda teva file anda anda lawsuit settle stay pende resolution fda certification invalidity group patent party appeal apotex caseapotex launch generic product reach settlement agreement pursuant group usa september additional generic product grant teva exclusive royaltybearing license distribute launch defendant march usa generic version lamotrigine chewable tablet addition group patent litigation synthon settle teva grant exclusive right manufacture sell tevas december enable marketing synthon paroxetine generic version lamotrigine tablets usa mesylate product follow settlement august expect launch date group nonus patent litigation synthon paxilseroxat consequence synthon free market paroxetine usa number distributor generic drug file application mesylate product market globally obtain fda market generic version paxilseroxatparoxetine marketing authorisation resolution damage respect hydrochloride prior expiration give effect country market remain outstanding paroxetine mesylate grant paediatric exclusivity fda group patent different salt form paroxetine market form paroxetine hyrdrochloride hemihydratethesedistributor seek seroxatpaxil certain market litigation synthon ongoing bring market anhydrate version paroxetine synthon assert counterclaim unfair competition hydrochloride case paroxetine mesylate response group group file action distributor infringement generic product contain anhydrate form paroxetine group patent basis generic anhydrate hydrochloride market european country version infringe contain andor convert whilst product subject continue litigation hemihydrate form andor infringe group patent action settle expect july gsk file action apotex district settle future litigation year standing court northern district illinois infringement group apotex culminate appeal court group patent paroxetine hydrochloride hemihydrate apotex decision group anhydrate process patent valid file anda fda seek approval introduce generic infringe result litigation apotex enjoin form paxil follow trial february judge rule gsk launch product year market patent valid infringe apotexs product group damage enquiry relate injunction ongoing settlement appealthe court appeal federal circuit cafc damage claim reach apotexs local hear appeal district court patent matter rule distributor group patent infringe invalid base public use paxil clinical trial prior filing date usa group file november mylan pharmaceutical file anda paxil petition cafc rehear appeal court paroxetine hydrochloride control release formulation april cafc vacate judgment remand certification invalidity noninfringement patent list matter panel concurrently entry decision fda orange book certification invalidity panel issue new opinion ruling patent invalid noninfringement patent cover paroxetine hydrochloride alternative theory group request rehear hemihydrate mylan admit active ingredient court panel new decision deny group file product patent expire june give effect grant petition review supreme court paediatric exclusivity fda group file patent infringement action mylan day period provide hatchwaxman month stay fda approval mylan anda conduct patent litigation gsk annual report stnemetat laicnanif note financial statement continuednote financial statement continue legal proceeding continue zofran august group commence action district requip court district new jersey reddycheminor april group commence action district reddys laboratories reddy certify invalidity patent court district delaware teva pharmaceutical usa ondansetron active ingredient zofrantablet include inc allege infringement group compound patent compound patent expire july method use ropinirole hydrochloride active ingredient requip patent later expire december method use patent treatment parkinson disease instance take account extension paediatric exclusivity list fda orange book compound patent july group file action reddys laboratory expire december method use patent district court infringement group patent defendant file anda fda certification relate orally disintegrate tablet presentation zofran invalidity noninfringement patent fda approval october group file action westward anda stay early august resolution pharmaceuticals inc district court infringement patent infringement action case progress group patent relate injectable presentation zofran discovery stage reddy disintegrate tablet case westward case valtrex consolidate early reddy case group commence action district prior trial reddycheminor westward withdraw court district new jersey ranbaxy laboratories challenge compound patent trial infringement allege infringement group compound patent valaciclovir validity group method use process patent active ingredient valtrex patent expire complete june closing argument hear defendant file anda fda certification date report decision group compound patent invalid infringe august announce ranbaxy file motion partial summary judgment ground patent invalid public use march group file similar action teva year file patent application pharmaceuticals usa inc district court district group file motion patent invalid delaware allege infringement method use patent groundsin march court rule group favour ondansetron teva certify invalidity noninfringement patent invalid ground discovery substantially method use patent teva challenge compound complete patent trial judge rule group favour uphold validity method use patent follow appeal teva wellbutrin cafc party reach settlement agreement term december biovail commence action district court confidential central district california anchen pharmaceutical district court southern district florida january group commence action kali abrika pharmaceutical case allege infringement biovail laboratory par pharmaceutical company district formulation patent wellbutrin april biovail file court district new jersey involve orally disintegrate action district court eastern district pennsylvania zofrantablet trial judge deny kalis summary judgment motion impax laboratory infringement patent grant group summary judgment motion june patent expire anchen abrika impax july affirm validity group method use file anda fda certification invalidity non patent hold kalis propose generic product infringement biovail patent group licensee infringe patent kali file notice appeal cafc patent hear abrikas motion summary judgment ruling date report hearing date hear november date report appeal announce decision announce trial date biovail action june group commence action district anchen set september group court district new jersey faulding party action september biovail commence pharmaceutical company mayne pharma inc allege action district court southern district new york infringement method use patent ondansetron watson laboratory allege infringement biovail faulding challenge compound patent case formulation patent group remain party counterclaim date report stay pende decision defendant base listing activity associate fda orange reddywestward case book additional action remain pende generic distributor december andrx pharmaceutical file action assert product infringe group patent group district court southern district florida reduce crystal size ondansetron expire march allege manufacture importation sale take account extension paediatric exclusivity wellbutrin xlproduct infringe patent issue andrx june assert invalidity noninfringement group ask treble damage attorney fee group compound patent emesis use patent act concert enjoin case early stage gsk annual report stnemetat laicnanifnote financial statement continue legal proceeding continue federal case consolidate multidistrict litigation proceed district court district washington productliability judge responsible proceeding deny class certification paxil strike class allegation federal personal injury group receive lawsuit claim file behalf patient consumer refund class action class certification deny alleging suffer symptom discontinue treatment california state court pennsylvania state court putative class paxilparoxetine separately group receive lawsuit action dismiss leave putative class action pende claim patient commence paxiltreatment commit group litigation substantial number case attempt commit suicide andor act violence group manufacturer defendant reach private consumer lawsuit allege group conceal trial state federal court manufacturer misrepresented data paediatric clinical trial paxil receive favourable outcome trial group receive lawsuit file state federal court baycol usa canada behalf thousand plaintiff include august bayer withdraw baycolcerivastatin sodium purport class action allege paroxetine active ingredient worldwide light report adverse event include death paxil addictive cause dependency withdrawal reaction involve rhabdomyolosis gsk participate marketing plaintiff seek remedy include compensatory punitive baycolin usa pursuant copromotion agreement bayer statutory damage cost fund medical monitoring licence holder manufacturer product federal judge district court central district california deny class action certification nationwide class follow withdrawal bayer gsk name california statewide class case file federal court defendant thousand lawsuit file state federal court district subsequently petition plaintiff counsel federal usa behalf individual putative class court case transfer district court consolidation baycoluser number suit allege plaintiff multidistrict litigation mdl january group conclude suffer personal injury include rhabdomyolosis use settlement pende claim base baycol claim person take baycol symptom discontinue paxiltreatment pende injure risk future injury suffer economic purport class action dismiss settlement damage purchase baycol plaintiff seek remedy group settlement admit liability include compensatory punitive statutory damage creation respect allegation suit litigation respect fund medical monitoring balance lawsuit include purport class action gsk bayer corporation principal subsidiary bayer california state court continues sign allocation agreement bayer corporation group receive numerous claim lawsuit allege agree pay settlement compensatory damage treatment paxil cause homicidal suicidal behaviour judgment party retaining responsibility exhibit user product purport attorney fee punitive damage federal case class action january fda approve black box warn consolidated multidistrict litigation proceed aboutsuicidal thought behaviourin paediatric patient district court district minnesota numerous case strengthen warning selective serotonin reuptake inhibitor ssri schedule trial state federal court datetwo product include paxil class statewide class action certify medical monitoring case pennsylvania consumer fraud deceptive business avandia practice act case illinois medical monitoring action group receive lawsuit claim file state federal dismiss court summary judgment class action court usa behalf numerous patient allege gsk name defendant certify rosiglitazone active ingredient avandia cause congestive oklahoma substantial number claim death injury heart failure liver damage case purport class settle allege muscle ache pain action case early stage voluntarily involuntarily dismiss phenylpropanolamine follow report yale haemorrhagic stroke project find suggestion association use phenylpropanolamine ppa decongestant haemorrhagic stroke group manufacturer voluntarily withdraw consumer healthcare product ppa active ingredient ppa product withdrawal group name defendant numerous personal injury class action lawsuit file state federal court allege personal injury increase risk injury use product contain ppa unfair deceptive business practice plaintiff seek remedy include compensatory punitive damage refund gsk annual report stnemetat laicnanifnote financial statement continue legal proceeding continue sale andmarkete andregulation marketing andpromotion fenphen february gsk receive subpoena attorney fda aware report cardiac valvular office colorado group sale promotional problem individual fenfluramine dexfenfluramine practice relate large selling product period combination phentermine prescribe january present particular government regimen weight reduction request voluntary inquire allege promotion drug offlabel use withdrawal fenfluramine dexfenfluramine market group sponsor continue medical education programme report cardiac valvular problem subsequent speaker event special issue board advisory board speaker withdrawal product fromthe market spawn numerous training programme clinical study relate grant fee travel product liability lawsuit file manufacturer entertainment original subpoena issue distributor fenfluramine dexfenfluramine phentermine attorney office colorado scope inquiry number manufacturer phentermine group nationwide group cooperate investigation remain defendant approximately provide request information group early respond thousand lawsuit file state federal district october letter fdas division drug marketing court usa group defendant advertise communication request information lawsuit seek relief include combination group allege promotion wellbutrin srfor offlabel use compensatory punitive damage medical monitoring refund june group pharmaceutical manufacturer purchase drug judicial panel multidistrict receive letter senate finance committee litigation issue order consolidate transfer federal committee express concern educational grant actions district court eastern district pennsylvania improperly promote drug product request court approve global settlement propose defendant company provide detailed information document use wyeth sell fenfluramine dexfenfluramine settlement educational grant january group subsequently approve circuit court appeal manufacturer receive second letter committee ask include phentermine defendant include group additional information group internal grant approval individual plaintiff elect opt class settlement process grant medicalphysicianprofessional organization pursue claim individually ten thousand plaintiff academic institution state agency support journal article elect wyeth continues settle individual state court publication grant patient education advocacy case trial group continue dismiss group group cooperate committee investigation lawsuit settle wyeth provide request information thimerosal february fda approve anda file roxane gsk number pharmaceutical company laboratorie generic form flonasenasal spray deny name defendant numerous individual personal injury citizen petition file group concern lawsuit state federal district court usa allege regulatory criterion apply determine thimerosal preservative manufacture vaccine cause propose generic product bioequivalent neurodevelopmental disorder injury include autism quality control standard asflonase february usdistrict case purport class action court district maryland grant temporary restraining determination case permit order suspend fda approval roxane andafor procee class action number purport class action day group file motion preliminary injunction jurisdiction withdraw dismiss plaintiff seek continue interim relief grant temporary restraining order remedy include compensatory punitive statutory damage request rule motion temporary cost fund medical monitoring research restrain order extend additional date report case schedule trial day expire lotronex february verona public prosecutor commence criminal follow voluntary withdrawal lotronex usa investigation gsk sale marketing practice italy specific november number lawsuit file area investigation include medical education programme clinical group state federal district court include individual personal study congresse interaction gsk injury action purport class action assert product liability representative physician similar issue investigate consumer fraud claim plaintiff seek remedy include bari public prosecutor ussecuritie exchange compensatory punitive statutory damage class previously commission secstaff initiate informal investigation certify west virginia decertifie action allegation group cooperate withall theseinvestigation dismiss large number claim bring follow withdrawal settle lotronexwas reintroduce usa february group receive subpoena sec subject risk management planimpose additional protection respect group participation united nations oil food prescribe dispense lotronex programme group cooperate sec provide document responsive subpoena gsk annual report stnemetat laicnanifnote financial statement continue legal proceeding continue paxilseroxat follow announcement new york state attorney general average wholesale price officeofthe state lawsuit subsequently settle august gsk respond subpoenas office inspector allege failure disclose datum use paxilin child general department health human service hhs adolescent similar case purport class action department justice states texas california file state federal canadian court private connection allegation pharmaceutical company plaintiff group respond discovery request case include gsk violate federal fraud abuse law federal false claim act respect texas california investigation remain pende medicine comparable state law result way average wholesale price healthcare product regulatory agency mhra determine awp determine report certain drug way group comply pharmacovigilence medicare medicaid programs reimburse drug obligation report datum clinical trial seroxatpaxilin september group reach civil settlement children adolescents department justice attorney district cidra puerto rico manufacturing site massachusetts office inspector general hhs follow fda inspection october november group agree pay government civil settlement result observation possible deficiency million settlement corporate integrity agreement manufacturing practice group manufacturing facility cidra group sign april connection prior puerto rico march fda halt distribution supply government investigation medicaid rebate issues amend paxil avandamet manufacturing issue fda address issue raise course investigation observation relate certain aspect production control process subsequent initial subpoenas state validation laboratory investigation respective attorney general county new york state cidra site engage tablete packaging range filedcivil lawsuit state federal court gsk gsk product primarily market include paxil paxil drug company action claim behalf state coreg avandiaand avandamet april group reach payer behalf instate patient consumer damage agreement fda consent decree consent decree restitution awpbase price report undefined set provide independent expert review manufacture pharmaceutical product cover state medicaid program process site compliance fda good manufacturing addition private payer class action lawsuit file practice gmp requirement provide consent decree gsk federal district state court federal case group provide report fda deficiency identify consolidated multidistrict litigation proceeding review set corrective plan timetable completion district court district massachusetts august fda inspector recently conduct general gmp inspection judge mdl proceeding grant deny followup group report january fda issue privatepayer plaintiff motion class certification form list observation narrow scope class claim fact discovery inspection group respond february proceeding closed group end august observation consistent finding independent expert discovery way discovery proceeding expert effectively include group suit file state attorney general state court remediation plan site group remain fully commit nominal pricing work cooperatively fda address issue timely group respond letter requestsfrom ussenate fashion group resume manufacture product site committee finance date april february financial penalty impose consent decree document information relate nominal price exception consent decree allow potential future penalty good price reporting requirement medicaid drug maximum million year group fail meet term rebate program activity connection thedecree inquiry committee group september group advise department justice group require post bond ensure product investigate certain group nominal pricing previously seize fda appropriately destroy arrangement determine arrangement qualify recondition group meet requirement bond exception good price reporting requirement violate expire march civil statute law group cooperate thatinvestigation april group receive subpoena usattorney provide document information department office boston request production record justice nominal pricing arrangement number manufacture cidra site cover type information group product collect usgovernment puerto rico gsk annual report stnemetat laicnanifnote financial statement continue legal proceeding continue relafen august district court district massachusetts antitrust rule group patent nabumetone relafen invalid paxilseroxat anticipatory art unenforceable ground inequitable paroxetine patent infringement action bring group conduct august cagc issue decision affirm describe intellectual property apotex alphapharm district court judgment invalidity decline rule basfand sumike file antitrust unfair competition judgment inequitable conduct counterclaim group usdistrict court eastern district ofpennsylvania base allegation group follow district court decision antitrust claim allege monopolised market forpaxilby bring allegedly sham patent competitive injury overcharge file teva eon litigation allegedly abuse regulatory procedure pharmaceutical generic manufacturer nabumetone list patent fdaorange book whilst apotex matter purport class direct indirect purchaser payer remain discovery stage action individual retail chain aspect litigation stay conclude exception appeal take certain indirect purchaser trial judge order give final approval november federal trade commission ftc staff settlement class appeal pende circuit advise group conduct nonpublic court appeal circuit investigation determine group violate section federal trade commission act monopolize canadian importation attempt monopolize market paroxetine hydrochloride group pharmaceutical companiesha prevent generic competition paxiland request group name seven purport class action lawsuit following submit certain information connection investigation group action reduce illegal importation prescription october ftc closed investigation basis drug canada lawsuit allege company enter find action warrant unlawful conspiracy prevent canadian pharmacy sell product customer lawsuit follow public reference ftc investigation paxil consolidate action district court purport class action file district court district minnesota group motion dismiss consolidated eastern district pennsylvania behalf indirect purchasersbase action grant court decision appeal allegation similar antitrust counterclaim bring circuit court appeal eighth circuit date apotex similar action file city new york report date oral argument announce eastern district pennsylvania indirect purchasers florida california minnesota pennsylvania class action relation matter minnesota state attorney general settle class settlement approve file civil investigative demand subsequently complaint certain objector appeal approval indirect purchaser allege group violate state antitrust commercial settlement city new york action settle action law group file motion dismiss complaint oral minnesota california action dismiss argument motion complete november florida action california action stay date report decision announce group settle similar threaten claim group group name defendant thirteen chain drug store conditionally settle threatenedclaim drug company state court action california state attorney general remains see state plaintiff independent pharmacy allege defendant join settlementsimilar class action file unlawfully conspire price artificially high usa provincial courts canada behalf direct indirect purchaser detriment plaintiff party involve extensive case early stage discovery trial date set september october competition directorate european wellbutrin commission initiate inspection concern allegation december january february lawsuit group abuse dominant position marketplace concern purport class action file district enforcement intellectual property right litigation surround court eastern district pennsylvania group regulatory approval marketing seroxatin europe group behalf direct indirect purchaser wellbutrin cooperate fully commission complaint allege violation antitrust law sham litigation fraud patent office group obtain enforce patent cover wellbutrin complaint follow introduction generic competition wellbutrin srin april district appellate court ruling generic manufacturer infringe group patent oral argument group motion dismiss complete february date report decision announce gsk annual report stnemetat laicnanifnote financial statement continue legal proceeding continue commercial corporate relenza biota holding limit file complaint victorian supreme court australia allege group fail tofulfil development promotion production obligation zanamivir relenza term licence agreement group biota biota seek substantial cash damage group believe adhere obligation licence agreement party involve extensive discovery security class action september attorney represent purport class purchaser gsk share american depositary share adss file second amend security class action complaint group district court southern district new york allege group violate security law failure disclose unfavourable clinical datum study paxil misrepresentation remain patent protection paxiland augmentinand violation federal false claim act basis group recent awp settlement government group file motion dismiss environmental matter gsk notify potential responsibility relate past operation past waste disposal practice certain site primarily usa matter subject litigation include proceeding initiate federal state government waste disposal site remediation cost tort action bring private party gsk advise responsible party approximately site appear national priority list create comprehensive environmental response compensation liability act superfund proceeding seek require operator hazardous waste facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost instance gsk involve allege generator hazardous waste site gsk involve current operator facility superfund provide defendant jointly severally liable cleanup cost proceeding frequently resolve basis nature quantity waste dispose site generator gsk proportionate liability cleanup cost substantially determine site refer gsk potential liability vary greatly site site cost investigation study remediation site time substantial gsk routinely accrue amount related share liability matter tax matter pende tax matter include disclosure tax liability billion billionare describe note taxation gsk annual report stnemetat laicnanifdirector statement responsibility director statement responsibility relation go concern basis company financial statement make enquiry director reasonable director expectationthat company adequate resource continue operational existence foreseeable future forthis reason responsible ensure maintenance proper accounting continue adopt go concern basis inprepare financial record disclose reasonable accuracy financial statement position company time financial statement prepare comply company combine code act board consider glaxosmithkline plc apply principle require law prepare financial statement financial combine code corporate governance financial period true fair view state affair report council asdescribe corporate governance company end financial period ofthe profit page comply provision loss period describe page responsible ensure operation system require listing rule financial service authority internalcontrol take reasonable step safeguard auditor haveconsidere director statement compliance asset company prevent detect fraud relation point combine code specify irregularity theirreview balance sheet year end december support note set pagestoof report director confirm suitable accounting policy consistently apply preparation financial statement support reasonable prudent judgement estimate asnecessary applicable accounting standard follow financial statement prepare go sir christopher gent concern basis chairman march responsibility auditor relation financial statement set independent auditor report annual report publish hardcopy print form available website director responsible maintenance integrity annual report website accordance legislation govern preparation dissemination financial statement access website available outside comparable legislation different director remuneration remuneration report page set remuneration policy operate glaxosmithkline disclosure director remuneration disclosable information relate director officer interest prepare accordance company act complie section combine code corporate governance gsk annual report stnemetat laicnanif glaxosmithkline plcgsk annual report stnemetat laicnanif glaxosmithkline plc independent auditor report members glaxosmithkline plc audit parent company financial statement basis audit opinion glaxosmithkline plc year end december conduct audit accordance international standard comprise balance sheetand relate note parent audit ireland issue auditing practice board company financial statement prepare audit include examination test basis evidence relevant accounting policy set audit amount disclosure parent company financial information director remuneration report describe statement director remuneration report audit audit include assessment significant estimate judgment director preparation parent report separately group financial statement company financial statement accounting policy glaxosmithkline plc year end december appropriate company circumstance consistently apply respective responsibility director auditor adequately disclose director responsibility prepare annual report plan perform audit obtain director remuneration report parent company financial information explanation consider necessary statement accordance applicable law united kingdom order provide sufficient evidence reasonable accounting standard united kingdom generally accept assurance parent company financial statement accounting practice set statement director director remuneration report audit free responsibility material misstatement cause fraud irregularity responsibility audit parent company financial statement error form opinion evaluate overall director remuneration report audit adequacy presentation information parent company accordance relevant legal regulatory requirement financial statement director remuneration international standard audit ireland report report audit include opinion prepare opinion company member body accordance section opinion company act purposewe give opinion accept assume responsibility purpose parent company financial statement true fair view person report show accordance united kingdom generally accept accounting hand come save expressly agree prior consent practice state company affair december writing report opinion parent company parent company financial statement financial statement true fair view director remuneration report audit properly parent company financial statement director prepare accordance company act remuneration report audit properly prepare accordance company act report opinion director report consistent parent company financial statement company keep pricewaterhousecooper llp proper accounting record receive charter accountant register auditor information explanation require audit london information specify law director remuneration march transaction disclose read information contain annual report consider isconsistent audit parent company financial statement information comprise onlythejoint statement chairman chief executive financial summary description business corporate governance statementand operate financial review prospectswe consider implication report aware apparent misstatement material inconsistency parent company financial statement responsibility extend informationcompany balance sheet gaap atst december restate note investmentin subsidiary company fix asset debtor cash bank current asset creditor amount year net current liability net asset capital reserve call share capital share premium account reserve profit loss account equity shareholder fund approve board onst march sir christopher gent chairman gsk annual report stnemetat laicnanif glaxosmithkline plcgsk annual report stnemetat laicnanif glaxosmithkline plc note company balance sheet gaap atst december apresentation financial statement taxation current tax provide amount expect pay apply description business tax rate enact substantially enact glaxosmithkline plc parent company gsk major global balance sheet date healthcare group engage creation discovery development manufacture marketing pharmaceutical company account taxation defer accelerate product include vaccine overthecounter otc medicine reason time difference originate reverse healthrelate consumer product balance sheet date defer tax asset recognise extent consider recoverable future taxable preparation financial statement profit financial statement draw accordance generally accept accounting principle ukgaap defer tax measure average tax rate expect accounting presentation december comparative apply period time difference expect figure december reverse defer tax liability asset discount permit company act profit loss cnew accounting policy account company present annual report accounting standard board asb issue financial reporting accounting convention standard stanard frs share base payment april balance sheet prepare historical cost company incur charge standard issuance convention complie applicable accounting standard company subsidiary grant company accounting principle policy option represent additional capital contribution company preparation balance sheet conformity generally subsidiarie additional investment subsidiary result accept accounting principle require management correspond increase shareholder equity additional capital estimate assumption affect report amount contribution base fair value grant issue allocate asset liability disclosure contingent underlie grant vest period asset liability date balance sheet actual amount theasb issuedfrs event balance sheet date differ estimate standard replacedstatement standard accounting balance sheet prepare accordance practice accounting post balance sheet event main company accounting policy approve board describe effect change prohibit recording provision note propose dividend dividend declare balance sheet date frs applicable accounting period begin baccounte policy january final dividend recognise profit loss account shareholder foreign currency transaction approve interim dividend recognise foreign currency transaction record exchange rate ruling pay date transaction forward rate hedge forward exchangecontract foreign currency asset liability year company adopt frs effect translate rate exchange rule balance sheet date change foreign exchange rate frs financial instrument forward rate disclosure presentation frs financial instrument measurement frs corresponding amount adoption dividend pay receive standard material impact company dividend pay receive include account period balance sheet relate dividend actually pay receive expenditure expenditure recognise respect good service receive supply accordance contractual term provision obligation exist future liability respect past event obligation reliably estimate investment subsidiary company investment subsidiary company hold cost provision permanent diminution valuenote company balance sheet gaap december dfixe asset restate share glaxosmithkline finance plc share glaxosmithkline service unlimited share glaxosmithkline holding limited capital contribution relate share base payment subsequent yearend company form new subsidiary glaxosmithkline holding limit sell entire share hold glaxosmithkline finance plc glaxosmithkline holdings limit issue new share company consideration edebtor amount year corporate tax amount owe group undertaking fcreditor restate amount year dividend payable amount owe group undertaking creditor gshare capital share premium account share ordinary share premium number share capital authorise december december share capital issue fully pay january issue share option scheme purchase cancel december issue share option scheme december december december number share issuable outstanding option number unissue share option december issue share capitalshare hold esop trust share hold treasury share andshare free issue issue share fully pay stnemetat laicnanif glaxosmithkline plc gsk annual report gsk annual report stnemetat laicnanif glaxosmithkline plc note company balance sheet gaap december profit hreserve reserve loss account total restate restate restate atstjanuary previously report prior year adjustment implementation frs prior year adjustment implementation frs atstjanuary profit attributable shareholder dividend shareholder ordinary share purchase cancel ordinary share purchase hold treasury share capital contribution relate share base payment december profitattributable shareholder dividend shareholder ordinary share purchase hold treasury share capital contribution relate share base payment december profit glaxosmithkline plc year million million dividend million million give retainedlossof million profit million cost share purchase cancel nil millionandshare purchase hold treasury share million million profit loss account reserve december stand million million million unrealised millionnoitamrofni rotsevni investor information section include financial record present historical information analyse accordance current reporting practice transition date ifrs gsk january information include year record accordance ifrs information accordance ukgaap provide link ifrs gaapinformation present ukgaap accounting policy preparation ukgaap information disclose annual report information prepare ifrs directly comparable information prepare gaap fiveyearrecord present information accordance gaap section discuss shareholder return form dividend share price movement provide information shareholder financial record quarterly trend year record shareholder information taxation information shareholder gsk annual report financial record quarterly trend gsk annual report noitamrofni rotsevni unaudite analysis provide quarter group result sterle financial year analysis comprise statutory result pharmaceutical sale therapeutic area income statement month cer cer turnoverpharmaceutical consumer healthcare total turnover cost sale sell general administrative expenditure research development expenditure operating income operate profit finance income financecost share tax profitslosse joint venture associate undertaking profit disposal interest associate profit taxation taxation tax rate profitafter taxation period profit attributable minority interest profit attributable shareholder earning share dilute earning share pfinancial record continue gsk annual report noitamrofni rotsevni cer cer cer pfinancial record continue gsk annual report noitamrofni rotsevni pharmaceutical turnover total group cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil paxil wellbutrin wellbutrin wellbutrin imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen retrovir agenerase lexiva epzicomkivexa herpe valtrex zovirax zeffix antibacterials augmentin augmentin augmentin zinnatceftin metabolic avandia avandamet bonvivaboniva vaccine hepatitis infanrixpediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart arixtra fraxiparine vesicare zantac total pharmaceutical turnover include copromotion incomefinancial record continue pharmaceutical turnover usa cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil paxil wellbutrin wellbutrin wellbutrin imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen retrovir agenerase lexiva epzicomkivexa herpe valtrex zovirax zeffix antibacterials augmentin augmentin augmentin zinnatceftin metabolic avandia avandamet bonvivaboniva vaccine hepatitis infanrix pediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart arixtra fraxiparine vesicare zantac total pharmaceutical turnover include copromotion income gsk annual report noitamrofni rotsevnifinancial record continue gsk annual report noitamrofni rotsevni pharmaceutical turnover europe cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil paxil wellbutrin wellbutrin wellbutrin imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen retrovir agenerase lexiva epzicomkivexa herpe valtrex zovirax zeffix antibacterials augmentin augmentin augmentin zinnatceftin metabolic avandia avandamet bonvivaboniva vaccine hepatitis infanrixpediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart arixtra fraxiparine vesicare zantac total pharmaceutical turnover include copromotion incomefinancial record continue pharmaceutical turnover international cer cer cer cer respiratory seretideadvair flixotideflovent serevent flixonaseflonase central nervous system seroxatpaxil paxil paxil wellbutrin wellbutrin wellbutrin imigranimitrex lamictal requip antiviral hiv combivir trizivir epivir ziagen retrovir ageneraselexiva epzicomkivexa herpe valtrex zovirax zeffix antibacterials augmentin augmentin augmentin zinnatceftin metabolic avandia avandamet bonvivaboniva vaccine hepatitis infanrixpediarix oncology emesis zofran hycamtin cardiovascular urogenital coreg levitra avodart arixtra fraxiparine vesicare zantac total pharmaceutical turnover include copromotion income gsk annual report noitamrofni rotsevnifinancial record continue year record record financial performance provide analysed accordance current reporting practice transition date ifrs glaxosmithkline january information include fiveyearrecord accordance ifrsas adopt use european unionfor gsk difference ifrs adopt use european union ifrs publish international accounting standard boardthe information accordance ukgaap provide link ifrs gaap information present gaap accounting policy preparation gaap information disclose annual report information prepare ifrs directly comparable information prepare gaap fiveyearrecord present information accordance gaap turnover business segment ifrs pharmaceutical consumer healthcare turnover business segment ukgaap pharmaceutical consumer healthcare pharmaceutical turnover therapeutic area ifrs respiratory central nervous system antibacterial antiviral metabolic vaccine oncology emesis cardiovascular urogenital pharmaceutical turnover therapeutic area ukgaap respiratory central nervous system antibacterial antiviral metabolic vaccine oncology emesis cardiovascular urogenital pharmaceutical turnover geographic area ifrs usa europe international asia pacific japan middle east africa latin america canada international gsk annual report noitamrofni rotsevnifinancial record continue pharmaceutical turnover geographic area ukgaap usa europe international asia pacific japan middle east africa latin america canada international pharmaceutical turnover include copromotion income consumer healthcare turnover ifrs otc medicine oral care nutritional healthcare consumer healthcare turnover ukgaap otc medicine oral care nutritional healthcare financial result ifrs turnover operate profit profit taxation profitafter taxation basic earning share penny dilute earning share penny weight average number share issue basic diluted return capital employ financial result ukgaap turnover operate profit profit taxation profitafter taxation basic earning share penny dilute earning share penny weight average number share issue basic diluted return capital employ return capital employ calculate statutory profit taxation percentage average capital employ year gsk annual report noitamrofni rotsevnifinancial record continue amount accordance gaap turnover net incomeloss basic net incomeloss share pence diluted net incomeloss share pence information present accordance gaap derive financial information prepare ifrs adopt use european union gaap information present gaap net incomeloss net incomeloss share result yearende december adjust reverse amortisation expense goodwill indefinitelive intangible asset sfas apply year adjusted net incomeloss adjust basic net incomeloss share pence adjust diluted net incomeloss share pence exchange rate guide holder adr follow table set period indicate information exchange rate dollar sterling report federal reserve bank new york noon buying rate average average rate year calculate average noon buying rate day month year feb jan dec nov oct sept high low noon buying rate february number employees usa europe international asia pacific japan middle east africa latin america canada international manufacturing sell administration research development number employee number permanent employ staff end financial period exclude employee employ manage glaxosmithkline contract basis gsk annual report noitamrofni rotsevnifinancial record continue balance sheet ifrs noncurrent asset current asset totalasset current liability noncurrent liability total liability net asset equity shareholdersequity minority interest balance sheet gaap fixedasset current asset totalasset current liability noncurrent liability total liability net asset equity shareholdersequity minority interest amounts accordance gaap total asset net asset longterm borrowing shareholder equity gsk annual report noitamrofni rotsevnishareholder information share price january high year low year december increasedecrease table set middle market closing price derive london stock exchange daily official list company share priceincrease byin price january december compare anincreasein ftse index year market capitalisation market capitalisation base share public issue glaxosmithkline december billion date gsk thefourthlargest company market capitalisation ftse index smithkline beecham plc float rate unsecured loan stock loan stock list exchange holder require smithkline beecham plc redeem loan stock par loan stock hold business day march june september december holder wish redeem loan stock complete notice loan stock certificate return registrar arrive day relevant redemption date taxation general information concern tax effect share ownership set taxation information shareholder page dividend glaxosmithkline pay dividend quarterly detail dividend declaredthe payment date give note dividend share table set dividend share pay year year penny gsk annual report noitamrofni rotsevni dividend ad table set dividend ad pay dollar year translate dollar applicable exchange rate year dividend calendar fourth quarter exdividend date february record date february payable april quarter exdividend date record date payable july second quarter exdividend date august record date august payable october quarter exdividend date november record date november payable january internet information company include detail share price available gsk website wwwgskcom information available website constitute annual report investor relation investor relation contact follow great west road brentford middlesex tel fax usa franklin plaza box philadelphia tel toll free tel outside usa fax shareholder information continue analysis shareholding number total total number analysis shareholding december account account share share hold share total hold nominee company investment trust company insurance company individual corporate body bny nominee limit hold treasury share glaxosmithkline total bank new york hold hold bny nominees limited represent company adr programme ad represent ordinary share nominal value february number holder record share usa holdings share thenumberof register holder adr holding adr certain share adrs hold broker nominee result number holder record register holder usa representative number beneficial holder orofthe residence beneficial holder control company far know company directly indirectly own control corporation government thecompany know arrangement operation result change control company major shareholder voting right share shareholder substantial shareholding february company receive notification follow interest share issue exclude treasury share bnynominee limited hold share represent share hold behalf holder adr evidence adss legal general investment management limited hold share represent barclays plc hold share represent far know company person owner share issue exclude treasury share company director officer interest director officer company define thecompanie act share option company give remuneration report page exchange control limitation affect securityholder currently law decree regulation restrict import export capital affect remittance dividend orother payment holder companys share nonresident limitation relate nonresident english law company memorandum article association right tobe holder tovote respect company share document display memorandum articles association company document refer annual report available inspection register office company publication late march gsk publish website corporate responsibility report cover performance area include community investment ethic integrity access medicine environment health safety gsk annual report noitamrofni rotsevnishareholder information continue nature trading market annual general meeting ordinary share company list london stock queen elizabeth conference centre exchange december share list broad sanctuary westminster new york stock exchange nyse inthe form american depositary london swp share adss date annual general meeting company principal forum follow table set period indicate high communication private shareholder addition formal low middle market closing quotation pence share business presentation chief executive officer london stock exchange high low report sale performance group future development price dollar adss thenyse opportunity question board chairmen board committee question matter relate glaxosmithkline penny share committee high low investor hold share company nominee service quarter end march arrange nominee service appoint february corporate representative proxy respect shareholde january order attend vote meeting december november adr holder wish attend meeting obtain proxy october bank new york enable attend meeting september vote business transact adr holder instruct quarter end december bank new york way share represent quarter end september adrs vote complete return voting quarter end june card provide bank accordance instruction give quarter end march quarter end december financial reporting quarter end september financial reporting calendar quarter end june quarter end march announcement quarter result april year end december announcement quarter result july year end december announcement quarter result october year end december preliminary announcement annual result february publication annual reportreview march dollar ad high low result announcement quarter end march result announcement issue london stock exchange february available news service shortly january issue medium available website send december ussecurities exchange commission nyse november october financial report september company publish annual report investor quarter end december need detail report annual review quarter end september available date publication website quarter end june annual review send shareholder date quarter end march publication shareholder elect receive annual report quarter end december writing company registrar alternatively shareholder quarter end september elect receive notification email publication financial quarter end june report register wwwshareviewcouk quarter end march year end december copy previous financial report available website year end december print copy obtain registrar year end december customer response center usa toth february gsk annual report noitamrofni rotsevnigsk annual report noitamrofni rotsevni shareholder information continue ordinary share company share list london stock exchange registrar company registrar lloyds tsb registrar causeway worthe west sussex wwwshareviewcouk tel inside tel outside registrar provide follow service glaxosmithkline investment plan glaxosmithkline individual saving account glaxosmithkline corporate sponsor nominee shareview service shareview deal service share deal service hoare govett operate postal dealing service company ordinary share enable investor buy sell share competitive commission charge detail obtain telephone glaxo wellcome smithkline beecham corporate pep share centre limited oxford house oxford road aylesbury buck tel provision detail intend invitation inducement engage investment activity advice share dealing obtain stockbroker independent financial adviser american depositary share company share list nyse form american depositary share evidence american depositary receipt adr represent ordinary share general nyse rule permit company follow corporate governance practice instead apply usa provide company explain significant variation explanation provide company website adr programme administrator adr programme administer bank new york shareholder relations box church street station new york wwwadrbnycom tel toll free tel outside usa customer response center tel toll free administrator provide global buydirect direct ad purchasesale dividend reinvestment plan adr holdersgsk annual report noitamrofni rotsevni taxation information shareholder information shareholder gift disposal subject inheritance tax estate gift tax estate gift tax convention summary main tax consequence holder share generally provide tax pay usa credit tax adr citizen resident usa set payable complete analysis possible tax consequence purchase ownership security intend stamp duty general guide holder advise consult adviser stamp duty stamp duty reserve tax sdrt subject certain respect tax consequence purchase ownership exemption payable purchase share rate share adr consequence state local tax purchase price minimum charge law usa implications new ukus income tax stamp duty liability arise convention shareholder statement base tax law practice date report follow summary certain taxation usa federal income tax consideration relevant usholder new ukus income tax convention come force share adrs summary apply shareholder hold march provision new treaty apply uktax share adr capital asset citizen resident usa purpose april ukcorporation tax april domestic corporation subject united states income tax capital gain tax federal income taxation net income basis respect share withholding taxis ustax purpose provision new adrs resident uktax purpose treaty apply withhold taxis january hold share purpose trade profession vocation ustaxe holder share adrs carry branch agency ability elect continue use provision previous treaty month follow new treatys entry force taxation dividend election advance event new gross dividend receivedwithout reduction treaty apply withholding tax treat foreign source dividend income tax purpose eligible dividend receive deduction holder adrs generally treat owner allow corporation dividend adr payable underlying share purpose current usauk double dollar dividend share payable sterling dividend pay taxation convention relate income gain income tax pound sterling include income dollar convention estate gift taxis estate gift tax convention calculate reference exchange rate day dividend purpose internal revenue code receive holder subject certain exceptionsfor short amend code term hedge position individual eligible holder follow analysis deal dividend pay april subject taxation maximum rate respect advance corporation tax act abolish qualified dividend receive shareholder advise consult tax adviser confirm eligibility shareholders taxation capital gain taxation dividend generally holder subject capital gain tax april rate tax credit reduce ninth subject tax capital gain realise sale result compensating reduction rate tax dividend disposal share adr income increase tax bear resident individual estate gift taxis shareholder tax credit long repayable estate gift tax convention shareholder shareholder tax liability associate tax credit generally subject inheritance tax taxation capital gain stamp duty shareholder liable tax gain disposal stamp duty sdrt subject certain exemption payable share adr entitle indexation relief issue transfer share adr custodian depository taper relief sale indexation relief calculate market rate price issue value share march cost subsequent consideration provide transfer sale value purchase date purchase indexation relief transfer consideration individual shareholder cease april taper relief available individual shareholder hold deem hold sdrt payable transfer adr stamp share year sell duty payable transfer adr provide instrument transfer execute remain time outside inheritance tax stamp duty transfer adr payable individual shareholder liable inheritance tax transfer rate consideration transfer sale share adr tax charge underlie share result liability stamp duty value shareholder estate reduce result transfer case sdrt rate minimum charge way gift disposal market value stamp duty liability arisesgsk annual report noitamrofni rotsevni glossary term term annual report equivalent brief description accelerate capital allowance tax allowance excess depreciation arise purchase fix asset delay charge payment tax equivalent tax depreciation advance corporation tax act advance payment tax dividend pay direct equivalent american depositary receipt adr receipt evidencing title ad glaxosmithkline adr represent ordinary share american depositary share adss ordinary share register new york stock exchange basic earning share basic income share calledup share capital ordinary share issue fully pay cer growth growth constant exchange rate combine code guideline require listing rule financial service authority address principal aspect corporate governance company glaxosmithkline plc creditor account payable currency swap exchange currency couple subsequent reexchange currency agree exchange rate date debtor account receivable define benefit plan pension plan specific employee benefit call final salary scheme define contribution plan pension plan specific contribution level pension dependent growth pension fund derivative financial instrument financial instrument derives value price rate underlie item dilute earning share diluted income share employee share ownership plan trust trust establish group satisfy share base employee incentive plan finance lease capital lease freehold ownership absolute right perpetuity gearing ratio net debt percentage total equity group glaxosmithkline plc subsidiary undertaking hedging reduction risk normally relation foreign currency interest rate movement bymake offset commitment intangible fix asset asset physical substance brand licence patent knowhow marketing right purchase outside party nonequity minority interest preference share issue subsidiary outside party preference share share issue vary dividend rate treat outside interest profit income profit attributable shareholder net income share capital ordinary share capital stock common stock issue fully pay shareholder fund shareholder equity share option stock option share premium account additional paidup capital paidin surplus distributable share issue share outstanding statement recognise income expense statement comprehensive income stock inventory subsidiary undertaking affiliate glaxosmithkline hold majority shareholding andor exercise control treasury share treasury stock turnover revenuegsk annual report noitamrofni rotsevni index accounting policy independent auditor report accounting presentation intellectual property achieve commercial operational excellence interest rate risk management acquisition disposal internal control framework annual general meeting inventory asset hold sale investment associate joint ventures associate joint venture investor information good place good people well work legal proceeding board movement equity build good product pipeline industry net debt cash cash equivalent new accounting policy future requirement combine code nonexecutive director term condition fee commitment nonexecutive director remuneration committee report note financial statement community investment operate financial review prospect consolidate balance sheet operating profit consolidated cash flow statement intangible asset consolidate income statement investment consolidate statement recognise income expense noncurrent asset consumer healthcare noncurrent liability contact detail operate income contingent liability provision corporate executive team outlook risk factor corporate governance pension postemployment benefit corporate responsibility pharmaceutical turnover critical accounting policy presentation financial statement description business principal group company dialogue shareholder product competition director senior management remuneration property plant equipment director interest quarterly trend director interest contract reconciliation accounting principle director statement responsibility regulatory environment dividend relate party transaction earning share remuneration report employee cost report director employee share scheme responsibility environment health safety exchange rate risk factor executive director term condition remuneration segment information finance cost share capital share premium finance income share option financial instrument relate disclosure shareholder information financial position resource strategy financial record taxation financial statement taxation information shareholder financial summary total equity financial trend ratio trade payable year record trade receivables foreign exchange risk management trademark global manufacturing supply transition ifrs glossary term treasury policy goodwill law regulation governance policy world economy ifrs adjustment world market pharmaceutical improve access medicine incentive plan discover important medicine eradicate disease improve quality people live make medicine available great number people matter people garnier leave sir christopher gent rightannual report corporate website brochure meet global challenge product commitment innovation health access medicine responsibility therapy area community mission research development well future investor like know medium centre career gsk wwwgskcom corporate annual responsibility review report human access medicine interview research innovation chairman ceo ethical conduct focus patient annual employee year vaccine human right growing brand report environment power performance community investment performance highlights business operating review summary remuneration report interview corporate governance chairman ceo summary financial statement financial summary shareholder information description business chairman ceo corporate governance closing letter remuneration report operate financial review prospect financial statement note financial statement investor information feel well live long head office register office glaxosmithkline plc great west road design cgi london brentford middlesex print midas press paper united kingdom production document pulp harvest tel sustainable forest sawmill residue wwwgskcom forest thinning elemental chlorinefree feel well live long glaxosmithkline annual report